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Abstract 
 
Neural crest cells are a multipotent cell population, which migrate 
from the dorsal neural tube in early vertebrate development throughout 
the embryo to form a variety of cell types including pigment cells, cranio-
facial cartilage and sensory neurons [1, 2]. Here I show that the small 
molecule compound leflunomide is able to inhibit neural crest 
specification genes. Leflunomide exerts its actions by inhibiting 
pyrimidine synthesis and therefore RNA transcription [4]. Neural crest 
genes are thought to be actively transcribed and like many embryonic 
stem cell genes may undergo an increased level of transcriptional 
pausing and subsequent elongation rendering them more sensitive to the 
effect of leflunomide [3, 5]. I have gone on to show that components of 
the transcriptional elongation regulatory machinery, Cdk9 and CyclinT1 of 
the P-TEFb complex are also able to regulate neural crest specification. 
In particular the expression of the protooncogene c-Myc and c-Myc 
responsive genes are affected. c-Myc has been previously implicated in 
embryonic stem cell transcriptional elongation and also is well 
characterised to play a role in neural crest specification [6]. We postulate 
that regulation of c-Myc expression at the level of transcriptional 
elongation is important for the correct temporal and spatial development 
of the neural crest. 
 
Key words: Neural crest cells, multipotent, leflunomide, transcriptional 
elongation, c-Myc, P-TEFb, Cdk9, CyclinT1 
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1. Introduction 
 
1.1 Using Xenopus as an animal model 
Xenopus laevis and Xenopus tropicalis are two species of African 
clawed frog commonly used as vertebrate animal models for studying 
early development. Xenopus are used because they can lay hundreds of 
eggs at once which will develop together in synchronicity to allow for 
experiments to be planned and regulated accordingly [7]. Xenopus laevis 
eggs are large (1.2-1.4mm in diameter) allowing for them to be easily 
manipulated. They are also robust and easily withstand micro-injection 
into targeted blastomeres. Xenopus tropicalis embryos are more 
commonly used today for genetic studies as they have a well sequenced 
diploid genome unlike the laevis tetraploid genome [7].  
The Xenopus life cycle (figure 1.1) is separated into key 
developmental stages using the Nieuwkoop and Faber fate map as a 
standard example of Xenopus stages. The stage 1 Xenopus embryo (or a 
fertilised egg) is separated into two regions, the animal pole, which is 
dark in colour and the vegetal pole, which appears lighter in colour [8]. 
Sperm will usually enter the unfertilised egg in the region of the animal 
pole. The embryo will undergo cleavage around two hours after 
fertilisation giving the embryo two blastomeres of equal size. Further 
cleavages occur every half an hour after this until the embryo consists of 
several thousand cells and reaches the blastula stage. This stage 
embryo will also contain a fluid filled cavity known as the blastocoel [8].  
After reaching blastula stage the embryos will undergo 
gastrulation, which involves rearrangement of the three germ layers 
(mesoderm, endoderm and ectoderm). At first a blastopore opens in the 
surface of the embryo at the position of the Spemann organiser, a crucial 
organiser for dorsal ventral patterning. Mesoderm and endoderm start to 
involute at the blastopore and the ectoderm will cover the surface of the 
embryo by a movement known as epiboly [8].  
  17 
 After gastrulation the embryos will undergo neurulation to form 
neurula stage embryos. During neurulation the neural plate will rise and 
fold along the midline to form the neural tube. Neural crest cells will 
format the border of the ectoderm and neuroectoderm. After neurulation  
the neural tube closes and the NCCs undergo epithelial to mesenchymal 
transition (EMT) and migrate away. The embryo then undergoes 
convergent extension movements to elongate into a tailbud stage 
embryo. At this stage organogenesis occurs and the embryo will further 
develop its neural tube, notochord and somites (muscle precursors) [8]. 
The embryo will continue to develop facial features such as the ear, eye, 
mouth and branchial arches. Finally it develops the heart, kidney, liver 
and blood to form a fully feeding tadpole [8].
Figure 1.1: The Xenopus life cycle. The embryos are staged here based on 
the standard Niewkoop and Faber fate map. The main stage types of the 
Xenopus are blastula, gastrula, neurula, tailbud and tadpole. After this the 
tadpole will undergo metamorphosis into the adult froglet. Timing of Xenopus 
development is temperature dependent. Retrieved from [8].  
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1.2 The neural crest  
1.2.1 Neural crest induction 
The neural crest is a transient embryonic cell population found 
exclusively in vertebrates. They migrate from the dorsal neural tube to 
various parts of the embryo where they differentiate to give rise to a 
variety of cell types due to their stem-cell-like multipotent potential [2, 6]. 
These include enteric ganglia, neuroendocrine cells, melanophores, 
neurons, craniofacial, skeletal and connective tissue. The induction and 
specification of neural crest cells (NCCs) occurs during gastrulation all 
the way up to organogenesis due to a multimodule gene regulatory 
network acting between the neural plate, nonneural ectoderm and the 
paraxial mesoderm (figure 1.2) [2, 9]. During neurulation the NCCs can 
be found within the neural folds and at the dorsal neural tube. A loss of 
cell-cell adhesion and the morphological changes which occur promotes 
the delamination and migration of these multipotent cells which will arrive 
at their correct destination and subsequently differentiate. Specific gene 
regulatory networks consisting of multiple signals and transcription 
factors are responsible for neural crest properties such as multipotency, 
induction, specification, migration and differentiation [2].  
 Wnt, fibroblast growth factor (FGF) and bone morphogenic protein 
BMP are the three important signalling pathways implicated in neural 
crest induction. The current model for neural crest induction at the neural 
plate border in Xenopus and zebrafish suggests that a dorso-ventral 
gradient of BMP4 and 7 activity regulated by BMP antagonists such as 
Chordin, Noggin and Follistatin found in the underlying paraxial 
mesoderm initiates the induction [10, 11]. However, this BMP gradient 
alone is not sufficient and so it is thought that this attenuated BMP signal 
must act in cooperation with Wnt signals to successfully induce neural 
crest [12-14]. The FGFs specifically involved in neural crest induction 
have been shown to be FGF2 and FGF8 secreted from the paraxial 
mesoderm [15]. Notch signalling acts upstream of BMP signals to refine 
the induced neural crest to the neural plate border. Overexpression of  
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Notch or Hairy2 (which acts downstream of Notch) results in neural crest 
expansion at the neural plate border [16, 17]. BMP signalling has also 
been shown to play a role in the maintenance of NCCs at neurula stages 
of development. Active rather than inhibited BMP4 signals in combination 
with Wnt signals from mesoderm adjacent the neural crest is required for 
this maintenance step [18]. The Zic factors (Zic1 and Zic3) and Pax3/7 
play a role in neural crest induction at the neural plate border. They are 
Figure 1.2: Neural crest induction, specification, survival and migration. Neural 
crest formation is regulated by a network of genes. Top image shows neural crest 
induction. This involves Wnt signals from the non-neural ectoderm and Wnt and FGF 
signals from the paraxial mesoderm acting in a BMP dependent fashion on the neural 
plate border to induce neural crest. The right image shows neural crest specification. This 
occurs due to the upregulation of neural crest specifiers such as c-Myc, Id3, Snail1/2, 
Sox10 and FoxD3. The bottom image shows genes involved in neural crest survival after 
neural tube closure. These include Id, Myc, FoxD3, Snail1/2 and members of the SoxE 
family. The left image shows neural crest migration. This occurs due to the upregulation 
of intrinsic matrix metalloproteinases and a change from typeI to typeII cadherins. 
Retrieved from [2] 
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thought of as neural plate border specifiers and will be upregulated in in 
this region by the attenuated BMP signal.  They are thought to upregulate 
neural crest specifiers such as Slug and FoxD3 by mediating the Wnt, 
BMP and FGF signals which influence their expression levels[19].  
Gain of function and loss of function experiments in Xenopus and 
Zebrafish have been used to show that the canonical Wnt pathway is 
important for induction and neural crest lineage specification [20, 21]. 
Specifically Wnt8 has been implicated in Xenopus and Zebrafish neural 
crest induction and Wnt6 in avian neural crest induction [15, 20, 22]. In 
addition to Wnt8, Wnt1, Wnt3a and Wnt7b have been implicated in 
Xenopus neural crest induction [12, 23, 24]. The downstream Frizzled 
receptors through which these Wnts are signalling in the Xenopus to 
induce neural crest have been characterised as being Frizzleds 3 and 7 
[25, 26]. 
 
 
1.2.2. Neural crest specification and survival 
 
Once the neural plate border is fully specified and the NC has 
been induced, NCCs will undergo specification by certain transcription 
factors known as neural crest specifiers (figure 1.2). These have been 
characterised as Snail1, Slug (Snail2), Sox8, Sox9, Sox10, FoxD3, AP-2, 
Twist, c-Myc and Id3 [2]. Specification occurs due to morphological 
changes to the neural crest cells including changes to shape, adhesion 
and cell motility to allow the cells to migrate from the dorsal neural tube 
(figure 1.2). These neural crest specifiers act cooperatively to regulate 
their expression [2]. The expression of both Slug and FoxD3 is regulated 
by Fgf8 from the paraxial mesoderm where it is regulated itself by Msx1. 
Also required for Slug and FoxD3 expression are Pax3 and Zic1 which 
act together in a Wnt dependent manner [27, 28]. Wnt-dependent Pax3 
regulation is also responsible for Sox10 expression which in turn is able 
to positively feedback on itself to maintain its own regulation [29]. Wnt 
signalling is also thought to directly activate the recently described neural 
crest specifier Gbx2. Gbx2 is considered to be the earliest factor in the 
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specifying cascade as it acts upstream of both Pax3 and Msx1. It 
functions in the posteriorization of the neural folds indicating a novel but 
essential role for this in neural crest specification [30]. Sox9 expression 
has recently been shown to be controlled by the binding of chromo-
domain helicase DNA binding domain 7 (CHD7) and polybromo-and 
BRG1 associated factor containing complex (PBAF) with a neural crest 
specific enchancer [31].  
Neural crest specifiers can be separated into two groups; early NC 
specifiers and late NC specifiers. The expression of early neural crest 
specifiers is first identified at the neural plate border. These include c-
Myc, Id3 and Snail. The expression of late neural crest specifiers is first 
seen in pre-migrating neural crest and is maintained throughout 
migration. These include Slug, FoxD3 and members of the SoxE family 
such as Sox10 [32]. It has been suggested that early neural crest 
specifiers such as c-Myc and Id3 may have a role in maintaining neural 
crest cell multipotency and proliferation through control of the cell cycle 
by maintaining a balance between cell death and proliferation during 
neural crest cell fate determination [33-35]. Id3 functions downstream of 
c-Myc and so loss of function experiments involving either of these genes 
results in a loss of NC progenitor cells. Overexpression of Id3 has been 
shown to promote the maintenance of the NCCs multipotent potential and 
so it is implicated to act as a switch in the cell cycle which will decide 
whether the NCC proliferates or dies [33-36]. Prohibitin1 has also 
recently been shown to act downstream of c-Myc to inhibit the 
transcription factor E2F1 and in doing so promotes the expression of 
FoxD3, Slug and Twist [1].  
Neural crest progenitors are also thought to be held in their 
multipotent stem cell-like state due to the active influence of epigenetic 
factors. These epigenetic influences occurring at the chromatin level 
include histone modifications such as methylation and demethylation. 
Such modifications are thought to keep the neural crest genes in a 
poised state ready for transcription. Trimethylation of histone H3 on 
lysines 4 and 36 (H3K4me3 and H3K36me3) is associated with 
transcriptionally active genes. Conversely trimethylation of histone H3 on 
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lysines 9 and 27 (H3K9me3 and H3K27me3) is associated with 
transcriptionally repressed genes. The histone demethylase JumonjiD2A 
(JmjD2A) is capable of removing H3K9me3 and H3K27me3 to control 
neural crest genes including Slug and Sox10 in vertebrates [37]. Recently 
the Polycomb repressive complex 2 (PRC2) have been shown to repress 
trimethylation of H3K27me3. Interactions of Polycomb with the Jumonji 
and ARID-domain containing protein (JARID2) promotes the interaction 
of PRC2 with H3K27me3. This interaction has been shown to be crucial 
in the correct differentiation of embryonic stem cells [38]. Similar 
interactions of polycomb associated proteins have been implicated in 
neural crest cell specification [39, 40].  
1.2.3 Neural crest cell migration 
Once NCCs have been specified they undergo an EMT in order to 
migrate away from the dorsal neural tube and reach their destinations 
where they will differentiate (figure 1.3).  Neural crest will migrate in four 
main streams; those of the enteric neural crest which will migrate into the 
gut, the cardiac neural crest which migrate to the heart loops, the 
cephalic neural crest which migrate anteriorly and the trunk neural crest 
which migrate down the trunk of the embryo [41]. It is still unclear as to 
whether neural crest cells lose their multipotency before or after they start 
to migrate. Recent data have shown that most neural crest cells 
differentiate after migration however there are some, which do not [42]. 
However, other recent studies have disputed this, claiming that all NC 
cells are still multipotent before migration occurs [43].  
EMT involves cytoskeletal, adhesive and cell junction 
modifications orchestrated by a network of transcription factors such as 
Snail, FoxD3 and Slug [44]. Slug plays a crucial role in EMT as it is 
responsible for changing cell adhesion molecules and cell junctions to a 
more migratory phenotype [45, 46]. In order for EMT to occur, NCCs 
must lose their apical-basal polarity and tight-junctions to allow them to 
detach from the neuroepithelium [44]. The type of cadherin expressed on 
the surface of NCCs is important during EMT. The cells will undergo a 
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switch from type I to type II cadherins to reduce the cells adhesiveness 
and increase motility [47]. E-cadherin expressed in neural crest cells is 
downregulated by direct binding of Snail to the promoter [48]. Similarly, 
type I cadherins N-cadherin and cadherin-6b are downregulated by 
FoxD3 and Slug [46]. Conversely type II cadherin-7 is upregulated by 
Sox10 and FoxD3 activity [47]. Snail is also responsible for regulating the 
repression of claudins resulting in the loss of tight junctions in NCCs. The 
loss of tight junctions allows NCCs to migrate from the dorsal neural tube 
and is associated with an upregulation of gap junctions [49, 50].  
In order for neural crest cells to migrate effectively they must 
remodel and invade the extracellular matrix. NCCs are able to migrate 
through a combination of collagen, fibronectin, proteoglycans and laminin 
due to the activity of intrinsic matrix metalloproteases (MMPs) both 
secreted and membrane bound. NCCs can tightly regulate MMP activity 
themselves by the release of tissue inhibitors of MMPs (TIMPs) [51]. 
MMPs recorded to be involved in NCC migration include MMP2 in cardiac 
NCC migration and a disintegrin and metalloprotease-10 (ADAM10) in 
cornea development [52, 53]. In Xenopus, ADAM13 has also been shown 
to play an important role in NCC detachment from the neuroepithelium 
and subsequent migration [54]. Membrane bound MMP-14 and 15 have 
been identified in migrating cranial and trunk neural crest cells [55]. 
 Whilst the NCCs are migrating they also undergo a large amount 
of cell division, which must be tightly regulated. NCCs are held in the G1 
phase of the cell cycle until they migrate and undergo the transition to S 
phase controlled by BMP dependent Wnt signals orchestrating cyclin 
levels [56]. It is thought that the decrease in Snail expression after 
delamination allows cyclin levels to increase and therefore promotes cell 
cycle progression. Pre-migratory cells which still have high Snail 
expression levels also show a reduced level of cyclin D1 and D2, 
important for cell cycle progression from G1 to S. These cells also have 
high levels of p21, an inhibitor of cyclin dependent kinases (CDKs) [57]. 
In order for neural crest cells to migrate effectively there is a type 
of cross talk between the neural crest cells and other surrounding cells. If 
one neural crest cell comes into contact with another it will repolarise due 
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to activation of the non-canonical Wnt pathway and migrate in a different 
direction. This is known as contact inhibition locomotion (CIL) [58, 59]. 
Despite this, large numbers of neural crest cells manage to migrate 
alongside each other in a continuous direction. This is because repulsive 
forces of CIL are balanced with attractive forces between neural crest 
cells due to the expression of chemoattractant C3a and the C3a receptor 
on their cell surface [60].  
1.2.4 Neural crest differentiation 
Neural crest terminal differentiation occurs due to specific groups 
of neural crest specifying transcription factors regulating specific effector 
genes which will in turn give the cell its fully differentiated properties and 
characteristics (figure 1.4). NCC differentiation is thought to be both 
spatial and temporally regulated. If a neural crest specifier i.e. Sox10 
plays a role in the cell’s differentiation it will continue to be expressed 
past NC specification in the migrating NCC. Sox10 is seen to be 
expressed in premigratory NC fated to become melanophores and 
Figure 1.3: Neural crest migration. Neural crest migrate after undergoing EMT which 
occurs due to a switch from tight junctions to gap junctions. Neural crest streams shown 
here in purple, migrate into four areas. Enteric neural crest will migrate into the gut. Cardiac 
neural crest into the heart loops. Trunk nural crest migrate past the somites and Cephalic 
neural crest into the head to form neural crest cranial structures such as the branchial 
arches. Retrieved from [41] 
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neurons but continues to be expressed in these differentiated cell types 
to upregulate the appropriate effector genes [2]. Taking NCC 
differentiation into melanophores as an example, SOX10 will act to 
upregulate microphtalmia-associated transcription factor (MITF) which in 
turn will regulate dopachrome tautomerase (Dct) expression. Dct is an 
enzyme which is used by melanophores to synthesise melanin [61, 62].  
Conversely certain factors are responsible for repressing the 
expression of genes specific to NC lineages to promote cells going down 
a different lineage. For example FoxD3 can repress MITF expressed in 
melanophores to cause a lineage switch to glial cells [63]. The 
differentiation of other cell types is due to a similar temporal regulation by 
genetic hierarchies shown in figure 1.4. Neural crest determination also 
requires the presence of specific ligands. In order for melanophores to 
maintain their cell fate and survive they require interaction of receptors on 
their cell surface with specific ligands. In mammalian melanophores these 
include the c-kit receptor and Endothelin receptor B signalling [64].  
There are two main streams of NCCs; those migrating cranially 
and those migrating in the trunk. Cephalic NCCs give rise to many cranial 
structures including bone, cartlilage, tendons and tissues of the ear, eye 
and teeth. They will also give rise to cranial melanophores and neurons. 
Trunk NCCs follow one of three paths, which in turn determines their cell 
Figure 1.4: Neural crest differentiation. Neural crest cell differentiation is regulated by a 
network of specifying genes such as members of the SoxE family which will in turn 
promote the expression of effector genes able to induce the cells to undergo terminal 
differentiation. This terminal differentiation leads to cell types including smooth muscle, 
cartilage, bone, pigment cells, sensory neurons, glia and adrenal cells. Retrieved from [41]  
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fate [41]. The first wave of NCCs will move ventrally to form sympathetic 
neuron progenitors. The intermediate wave will migrate to the anterior 
sclerotome to form peripheral neuron progenitors and the final wave will 
migrate beneath the epidermis to form melanophores [65].  
1.2.5. Melanophores 
Melanophores are a neural crest derived cell type which function 
critically to protect organisms from damage caused to DNA by ultraviolet 
light [66]. They are capable of producing and transferring melanin to 
surrounding cells to give varying pigmentation patterns in vertebrates. 
Amphibians and fish contain melanophores which can rapidly change in 
pigmentation to allow the organism to adapt to its surrounds, evade 
predation and encourage sexual selection [66]. Mitf plays a key role in 
melanogenesis and is often referred to as the master regulator of the 
process. Its expression can be detected in the melanoblasts during their 
migration from the neural tube indicating that it plays a role in 
Figure 1.5: Melanophore development. Neural crests migrating along ventral (blue) 
and dorsolateral (red) pathways are specified by various transcription factors. 
Melanophores are formed from neural crests migrating along the dorsolateral pathway 
and are specified by transcription factors shown here. Retrieved from [68] 
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melanophore specification and survival (figure 1.5) [67]. Mitf mutants 
have been shown in mice and chicks to result in pigmentation defects. It 
has been determined to upregulate many genes involved in 
melanogenesis including tyrosinase and tyrosinase related protein 1 
(Tyrp-1) [68]. Mitf itself is upregulated in melanophores by Wnt3a which is 
expressed in the dorsal neural tube during neural crest migration. 
Another important signal in melanophore development is that of the Kit 
receptor and its ligand KitL. Mutations in these have been identified to 
cause pigmentation disorders [68]. Heterozygous Kit mutations in 
humans is the cause of the disorder piebaldism. Kit receptor activation by 
KitL results in a signal cascade which results in the phosphorylation of 
Mitf, increasing its transcriptional activity [68].  
Endothelin signalling also plays a role melanophore development 
and migration. It is currently thought that Edn-3 signalling interacts with 
the Kit receptor signal cascade in mammals to promote melanoblast 
differentiation [68]. In chick EdnrB1 has been shown to be expressed in 
early neural crest [69]. When these differentiate into melanophores this 
EdnrB1 expression is replaced by EdnrB2 expression. It has also been 
demonstrated that the Edn3 ligand which binds specifically to EdnrB2 is 
expressed in the ectoderm at the same stage of pigment cell 
development [69, 70]. Additionally, experiments in chick have shown that 
knocking down EdnrB2 significantly reduces the number of 
melanophores present [71]. 
 
1.2.6. Neural crest and melanoma 
Melanomas are considered to be extremely aggressive malignant 
tumours which arise from the neural crest derived melanophores 
predominantly found in the epidermal basal layer. Mortality rate due to 
melanoma tends to be high due to the cancer’s ability to resist most 
chemotherapies. Melanoma is often fatal if diagnosed too late and may 
arise due to all manners of genetic and environmental factors but are 
most commonly associated with increased ultraviolet light exposure. 
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Many of the genes which are seen to promote neural crest and 
melanophore development are also often misregulated in melanoma[72]. 
Fully developed melanomas are able to grow vertically invading the 
basement membrane where they can metastasise and spread throughout 
the body [72, 73]. The most common mutation found in melanomas are 
those of the BRAF oncogene. 60% of melanoma cases have mutations in 
this gene. The most common mutation results in a V600E substitution 
causing a 700-fold increase in BRAF kinase activity [72]. Melanomas 
resembling those found in humans can be induced in p53 loss of function 
zebrafish by expressing the BRAFV600E  mutation using a Mitf promoter. 
This gives evidence for the role of this mutation in melanoma formation 
[74].  
Several genes involved in neural crest development are implicated 
in melanoma formation. These include Mitf which may be overexpressed 
in melanoma to promote tumour cell survival and cell cycle progression 
[75]. C-Kit may be overactive in rare acral and mucosal melanomas [76]. 
Slug is thought to play a role in melanoma tumour cell metastasis as Slug 
knockdown in melanoma cells has shown decreased cell migration 
associated with only moderate primary tumour formation [72, 77]. 
Endothelin receptor B (ENDRB) is found to be overexpressed in many 
human melanomas. This may act to increase Snail expression and 
therefore the tumours invasive potential [78]. It is also thought that 
ENDRB overexpression leads to increased BRAF activity [72]. Neural 
crest specifiers Sox9 and Sox10 have similarly been shown to be 
expressed in advanced melanoma and are considered prognostic 
markers of melanoma aggressiveness [79].   
 
1.2.7. Cranial cartilage development 
 Vertebrates are able to form facial structures such as the jaw and 
pharynx due to the differentiation of cranial neural crest cells into 
branchial arch cartilage. Cranial neural crest cells form at the anterior 
dorsal neural tube and migrate into the branchial arches where they are 
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able to form cranio-facial cartilage. These neural crest migrate in three 
streams; the mandibular, hyoid and branchial streams (figure 1.6) [80, 
81]. NCCs migrating into the mandibular arch will form Meckel’s and 
palatoquadrate cartilage which gives rise to the jaw [82]. The hyoid arch 
will go on to form skeletal structures able to support the jaw and tongue. 
Finally the branchial arches will form skeletal support for the gills and 
throat [81]. Neural crest are patterned into these three tissue types due to  
Hox gene expression such as Hoxa2 which is thought to be expressed in 
the crest of the branchial regions [83].  
 Cranial neural crest differentiate into cartilage derivatives due to 
expression of Sox9. This SoxE family member will bind to the 
chondrocyte enhancer of the collagen type 2 (Col2a1) to promote 
cartilage production. Mutations in the Sox9 gene result in a loss of 
branchial cartilage and are associated with congenital jaw defects [84].  A 
hierarchy of Runx gene expression (Runx1, 2 and 3) is then required for 
chondrocyte maturation into cartilage [85]. Endothelin-1 and endothelin 
receptor a (Ednra) signalling is also known to be important for pharyngeal 
arch dorso-ventral patterning. The receptor is expressed in the migrating 
crest of the pharyngeal arches and the ligand is produced by the 
Figure 1.6: Cranial neural crest migration and differentiation. Cranial neural crest 
cells will migrate into 3 regions of the embryonic face. The mandibular region (yellow) 
which will go on to form the meckel’s cartilage (M) and palatoquadrate cartilage (Q).  
The hyoid region (blue) will form ceratohyal cartilage (C). The branchial region (pink 
and purple) will give rise to the ceratobranchial cartilages (G) Retrieved from 
reference [81]  
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surrounding mesoderm. Endothelin-1/Ednra signalling is known to further 
regulate the transcription factor Dlx6 which is also important for 
pharyngeal arch patterning [86, 87].  
1.2.8. Sensory neuron development 
 Sensory neurons are the neurons of the peripheral nervous 
system, which respond to external stimuli such as touch or heat. They are 
known as the dorsal root ganglia in the trunk of the embryo and the 
trigeminal ganglia in the head. NCCs of the trunk will migrate between the 
somites to form the dorsal root ganglia [88]. Sensory neurogenesis is 
thought to be stimulated by Wnt signalling. Treating NCCs with Wnt1 can 
induce sensory neuron differentiation [89]. Transcription factor signalling 
also plays a key role in sensory neuron differentiation. The first factors 
involved are those of the neurogenin family. Neurog1 and 2 are 
expressed in the migrating cranial and trunk neural crest fated to form 
sensory neurons and drive sensory neurogenesis [90-92]. 
 Brn3a and Islet1 are transcription factors, which are also thought to 
regulate sensory neurogenesis. Loss of either of these leads to a 
reduction in sensory function [93, 94]. They are able to promote sensory 
neuron differentiation by their binding and upregulation of other genes 
expressed in differentiated sensory neurons. These genes are the Runx 
family genes, which regulate the final maturation of sensory neurons [95]. 
Runx1 promotes the differentiation of nociceptors, the class of neuron, 
which respond to external stimulus leading to pain. Runx3 will promote 
the differentiation of proprioceptors, the class of sensory neuron 
responsible for tactile stimulus and the space in which you are occupying 
[96, 97].  
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1.2.9. Cranial sensory placode development and neural crest 
 Cranial placodes develop alongside neural crest (figure 1.7A) to 
give rise to sensory organs such as the nose, lens of the eye, ear and 
sensory neurons of the cranial region. Placodes form from thickenings of 
the ectoderm and are patterned based on their anterior-posterior position. 
These placodes are the adenohypophyseal, olfactory, lens, trigeminal, 
profundal, otic and lateral line placodes [98-101]. Both neural crest and 
placodes develop at the neural plate border and have a multipotent 
potential to differentiate into various cell types. Placodes will form from a 
multipotent precursor region known as the preplacodal region and from 
here they will undergo morphogenesis or invaginate to produce the 
different placode types [102, 103]. By the end of neurulation (stage 21) 
Xenopus embryos will have 3 placodal regions. The most anterior 
placode region contains the adenohypophyseal and olfactory placodes. 
The next region at the edge of the presumptive eye contains the 
trigeminal  and profundal placodes. The most posterior region contains 
the otic and lateral line placodes (Figure 1.7B). These placodes along 
with the lens placode continue to develop into tailbud stages of Xenopus 
development (Figure 1.7C) [104, 105].  
Figure 1.7: Placode development in Xenopus. (A) At stage 14 the presumptive neural 
crest and placodes develop alongside each other at the neural plate border. (B) At stage 21 
placodes develop close together but are separated into the different placode types. Neural 
crest are shown as dashed lines. (C) At stage 27 placodes are spread out and defined by 
their anterior posterior position. VII facial epibranchial placode, IX glossopharyngeal 
epibranchial placode, X1 first vagal epibranchial placode, X2/3 second and third vagal 
epibranchial placodes, AD anterodorsal lateral line placode, AV anteroventral lateral line 
placode, L lens placode, LL lateral line, Ot otic, EB epibranchial, M middle lateral line 
placode, Ot otic placode, Ol olfactory placode, P posterior lateral line placode, Pr profundal 
placode, V trigeminal placode. Retrieved from reference [98]  
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 The adenohypophyseal placode will invaginate to form the 
anterior lobe of the pituitary gland, important for hormone secretion in 
most vertebrates [106-109]. The olfactory placode will invaginate to form 
supporting, mucus secreting cells and chemoreceptive axons, which 
respond to odorants of the nasal cavity [110, 111]. The lens placode will 
form the crystallin producing cells of the eye [112-114]. Trigeminal and 
profundal placodes form the sensory cranial ganglia along with neural 
crest cells. These ganglia will respond to somatosensory stimulis such as 
heat or touch [115-117]. The otic placode will differentiate into the 
vestibulocochlear ganglia of the inner ear, which will innervate 
mechanosensory hair cells [118, 119].  Lateral line placodes will form 
lateral line sensory neurons, which can respond to electrical currents or 
mechanosensory stimulus [120-122]. Finally, epibranchial and 
hypobranchial placodes give rise to facial and vagal sensory neurons, 
which ennervate receptors such as taste bud [123, 124].  
 Many transcription factors have been shown to be important for 
placode development, some overlapping with those important for neural 
crest development [103]. Six1/2, Six4/5 and Eya genes are panplacodally 
expressed in the pre-placodal ectoderm. Mutations in these genes are 
associated with placode defects [104, 125]. As development proceeds 
other transcription factors are upregulated based on the anterior-posterior 
postion of the placode to define specific placode types. These include 
Otx2, expressed in the adenohypophyseal, olfactory, and lens placodes 
[126, 127]. Emx genes are restricted to the olfactory and otic placodes 
where they promote proliferation and differentiation [128, 129]. Six3/6 are 
expressed in the anterior neural plate where they inhibit Wnt and BMP to 
promote the development of adenohypophyseal, olfactory, and lens 
placodes [130-133]. Tbx genes are placode specific, Tbx1 is expressed in 
the pharyngeal pouches, pharyngeal arches the otic placode. Tbx2 is 
expressed in the trigeminal and profundal placodes and also the posterior 
placodes forming dorsal root ganglia [104]. Finally Pitx genes play an 
important role in lens and adenohypophyseal development [134, 135].  
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 As mentioned, neural crest and placodes develop alongside each 
other and have similar evolutionary origins. This has resulted in some 
overlap in the transcription factors required for the development of these 
two cell types. Msx genes are expressed in the early neural crest and the 
preplacodal areas of the anterior neural plate border where they act to 
pattern the anterior ectoderm [136, 137]. Pax3 and Pax7 are both 
expressed in the neural plate border and are important for the 
development of both neural crest and the profundal placodes which both 
form cranial senory ganglia [104, 138]. Interestingly, c-Myc is implicated 
to not only regulate the expression of neural crest markers such as 
Sox10 but it has also been shown to be important for placode 
development [139]. Morpholino knockdown of c-Myc in Xenopus results 
in a loss of cranial ganglia derived from trigeminal neurons implicating the 
importance of c-Myc in trigeminal placode development [33, 103].  It has 
also been shown that Six1 and Eya are able to stimulate c-Myc 
expression [140].  
 Both placodes and neural crest will produce migratory cell types, 
which can form the cranial sensory glia (figure 1.8) [141]. There are both 
similarities and differences in the induction of these two cell types. They 
both form at the neural plate border however placodes are restricted to 
the anterior neural plate whilst neural crest can also form in the trunk 
[141]. It is also known that there is a temporal difference in their 
specification. Neural crest are thought to be specified at the neural plate 
border before placodes [142, 143]. As both cell types form in the same 
region of the embryo it is not unexpected that the inductive signals for 
both are very similar. Both cell types receive these signals from the 
adjacent ectoderm and the underlying mesoderm. However slight 
differences allow for these distinct cell types. Signals from the paraxial 
mesoderm signal to neural crest whereas signals from the dorsal lateral 
plate mesoderm signal to presumptive placodes [19, 144]. It is known 
that the signals from this mesoderm important for neural crest induction 
are Wnt, FGF and an attenuated BMP signal.  The signals important for 
placode development are similar but not the same. It is unclear whether 
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 BMP signals are important for placode development but studies 
removing BMP from the area of the presumptive placode have shown 
that the placodes will still develop indicating that BMP is not important in 
placode development [144]. FGF signals will switch on the transcription of 
Msx1, Zic1, Pax3 and Sox9, which are important in the development of 
both neural crest and placodes. These will upregulate different genes in 
these different cell types due to the presence of different co-factors 
present in turn promoting the divergence of the two cell types [141]. Wnt 
Figure 1.8: Cranial placode and neural crest development. Both placodes and neural 
crest will form migratory cell types capable of forming many different derivatives. These 
derivatives even overlap sometimes as both placodes and crest are capable of producing 
sensory neurons and glial cells. Adapted from reference [141]  
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is important for both placodes and neural crest as it acts to inhibit placode 
induction and stimulates neural crest development. Placodes are able to 
form in the anterior most neural folds as Wnt inhibitors are secreted here  
blocking neural crest induction [22, 27, 144].  
 
1.3. Chemical genetics 
1.3.1 Chemical screens 
Chemical genetic screens utilise small organic molecules (less 
than 2000 Da) to alter the function of specific genes and so determine 
their role in developmental processes. They are easy to set up, cheap to 
run and can be used to target a specific gene at a specific time point by 
adding or taking the compound away. Screens can be used for high-
throughput phenotype analysis to uncover novel drugs and drug targets 
with therapeutic potential for a whole manner of diseases. The use of 
small vertebrates such as the Xenopus or Zebrafish is advantageous 
over the use of mammalian models as they provide a cost effective way 
to discover new drugs, their targets and test their toxicity levels [145, 
146]. Amphibians can be used successfully in chemical screens due to 
their transparency which makes phenotypic analysis easier, their fast 
development time and production of thousands of eggs at any one time 
which makes the process high-throughput and their ability to take up the 
compounds from their surrounding media [145]. Xenopus embryos have 
been used in chemical screens for these reasons mentioned. The vast 
number of Xenopus embryos which can be collected are also small 
enough to fit in a 96-well plate. Here the compounds can be added to the 
salt media the embryos will grow in optimally and can be easily absorbed 
past the permeable vitelline membrane and through the Embryo 
epidermis [145, 147].  
1.3.2. Leflunomide 
 Leflunomide is an inhibitor of dihydroorotate dehydrogenase 
(DHODH), which was shown to be a compound capable of altering 
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pigment development after a chemical screen carried out in Xenopus 
laevis and Zebrafish. During this screen of 2000 different compounds, 
NSC210627 was identified to inhibit pigment cell development in 
Xenopus and Zebrafish. The chemoinformatic DiscoveryGate algorithm 
was used to identify compounds with a high level of structural similarity. 
This led to the identification of Brequinar, an inhibitor of DHODH. 
Leflunomide is structurally dissimilar to brequinar but also inhibits 
DHODH and phenotypically mimics the affect of NSC210627 [3]. As 
Leflunomide is cheaper, readily available and already FDA approved as 
an arthritis treatment it was selected for further experiments. DHODH is 
an enzyme responsible for pyrimidine synthesis and is therefore required 
for RNA transcription and DNA replication. Leflunomide is therefore 
thought to act by inhibiting the transcription of genes involved in 
melanophore development [3, 4].  
Recent work in Zebrafish has shown that Leflunomide treatment 
causes an abrogation of melanophores 36-48h and iridophores 72h post 
fertilisation (figure 1.9). Leflunomide was also shown to reduce the 
expression of Sox10 and other genes expressed in neural crest and 
genes such as Dct and Mitf expressed in melanophores (figure 1.9) but 
was shown to have no effect on genes expressed in tissues such as 
blood or notochord [3]. Leflunomide has also been shown to reduce the 
number of neural crest cells in cell culture further suggesting this drug 
specifically affects the self renewal of this multipotent cell type [3]. As 
melanomas have been documented to adopt a similar genetic signature 
to that of the neural crest by expressing many of these genes involved in 
normal neural crest development and melanophore specification, it is 
thought that Leflunomide may have therapeutic potential for melanoma 
treatment [3]. Using a combination of leflunomide and a BRAFV600E 
inhibitor  (PLX4720) administered into mouse melanoma xenografts has 
been shown to block in vivo tumour growth [3]. 
Leflunomide is thought to carry out its function through the 
inhibition of transcriptional elongation by preventing the synthesis of 
pyrimidines. Leflunomide treated Zebrafish phenotypically mimic 
spt5/spt6 Zebrafish mutants. Spt5/spt6 is required for transcriptional 
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elongation to commence so it is thought that these mutants have 
increased levels of transcriptional pausing [3, 148]. Spt5 mutants also 
show an almost complete overlap of genes affected to that of leflunomide 
treated embryos. This includes a reduction of the expression of neural 
crest genes Sox10, Crestin and Mitf as shown by microarray. Work 
carried out in human melanoma cell lines showed leflunomide to 
specifically inhibit the transcriptional elongation of Myc target genes. This 
is of particular interest to us as Myc is implicated to play roles in both 
neural crest specification and transcriptional pause release in embryonic 
stem cells [6, 33, 36].  
1.4. Transcriptional elongation 
1.4.1. The process of RNA polymerase pausing and transcriptional 
elongation 
In order for genes to undergo transcription, RNA polymerase II 
(Pol II) must be recruited to the promoter region by certain DNA-binding 
transcription factors [149]. Subsequent to this RNA Pol II may undergo 
regulation to temporally control the expression of genes in specific cell 
types. Such regulation includes the promoter proximal pausing of Pol II 
Figure 1.9: The effect of leflunomide on Zebrafish. Top two images show that after 
leflunomide treatment zebrafish loose melanophores, a neural crest derivative, entirely 
when compared to the DMSO control. The bottom two images show neural crest 
progenitors using GFP regulated by a Mitf promoter. After leflunomide treatment there is 
a loss of these progenitors shown by the loss of GFP expression. Retrieved from [3] 
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(figure 1.10). This is the process by which Pol II undergoes stalling or 
poising at the 5’ end of a gene just downstream of the transcription start 
site [150]. This occurs due to the binding of pause factors DRB-sensitivity 
inducing factor (DSIF), negative elongation factor (NELF) and 
transcription factor IIS (TFIIS)  [151, 152]. NELF is able to bind to the 
clamp domain of RNA Pol II through associations with its NELF-A 
subunit. DSIF is composed of two subunits Spt5 and Spt6, mutations in 
which have both shown inhibition of transcriptional elongation [148, 153]. 
In order for transcriptional elongation to commence the positive 
transcription elongation factor, P-TEFb, must be recruited to the 
transcription elongation complex. P-TEFb is known to be a complex 
composed of cyclin dependent kinase 9 (CDK9) and cyclin T1 [154-156].  
The poised RNA Pol II is associated in a complex with both DSIF 
and NELF. To initiate transcriptional elongation, phosphorylation of the 
serine residues in positions 2 and 5 of the YSPTSPS repeat in the C-
terminal domain (CTD) of the large subunit of Pol II must occur. This 
phosphorylation of Pol II at the CTD and phosphorylation of the Spt5 
subunit of DSIF is carried out by P-TEFb to allow for transcription and the 
production of full length transcripts. After this phosphorylation, NELF 
dissociates from the complex and DSIF remains bound to RNA Pol II 
switching roles to promote transcriptional elongation [155]. Other general 
transcription factors TFIIF and TFIIS contribute to pause release. This 
pausing and subsequent elongation is known as transcription elongation 
checkpoint control (TECC) [157].  
  39 
Transcriptional pausing of subsets of genes has recently been 
shown to be a crucial step in regulating expression for normal 
development and also inappropriate regulation arising in diseases such 
as cancers [3, 158-160]. 30% of genes present in embryonic stem cells 
will undergo transcriptional pausing with no subsequent elongation. This 
would suggest the importance of polymerase pausing in maintaining 
stem-cell pluripotent potential and preventing the transcription of genes 
involved in differentiation. It is also now known that RNA Pol II can 
instigate transcription in both a sense and antisense direction. This may 
also indicate a role for polymerase pausing in the prevention of antisense 
transcription [6, 161].  
 
Figure 1.10: RNA polymerase pausing and transcriptional elongation. RNA Pol II is 
able to stall after transcription initiation 30-50 nucleotides downstream of the start site. 
Release from polymerase pausing is kick started by developmental and environmental 
signals. In the paused state Pol II is associated with both DSIF and NELF and the C-termial 
is phosphorylated only on serine 5. The P-TEFb complex is able to induce pause release by 
phosphorylating the serine 2 residue and also DSIF and NELF. NELF will dissociate from 
the complex and transcriptional elongation will commence.  
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1.4.2. The PTEF-b complex 
 In order for productive transcription to occur after polymerase 
pausing, the positive transcription elongation factor complex (P-TEFb) 
must be recruited. This complex is highly conserved from yeast all the 
way up to humans and localised in the cell nucleus. Like most cyclin 
dependent kinase arrangements it consists of a CDK acting as the 
enzymatic functional subunit and a cyclin subunit which will undergo a 
conformational change to promote the activation of the kinase[162]. The 
CDK common to all P-TEFb complexes is CDK9. This itself must be 
phosphorylated at the Thr186 of the T-loop region of CDK9 before kinase 
activity is fully activated[163].  
 It is crucial that the enzymatic activity of P-TEFb is tightly 
regulated to control the transcription of poised genes at the specific time 
they are required. P-TEFb has its own unique mechanism of doing this 
through its reversible binding with the 7SK small nuclear 
ribonucleoprotein particle (snRNP) (figure 1.11). P-TEFb can be found 
simultaneously in either an active or inactive state in the cell nucleus. It is 
inactive if bound to 7SK snRNP and will become active when rapid 
transcription is needed to occur by its recruitment into the super 
elongation complex (SEC) [162, 164].  
 Inactive P-TEFb is bound to the inhibitory domain of RNA binding 
proteins HEXIM1 or HEXIM2 (hexamethylene bisacetamide inducible 
proteins), which are in turn bound to 7SK snRNP. HEXIM1 and HEXIM2 
have been shown to be able to compensate for each other both in vitro 
and in vivo. They act by inhibiting the P-TEFb function and so are 
considered to be entirely novel CDK inhibitors (CDKI) as no other CDKIs 
interact with RNA to mediate inhibition[165-170]. La-related protein 7 
(LARP7) and methyl phosphate capping enzyme (MePCE) bind to the 
7SK snRNP complex to help stabilise its binding to P-TEFb [171-173]. 
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 The inhibitory complex formed between P-TEFb and 7SK snRNP 
means that P-TEFb activity is carefully regulated and its activity can be 
pinpointed to precise genes when it is required. This prevents the 
premature release of other poised genes which are not yet needed [162]. 
Details of how P-TEFb targets specific genes are still unknown. It is 
thought that P-TEFb can be directed by the different variety of 
transcription factors which can bind to it in response to numerous 
signalling cascades allowing it to incorporate into diverse forms of the 
super elongation complex increasing the specificity between P-TEFb and 
its gene targets [157]. Incorporation into the super elongation complex 
has been shown to enhance P-TEFb’s enzymatic activity [174]. 
Figure 1.11: Inhibition of P-TEFb by binding to 7SK snRNP.  7SK snRNP is 
found bound in a complex with LARP7 and MePCE. PTEF-b will only bind to this 
and become inactive if HEXIM is present and bound to the 7SK snRNP. HEXIM 
bound to 7SK snRNP has its inhibitory domain revealed allowing P-TEFb to bind. 
Retrieved from reference [163] 
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1.4.3. Regulation of the productive elongation phase. 
 Upon activation of P-TEFb, the complex will phosphorylate 
NELF and DSIF causing NELF to dissociate from RNA Pol II allowing 
transcription elongation to occur. DSIF is retained in the RNA Pol II 
complex switching roles from inhibiting the productive elongation phase 
to promoting it [6]. Once P-TEFb has phosphorylated its targets it is no 
longer required and can be sequestered in its inactive state.  Elongation 
is then regulated by transcription factor IIS (TFIIS) and the rate of 
elongation is maintained by transcription factor IIF (TFIIF) [162, 175]. 
These factors both play a key role in regulating transcription arrest. If 
RNA Pol II is held in a paused state for too long it will enter into arrest. 
This can occur if the amount of nucleoside triphosphates available is 
limited [176].  
 TFIIS is able to save arrested Pol II by promoting the cleavage 
of the arrested RNA transcript allowing it to form a new 3’ end which is 
reinserted into the RNA Pol II active site and transcription can continue 
from here[175]. TFIIS depletion in Drospophila by RNAi has shown that 
there is no effect on global gene expression however it does seem to 
have an effect on specific actively transcribed genes such as those 
encoding for heat shock proteins. These will remain in a paused state 
following TFIIS depletion [177, 178]. TFIIS will then act to sustain the rate 
of transcription elongation [179]. TFIIF will bind to the paused Poll II 
altering its conformation to an elongation competent one [162]. TFIIF has 
been shown to bind to human genes before the transcription initiation 
start site and also on specific elongating genes downstream of the 
promoter in the transcribed regions. This suggests a role for TFIIF in both 
initiation and elongation of RNA transcripts[180].  
 In order for productive elongation to occur it is also necessary that 
histone modifications occur. RNA Pol II is found to associate with PAFc 
(RNA polymerase associated factor c) a protein capable of the 
methylation of H3K4 and H3K79. This association occurs due to a 
complex which forms between the SEC and PAFc. H3K4 and H3K79 are 
positive methylation marks and are associated with actively transcribing 
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genes[181]. It is also able to remove histone modifications associated 
with polymerase pausing such as H2B by ubiquitination. PAFc itself is 
made up of several individual components; Paf1, Ctr9, Cdc73, Rtf1, and 
Leo1[181, 182]. PAFc itself has no enzymatic activity and so it relies 
upon recruiting enzymes such as Rad6 for ubiquitination and SET for 
trimethylation of histones [183-187]. This provides a link between 
transcriptional elongation and histone modification. PAFc itself only acts 
as an adaptor complex bridging the gap between methytransferases and 
RNA Pol II. It has also been shown to be in a complex itself with the SEC, 
P-TEFb and other Pol II associated factors such as DSIF and TFIIS[188-
190]. CHIP-seq experiments have shown that PAFc is found all along the 
length of genes when in an actively transcribed state. A peak 
representing PAFc is also found at the 3’ end indicating a potential role 
for PAFc in 3’ mRNA bio-genesis [182, 191].  
1.4.4. The super elongation complex (SEC) 
When P-TEFb is in its active form it is usually within a collective of 
several proteins known to regulate transcriptional elongation. This 
combined complex is known as the super elongation complex (SEC) 
(Figure 1.12). In addition to housing the active P-TEFb complex it has 
also been shown to contain ELL-1 and ELL-2 (eleven-nineteen lysine-rich 
leukemia 1 and 2), ENL, AF9 (ALL1-fused gene from chromosome 9), 
AFF1 (AF4/FMR2 family, member 1) and AFF4 (AF4/FMR2 family, 
member 4)[192, 193]. Each SEC will contain a different combination of 
these extra proteins depending on the gene upon which they are acting. 
For example it is known that the different ELL proteins can compensate 
for each other, as can the AFF proteins [194]. AFF proteins act to hold 
the complex together, supporting the formation of the SEC[157]. 
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These complexes are recruited to the promoter region of genes 
when rapid transcription is required in response to specific developmental 
signals, changes to available nutrition or even acute temperature change. 
It is because of this that the genes primarily regulated by RNA 
polymerase pausing are master regulator genes and/or rapid response 
genes such as heat shock and serum inducible genes [157, 195]. The 
recruitment of the SEC to paused polymerases has been demonstrated 
using chromatin immunoprecipitation (CHIP) sequencing in embryonic 
stem (ES) cells. One experiment showing this very clearly used retinoic 
acid to induce retinoic acid inducible genes in ES cells and observing the 
SEC components recruited to the promoters of these genes. It is this 
recruitment of the SEC which is thought to be responsible for the rapid 
transcription induction of such genes [196]. 
It has also been suggested that the main function of SEC 
recruitment to paused genes is not necessarily to allow rapid induction 
but also to increase the amount of synchronicity between genes in 
Figure 1.12: The super elongation complex (SEC). In mammals the SEC is 
comprised of  the positive transcription elongation factor b complex (P-TEFb) A 
member of the AFF family usually either 1 or 4. One of the eleven-nineteen lysine-rich 
leukemia (ELL) proteins, ENL and AF9. These are also associated with RNA 
polymerase associated factor c  (PAFc) via the YEATS domain of AF9. When 
associated with the SEC, P-TEFb is active and able to phosphorylate the C terminal 
domain of RNA Pol II, DSIF and NELF allowing NELF to dissociate and positive 
transcription elongation to occur. Retrieved from reference [163]. 
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development. Work using Drosophila has shown that during embryonic 
development some genes termed ‘synchronous’ genes will have a 
paused pol II at the promoter. These genes, for example short 
gastrulation (sog), tended to be those found in complex gene regulatory 
networks. Other genes did not show this necessity for paused pol II. 
These were termed stochastic genes and they demonstrated erratic and 
unpredictable gene expression, for example thisbe (ths) (Figure 1.13) 
[197]. Convincing studies have shown that pausing is important and 
present on rapidly induced genes and also on those considered master 
regulator genes whose expression is tightly regulated. One study using 
Drosophila has shown that genes known to be rapidly induced such as 
antibacterial genes do not have a paused pol ll. However genes involved 
in the careful regulation of the fly’s innate immune system, will undergo 
pausing [198]. It is therefore still unknown exactly which gene types 
pausing is crucial for the expression of.  
Figure 1.13: Stochastic and synchronous gene expression. In-situ hybridisation 
experiments in drosophila clearly demonstrate a less organised early expression pattern 
for genes such as thisbe which have no paused Pol ll at the promoter. Conversely, those 
genes thought of as tightly regulated as they play key roles in complex gene regulatory 
networks showed a more uniform expression pattern. An example of this is short 
gastrulation shown here. Retrieved from [198]. 
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Most evidence for a paused RNA polymerase II has come from 
ChIP sequencing experiments carried out in embryonic stem cells. Such 
experiments were the first to show that a paused polymerase associated 
with the components of the SEC can be recruited consistently to 
embryonic stem cell genes [196]. Two genes which have specifically 
been shown to have a paused RNA polymerase associated with them are 
the c-Myc gene and the heat shock protein hsp70. Recruitment of the 
SEC to these genes occurs via the N terminal domain of a mediator 
protein subunit known as Med26 (figure 1.14). Knockdown of Med26 
leads to a reduction in the amount of SEC associated RNA polymerase II 
found along the length of the two genes in human cell lines shown using 
ChIP sequencing. SEC components and the mediator complex can be 
found at 
Figure 1.14: Med26 recruits the SEC to RNA polymerase II. The N terminal domain of the 
mediator subunit Med26 will interact with TFIID associated with paused polymerases at the 
the promoter region. The induction of certain signals will promote the release of Med26 from 
TFIID allowing it to associate with the SEC via EAF and allowing positive transcription 
elongation to occur. Retrieved from reference [200]. 
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the promoter region of hsp70 prior to simulation by heat shock [199]. It 
was also shown in the same study that the knockdown of Med26 led to a 
reduction of serine 2 phosphorylation (associated with positive 
transcription elongation) on both the c-Myc and hsp70 genes indicating 
that Med26 is necessary not only for the recruitment of the SEC but also 
the regulation and maintenance of the positive transcription of these 
genes [199]. 
 The SEC complex combined with the P-TEFb complex is the most 
common active form of P-TEFb however it is not the only one. P-TEFb 
can also be found in a complex with bromodomain containing protein 4 
(Brd4) capable of directing and promoting the activity of P-TEFb [200, 
201]. Brd4 will bind to P-TEFb via its C terminal domain and then will bind 
to chromatin via the bromodomains found in the N terminal domain. 
These bromodomains specifically bind to acetylated histone H3 and H4 
[202]. This binding will occur at mid-late anaphase before other 
transcription factors are able to enter the nucleus. These will enter the 
nucleus at G1 phase of the cell cycle and so this is when transcription of 
P-TEFb dependent genes will occur [203]. Brd4 is also implicated in the 
transfer of epigenetic modifications or ‘epigenetic memory’ due to its 
ability to bind to chromatin at these early phases of the cell cycle [202].  
 It is known that both Brd4 and the SEC can associate with P-TEFb 
to allow it to carry out its function and promote transcription elongation. It 
is however unclear as to the differences between these two variations in 
the active form of P-TEFb [204]. Both forms have been shown in vitro to 
be capable of promoting transcription of paused HIV viral genes. The 
SEC containing P-TEFb in this example is considered the dominant 
version as the Brd4 containing complex is only capable of promoting a 
low level of viral gene transcription [201]. Brd4 containing complexes are 
not always considered as the true active form of P-TEFb. P-TEFb is 
usually recognized as fully active when it is in a complex with the SEC. It 
is only in the presence of P-TEFb that rapid induction of transcription can 
occur. An example of this uses the retinoic acid induced gene Homeobox 
A1 (HoxA1) [196]. HoxA1 remains in a paused state until retinoic acid is 
present in the cell. RNAi knockdown of SEC components show a 
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dramatic reduction in the transcription of this paused gene however 
knockdown of Brd4 has very little effect. This gives evidence for the SEC 
bound to P-TEFb being the dominant form of active P-TEFb [196]. 
Although it is quite likely that both will cooperate together to provide 
some redundancy. It is possible to separate out all three of the possible 
complex combinations associated with P-TEFb from the same cell 
samples. These complexes are; SEC/P-TEFb, Brd4/P-TEFb and the 
inactive HEXIM bound 7SK/PTEFb (Figure 1.15) [204]. 
 
 New components of the SEC and other proteins playing a role in 
polymerase pausing are still being discovered. An example of such 
proteins includes Gdown1, recently shown by ChIP-seq to associate with 
paused polymerases across the whole of the human genome. This 
protein was shown to bind to paused RNA Pol ll and stabilize this paused 
state by promoting the function of negative elongation factors NELF and 
DSIF [205]. Transcription termination factor TTF2 has recently been 
shown to associate with exonuclease Xnr2. These two proteins are 
localized to the start site of paused genes and are thought to promote 
premature transcription termination. This is because knockdown of these 
two proteins saw a shift of paused gene transcripts from the start site to 
the length of the gene body [206].  
Figure 1.15: The three forms of P-TEFb. All three of the possible forms of P-TEFb 
shown above can be found at any one time in the cell. On the left is the most 
commonly found and most active form SEC/P-TEFb. In the middle is another active 
form which shows less activity, the Brd4/P-TEFb conformation. On the left is the 
inactive form of P-TEFb found bound to HEXIM and 7SK-snRNP. Retrieved from 
[205]  
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1.4.5. P-TEFb and the SEC in development and disease 
 To date P-TEFb has been identified to play a role in many 
processes including cell differentiation, embryonic development and 
diseases such as cancer and HIV. The eleven-nineteen lysine-rich 
leukemia (ELL) component of the SEC is well characterized to associate 
with the mixed lineage leukaemia (MLL) gene. Mutations in this gene are 
commonly seen in many childhood leukaemias [207]. These mutations 
may arise in an MLL fusion protein and it is such fusion proteins which 
have been found to associate with the SEC [192]. The association of MLL 
with the SEC allows the misexpression of MLL target genes such as 
HoxA9 and HoxA10 (Figure 1.16a) due to a disruption in regulation of 
the expression at the transcription elongation checkpoint control (TECC) 
stage resulting in leukemogenesis [157, 208]. The SEC complex has 
been implicated in other cancers including ovarian cancer for which, 
Hexim1 was identified as a possible therapeutic target [209]. Similarly, 
Hexim1 has been identified as a prognostic marker of breast cancers. 
Hexim1 is able to bind to the estrogen receptor ERα inhibiting ERα 
dependent gene expression. Breast cancer patients have been found to 
have elevated levels of Hexim1 in their breast tissue compared to those 
with normal breast tissue [210, 211].  
 One disease model which uses RNA polymerase pausing to 
regulate gene expression extensively is that caused by the human 
immunodeficiency virus (HIV). The role of RNA polymerase pausing and 
transcription elongation in HIV has been well characterized for many 
years. It was the first system shown to use this transcription regulation 
and since has proven as a preferred model for further research into 
polymerase pausing [212, 213]. HIV is a lentivirus, which means that this 
virus does not rely solely on the host’s transcription machinery but will 
produce its own transcription proteins. In the case of HIV this is the 
transcriptional transactivator (Tat) protein [212].  Very early experiments 
were able to show that knockdown of Tat lead to HIV genes stalling close 
to their promoter region producing only short transcript, representing the 
phenomena now known as RNA polymerase pausing [213].  
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 It has since been shown that this occurs due to an association of 
Tat with the P-TEFb component cyclinT1 [214, 215]. Once Tat has 
associated with P-TEFb, HIV viral genes are transcribed as P-TEFb 
carries out its normal function of phosphorylating the negative elongation 
factor and releasing RNA polymerase from its paused state (Figure 
1.16b) [216]. Brd4, which will normally bind to P-TEFb in the host cell, will 
compete with Tat for the binding space on cyclinT1. Overexpression of 
Brd4 in HIV infected cells leads to a reduction in the amount of P-
TEFb/Tat complexes and therefore the amount of viral genes transcribed 
[217]. Affinity purification and mass spectrometry studies have shown that 
the P-TEFb found bound to Tat is also in a complex with AF4, ELL2, ENL 
and AF9. From this we can assume that the active P-TEFb used by the 
HIV is in a complex with the SEC [218, 219].  
 Paused polymerase II and transcription elongation is not just 
important for diseases. It is also found in several developmental genes 
and can therefore be considered to be important in the regulation of 
transcription coordination of synchronous gene expression during 
development in certain cell types. So far studies of this have mainly been 
using embryonic stem cells and Drosophila as models [196, 220]. 
Genome wide studies in embryonic stem cells have revealed that Hoxa 
genes such as Hoxa1 had paused polymerases at their promoter regions 
shown using ChIP-seq. This was not seen on other Hox genes such as 
the Hoxb genes including Hoxb1. The developmental stimulus, retinoic 
acid caused recruitment of the SEC to the promoter of Hoxa1 and this 
resulted in rapid transcription. This was not seen for Hoxb1 which 
underwent relatively slower transcription activation [196].  
 Both Hoxa1 and Hoxb1 have been shown to regulate the 
development of cranial neural crest and the hindbrain [221]. Hoxa1 is the 
most anteriorly expressed Hox gene and its expression appears more 
rapidly than that of Hoxb1 [222]. Hoxa1 expression is induced in the 
presence of retinoic acid due to a retinoic acid response element (RARE) 
found at its 3’ end. After its own induction Hoxa1 will bind to the 
autoregulatory region of the Hoxb1 5’ end causing subsequent activation 
of Hoxb1 transcription [223, 224]. Hoxa1 is therefore a direct target of the 
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SEC and Hoxb1 expression is a secondary target explaining why a 
reduction of both genes can be seen after inhibition of Cdk9 in ES cells 
[196].  
 This study using retinoic acid stimulation to induce transcription of 
Hoxa1 also revealed other genes which similarly held a paused pol ll at 
the promoter region and then recruited the SEC to promote rapid 
transcription. These included the serum inducible genes c-Fos, c-Jun and 
early growth response gene (EGR), which have previously been 
implicated to undergo pausing in several studies using mouse and 
human cell lines [225-227]. c-Fos and c-Jun together form the activator 
protein-1 (AP-1) complex capable of binding AP-1 sites at the promoter of 
many genes[228]. In development this has been shown to be important 
for Spemann organizer gene expression (such as noggin, chordin and 
goosecoid), hematopoiesis and bone development [229-232].   
 EGR is a transcription factor, which is important for hematopoiesis 
[233, 234]. One thing all these developmental genes undergoing pausing 
have in common is that they are all considered rapidly transcribed genes 
and are known to be immediate-early transcription factors or primary 
response genes. These genes are thought to be on the front lines of 
transcription and will be the first to respond to a given stimulus. It is 
perhaps because of this paused state, which makes them primed and 
ready to go within seconds of stimulation [235, 236]. One other gene 
previously identified to undergo pausing is the transcription factor c-Myc 
(figure 1.16c), which similarly is considered a primary response gene 
although not due to retinoic acid stimulation like c-Fos, c-Jun and EGR 
[235]. Rapid c-Myc transcription has been shown to be stimulated by 
other factors such as the platelet derived growth factor (PDGF) and 
endothelin [237, 238]. c-Myc is interesting to this study as it has been 
separately implicated in both RNA polymerase pausing and neural crest 
development which will be discussed in more detail later [33, 199].  
 Also as mentioned previously, wild type cells have been shown to 
have paused polymerases at the promoter regions of heat shock proteins 
(figure 15c) [199]. Heat shock proteins are transcribed in response to 
stress upon the cell and act to prevent protein denaturation giving the cell 
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resistance to apoptosis [239-242]. From this it is not surprising that heat 
shock protein are known to be involved in cancer. HSP27 and HSP70 are 
highly expressed in many different cancers but are also thought to play a 
role in promoting tumor cell resistance to many chemotherapeutic drugs 
[242-244]. Upregulation of these HSPs leads to an upregulation of 
protooncogene, c-Myc [243]. From a developmental perspective it is also 
interesting that although upregulated in cancer, heat shock proteins are 
found to be downregulated in correlation with ageing [245].  
 Heat shock genes are thought to be held in a paused state due to 
the presence of a paused polymerase at their promoter region. This 
pausing is released after stress induction by the recruitment of the SEC 
with P-TEFb. Studies in ES cells and Drosophila have shown that heat 
shock proteins such as HSP70, HSP26 and HSP27 are all capable of 
undergoing polymerase pausing [220, 246, 247]. Like other genes found 
to undergo pausing such as c-Myc and c-fos, heat shock proteins are 
considered rapidly induced genes [248]. After heat shock stimulation, the 
heat shock factor 1 (HSF1) transcription factor will recruit P-TEFb to the 
promoter region by directly interacting with mediator of the SEC. This 
promotes the phosphorylation of NELF and the CTD of RNA pol ll and 
allows heat shock transcription to occur [249, 250].  
 Inhibiting the process of transcription elongation by knockdown of 
the positive transcription components such as cdk9 by molecular 
methods or by small molecule compound treatment leads to a reduction 
in transcription of the genes described here to undergo polymerase 
pausing. However this knockdown of genes is also coupled with an 
increase in certain gene transcription due to the feedback loops put in 
place throughout the transcriptome [251]. One example of this seen when 
overall transcription is inhibited is an accumulation of p53 due to an  
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Figure 1.16: Recruitment of the SEC. a) In certain leukaemias, chromosomal 
translocations occur which result in fusion proteins of the mixed lineage leukaemia (MLL) 
gene and components of the SEC including ENL, ELL and AF1. This results in the release 
of paused polymerases found on MLL target genes such as HoxA9 and HoxA10 leading 
to the onset of leukaemia. b) The HIV transcriptional transactivator (Tat) protein will bind 
to the P-TEFb of the SEC found in infected host cells. This promotes the transcription of 
viral genes. c) Certain wild type genes will also undergo pausing such as c-Myc and 
Hsp70. These are released from pausing due to the SEC containg P-TEFb. Retrieved 
from reference [158]  
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increased level of its transcription and inhibition of feedback loops 
leading to a reduction in the breakdown of the protein [252-254]. 
Transcription inhibition leads to an increase in ribosomal proteins such as 
RPL26, which will bind to human double minute-2 (hdm2), an E3 ubiquitin 
ligase which normally targets p53 for degradation [255].  
1.4.6. The role of c-Myc in transcriptional elongation 
Very recently the transcription factor c-Myc has been implicated to 
play a crucial role in proximal pause release in embryonic stem cells [6]. 
c-Myc had previously been associated with both the self-renewal of 
embryonic stem cells and multipotent neural crest cells. One study has 
shown that myc is able to bind to P-TEFb and is therefore involved in 
RNA polymerase pause release [33, 256, 257]. c-Myc is now thought to 
regulate pause release in embryonic stem cell genes by recruiting P-
TEFb to RNA Pol II. Inhibiting the function of c-Myc reduces the levels of 
Figure 1.17: Myc undergoes RNA polymerase pausing. (a) In order for the myc 
gene to be transcribed it must first associate with the active form of P-TEFb in 
association with the SEC. This occurs as Brd4 will also associate with P-TEFb and 
attach to the chromatin at the myc promoter region. (b) Possible therapeutic targets 
of myc overexpressing cancers is Brd4. Inhibitors of Brd4 have been shown to 
downregulate myc gene expression. Retrieved from reference [158] 
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Ser2-phosphorylated Pol II and therefore levels of elongation. Ser5-
phosphorylation associated with initiation is unaltered and therefore there 
is no change to the amount of RNA Pol II pausing. The genes 
predominantly regulated by c-Myc are those found to be most actively 
transcribed which will undergo more pausing and subsequent elongation 
[6]. It could be assumed from this that c-Myc is playing a key role in 
transcriptional elongation in other proliferative cell types. Also the 
increase in proliferative genes seen in many cancers may be due in part 
to an increase in the expression of c-Myc. Drugs targeting c-Myc or c-
Myc target genes such as Leflunomide may therefore make excellent 
therapeutics’ in a range of cancers [3, 6].  
 c-Myc itself is also thought to undergo RNA polymerase pausing 
(figure 1.17a). Studies using human ES cells have knocked down the 
SEC subunit Med26 and Paf1 to show a loss of SEC components along 
the gene body of both c-Myc and other paused gene Hsp70. RNA pol ll is 
shown to accumulate at the promoter region of these genes by ChIP-Seq 
and this results in a reduction of their transcription and therefore their 
overall mRNA level present in the cells. It also results in a reduction of 
Ser2 phosphorylation, which is associated with positive transcription 
elongation. From this study it is hypothesised that c-Myc transcription 
requires the transcription co-activators Med26 and Paf1 to recruit the 
SEC to its promoter region [199].  
 Interestingly, it has been shown that knockdown of Brd4 also leads 
to a reduction of c-Myc expression. Brd4 is present in the other P-TEFb 
active complex which is usually associated with basal level transcription. 
This study was carried out using human acute myeloid leukaemia (AML) 
cells. It was shown that Brd4 knockdown reduces c-Myc expression and 
decreases the amount of cancer cell self-renewal [258]. Brd4 was shown 
to associate with the chromatin at the promoter region of myc. Treatment 
of the cells with a Brd4 inhibitor (I-BET151) caused a dissociation of Brd4 
and the SEC causing a loss of myc expression (figure 1.17b) [258]. The 
same loss of c-Myc after Brd4 knockdown was shown in a separate study 
using HeLa cells and mouse mammary tumour line, C127. RNAi 
knockdown of Brd4 reduced c-Myc and c-Jun expression levels (both 
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early immediate response genes) and reduced the amount of cdk9 
present along their gene bodies. These Brd4 knockdown cells were 
shown to be less proliferative and many cells underwent G1 cell cycle 
arrest [203]. These studies suggest that inhibiting myc expression by 
preventing the function of P-TEFb could be a potential target for cancers 
overexpressing the myc gene. 
1.4.7. CDK9 and cancer; CDK9 as a drug target 
 Uncontrolled and excessive transcription elongation caused by the 
abnormal activation of the P-TEFb complex can lead to these diseases 
described such as leukemia and HIV/AIDS. A greater understanding of 
the regulation and action of P-TEFb and the SEC will lead to improved 
therapies for these diseases as very specific variations of the SEC are 
found in these cell types and therefore targeted therapies could be 
developed. This also suggests a possibility for the use of CDK9 inhibitors 
and other inhibitors of transcription elongation in the treatment of cancers 
including leukemia [157]. Many inhibitors of CDK9 and transcriptional 
elongation are now in clinical trials for cancer treatment. These include 
Seliciclib, a cdk9 inhibitor currently in phase ll clinical trials for the 
treatment of non-small cell lung carcinoma [259]. Studies using multiple 
myeloma cells have shown that CDK9 inhibition by Seliciclib causes a 
downregulation of anti-apoptotic factor Mcl-1 resulting in an increased 
amount of apoptotic cancer cells [260, 261].  
 Another example is the drug Alvocodib also known as flavopiridol. 
Flavopiridol is commonly used in genetic studies as it is known to inhibit 
CDK9. It is therefore often used as a tool to inhibit transcriptional 
elongation [262]. It is currently in human clinical trials for cancers 
including many B-cell lymphomas and ovarian carcinomas [263, 264]. 
Similarly to Seliciclib, flavopridol has been shown to down regulate Mcl-1 
resulting in tumour cell apoptosis [263]. Since the discovery of flavopiridol 
many other CDK9 inhibiting compounds have been compared to it. There 
are now known to be compounds with even greater specificity for cancer 
cells and lower toxicity than flavopiridol. The compound CDKI-71 is 
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another CDK9 inhibitor that has been shown to be more specific for 
leukaemia cell lines and not normal B or T cell lines when compared to 
flavopiridol [265].  
 Cancer therapies targeting CDKs are now moving away from 
those involved in cell cycle and towards those involved in transcription 
regulation such as CDK9. Cancer cells seem more sensitive to these 
compounds and will undergo apoptosis more readily than wild type cells. 
One issue often faced when using compounds, which target CDK9, is the 
large amount of off target effects that can occur [266]. This often occurs 
due to the high similarity between the CDK drug target sites. Drugs which 
target CDK9 are often found to target CDK2 as well which is a CDK 
functioning solely in the cell cycle making these compounds more toxic to 
normal as well as cancer cell types. It is now thought that compounds 
with high specificity for CDK9 alone rather than general CDK inhibitors, 
will be more useful for cancer therapy [267].  
 Compounds which limit the available nucleotides present for RNA 
transcription may also inhibit transcriptional elongation. Genes 
undergoing polymerase pausing have been shown to be more sensitive 
to such compounds. One compound previously mentioned to have this 
effect is Leflunomide. This was shown in Zebrafish and Xenopus 
embryos to decrease the amount of neural crest derivatives such as 
melanophores and also to decrease the cell viability of the melanoma cell 
line A375 [3]. Subsequent to these studies Leflunomide is now in clinical 
trials for human melanoma treatment. Further studies treating A375 cells 
with leflunomide have identified the aryl hydrocarbon receptor as a target 
of leflunomide, mediating its anti-proliferative affects on melanoma cells 
[268]. Following on from the success of using leflunomide to treat 
melanoma its effects on other cancer types, for example human 
medullary thyroid cancer, are now being investigated [269].  
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1.5 Aims  
Using leflunomide as a tool to inhibit transcriptional elongation I 
aim to show the importance of this process during neural crest 
specification. It has already been shown from the work of our lab and the 
Zon lab that leflunomide’s action inhibits the transcriptional elongation of 
c-Myc target genes in Zebrafish and melanoma cell lines [3]. It has also 
been shown that c-Myc plays an important role in initiating the 
transcription of genes required for neural crest specification [33]. I aim to 
show that administration of leflunomide on X.laevis embryos is capable of 
preventing expression of various neural crest specifying genes such as 
Slug, Sox10 and FoxD3 and c-Myc. This will implicate the importance for 
transcriptional elongation during neural crest development. It is quite 
likely that this would be the case as transcriptional pausing and 
subsequent elongation has already been shown to regulate genes 
associated with embryonic stem cell pluripotency [6]. We would 
hypothesise that this would also be the case for neural crest cells as 
these share this same stem-cell like multipotent potential. Genes involved 
in neural crest cell specification must be tightly regulated to prevent 
improper differentiation and so transcriptional pausing would prevent the 
transcription of such genes keeping their multipotent potential. I therefore 
aim to investigate this process in neural crest cells by inhibiting the 
function of P-TEFb by morpholino knockdown of components of the P-
TEFb complex, Cdk9 and CyclinT1 or the use of inhibitors. Inhibiting P-
TEFb function in the Xenopus embryo will allow me to investigate the 
effect of inhibiting transcriptional elongation on neural crest specific 
genes to show that transcription regulation at this level is important for 
neural crest specification.  
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Chapter II 
Materials and Methods 
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2.1 Obtaining Embryos 
 Females were primed 5-10 days before eggs are required with 100 
units of PMSG (pregnant mare serum gonadotrophin). To induce 
ovulation primed female Xenopus laevis were injected with 500 units of 
human chorionic gonadotrophin (hCG) into their dorsal lymph sac and 
stored at 18oC. Eggs were then be collected 14-16 hours prior to this. To 
obtain eggs, the abdomens of the frogs were manually squeezed over a 
clean petri dish. Testes were isolated from a euthanized male frog and 
placed in testes buffer. A piece of masticated testes was first swiped 
gently over the eggs then crushed with 1ml of high salt solution, 1xMMR 
and distributed over the collected eggs and left for 5 minutes at 18oC. 
0.1xMMR was then be added to the eggs and left for 20 minutes at 18oC. 
After fertilisation, the jelly coat which encases the eggs was removed. For 
this they were added to a 250ml beaker containing 2% L-cysteine 
(Sigma, UK) pH 8.0 dissolved in 1XMMR. Swirling the eggs in this 
solution gently removed the jelly. Eggs were then washed in 1X MMR 
then 0.1XMMR to remove cysteine. Embryos were then left to develop 
until they reach the required stage according to Niewkoop and Faber 
1967.  
 
Solutions 
• 0.1XMMR: 10mM NaCl, 0.2mM KCl, 0.1mM MgCl2,0.2mM CaCl2, 
0.5mM HEPES (pH 7.5) 
• 1XMMR: 100mM NaCl, 2mM KCl, 1mM MgCl2, 2mM CaCl2, 5mM 
HEPES (pH 7.5) 
• Testis Buffer: 80% fetal calf serum, 20% 1x MMR, gentamycin 
(Sigma 1:1000u) 
• PMSG (Intervet): 100U/ml PMSG prepared in solvent and stored at 
4oC 
• Chorulon (Intervet): 1000U/ml Chorulon prepared in solvent and 
stored at 4oC 
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2.2 Fixing Embryos 
 Once Xenopus embryos or animal caps reached their desired 
stage (depicted by Nieukoop and Faber 1967) they were fixed. The 
embryos were fixed using MEMFA (3.7% formaldehyde (Sigma, UK), 1x 
MEM salts made up with DEPC H20). They were then left at room 
temperature for 1 hour or overnight at 4oC, washed 3 times in PBST and 
then left at 20oC for storage in 100% methanol (Sigma UK).  
2.3 Preparation of competent cells 
 A 5ml culture of DH5α e.coli was grown overnight in Luria Broth 
(LB) at 37oC and shaking at 200 rpm. 1ml of this culture was added to 
200ml of LB and grown at 37oC with shaking until optical density (OD) at 
600nm reaches 0.3 to 0.4. At this point the culture was divided into 4x 
50ml falcon tubes and put on ice for 15 minutes. The cells were 
centrifuged at 4oC for 10 minutes at 2000rpm. The supernatant was 
discarded and the bacterial pellet was resuspended in 16mls of filter 
sterilised TB I buffer. Cells were put on ice for 15 minutes then 
centrifuged at 4oC and 2000 rpm for 10 minutes. The supernatant is 
discarded and the pellet was resuspended in 4mls of filter sterilised TB II. 
Aliquots are stored at -80oC.  
 
Solutions 
• TB I pH 5.8: RbCl2 0.1M, MnCl2H2O 0.068M, CaCl2 0.01M, 1M KAc 
pH 7.5, 37.5ml Glycerol adjust to 250ml and pH using 0.2M HAc 
• TB II: MOPS 0.5M pH 6.8, RbCL2 0.01M, CaCl2H2O 1.04M, 37.5ml 
Glycerol adjust to 250ml aliquoted and stored at -80oC.  
 
2.4 Transformation 
 1µl of plasmid was added into 100µl of competent E.coli cells and 
left on ice for 30 minutes. These were heatshocked at 42oC for 90 
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seconds to open the cells and allow the plasmid to enter followed by 5 
minutes on ice. 300µl of LB media was added and cells are left for 1 hour 
at 37oC to allow growth. 200µl of ligated cells were plated out onto agar 
and LB plates containing the correct antibiotic. These were left at 37oC 
overnight to allow colonies to form. For blue/white selection 40µl Xgal 
(20mg/ml in DMF) and 4µl IPTG (200mg/ml dH2O) was added to the agar 
and LB plate.  
 
2.5 DNA Mini prep 
 Colonies from the transformation were taken to be incubated in 5ml 
LB/carbicillin liquid media overnight at 37oC with rocking. The DNA 
plasmid was then isolated using the Qiagen mini plasmid purification kit 
(Qiagen, UK) according to manufacturers instructions. 1µl of the final 
product was run on agarose gel by electrophoresis and analysed using a 
Nanodrop to determine DNA concentration 
 
2.6 DNA Midi prep  
 Colonies from the transformation were taken to be incubated in 
50ml LB/carbicillin liquid media overnight at 37oC with rocking. The DNA 
plasmid was then be isolated using the Qiagen Hi-speed plasmid 
purification kit (Qiagen, UK) according to manufacturers instructions. 1µl 
of the final product was run on agarose gel by electrophoresis and 
analysed using a Nanodrop to determine DNA concentration. 
 
2.7 Capped RNA synthesis 
 10µg of plasmid DNA was digested using 5µl buffer, 2µl restriction 
enzyme (Xba1 for Wnt and Not1 for Noggin) made up to 50µl with RNAse 
free water. This was left at 37oC for 2 hours and purified using a Qiagen 
PCR purification kit according to kit instructions. The linearised DNA was 
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then analysed using a Nanodrop to determine the concentration. For 
capped RNA synthesis 1µg linearised DNA, 10µl NTP/CAP, 2µl buffer, 
2µl SP6/T7 RNA polymerase and made up to 20µl with RNAse free 
water. This was left for 2 hours at 37oC. 1µl of Turbo DNAse was added 
for 15 minutes at 37oC.  1µl of this was run on a gel. The capped RNA 
then underwent lithium chloride purification and was made into 1ng/10nl 
stocks used to make 10µl aliquots. The plasmids used are shown in table 
1.1 
 
Table 2.1 Plasmids used to make capped RNA 
Clone name Sense RE Sense 
polymerase 
Source 
Noggin Not1 Sp6 Dr Dave Hsu 
Wnt1  Xba1 Sp6 Dr Oliver Destree 
Lac-Z Not1 Sp6 Dr Maggie Walmesly 
c-Myc Not1 SP6 Dr Carol Labonne 
Cdk9-a Mutant Asc1 Sp6 Synthesised  
Cdk9-b Mutant Asc1 Sp6 Synthesised 
CyclinT1 Mutant Asc1 Sp6 Synthesised 
 
 
2.8 Animal cap assay 
 Embryos were injected at the one cell stage with either Noggin 
alone to induce neuroectoderm or Noggin and Wnt. Non-injected 
embryos will give caps with ectodermal cell fate (figure 2.1). These were 
left to develop to stage 9 when animal caps can be cut. Caps are cut in 
filter-sterile 1XMMR. The vitelline membrane was removed using sharp 
forceps and the cap was cut from the center of the animal hemisphere. 
Caps were transferred to 12 well dishes containing 0.7XMMR, 1mg/ml 
Bovine serum albumin (Fischer, UK) 100µg/ml gentamycin (Sigma, UK) 
and either DMSO (Sigma, UK) for controls or 60µM leflunomide (Sigma 
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UK). Caps were kept at a constant temperature until they reach stage 18 
when they will either undergo RNA extraction or in situ hybridisation.  
 
2.9 RNA extaction 
 Animal tissue was placed in a 1.5ml eppendorf tube and all fluid 
was removed from animal tissue and then flash frozen on dry ice for 15 
minutes. 1ml of TRIzol was then added and left on ice for up to 1 hour. 
The tissue and TRIzol was then vortexed until all tissue is broken down to 
leave a homogenous solution. RNA is stable in TRIzol as it deactivates 
RNases so at this step the solution can be stored in a -80oC freezer until 
needed. Next, 0.5ml of chloroform was added to the trizol, shaken for 15 
seconds and incubated at room temperature for 5 minutes. The tubes 
were then spun at max speed at 4oC for 20-40 minutes. After this tubes 
were immediately placed on ice and the aqueous upper phase was put 
into a new tube. To this 500µl of isopropanol (Fischer, UK), 50µl 5M NaCl 
and 2µl of glycogen (Roche, UK) was added. This was quickly vortexed 
and incubated for 10 minutes at room temperature before spinning at 
max speed for 30 minutes at 4oC. The supernatent was removed and 
discarded and the RNA pellet was washed with 70% ethanol prepared in 
RNase free water. This was spun at max speed at 4oC again for 10 
Figure 2.1: Animal cap assay. Embryos are injected at the one cell stage and left to 
develop to stage 9 when they undergo animal capping. These caps can then be placed 
in either DMSO or leflunomide and left to develop until stage 18 when they will undergo 
in situ or RNA extraction.  
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minutes and the ethanol was removed and the pellet dissolved in 45µl of 
RNase free water ready for DNase treatment.  
 
2.10 DNase treatment  
 10x DNase I buffer (Roche, UK) was added to each RNA sample 
so final concentration is 1x. 1µl of DNase I (Roche, UK) was then added 
and incubated at 37oC for 30 minutes. To this 50µl of RNase free water 
was added so sample final volume is 100µl. 100µl of acidic 
phenol/chloroform was then added, tubes are inverted for 10 seconds 3 
times and then spun at max speed at 4oC for 40 minutes. The aqueous 
phase was transferred to a clean 1.5ml eppendorf tube. 70µl of 
isopropanol (Sigma, UK) and 7µl of 5M NaCl was added and tubes are 
quickly vortexed before spinning at max speed for 30 minutes at 4oC. The 
supernatant was removed and the pellet washed with 75% ethanol 
(Sigma, UK). This was centrifuged again at max speed for 10 minutes at 
4oC. The pellet was air dried and resuspended in 20µl of RNase free 
water. Concentration was determined using a Nanodrop.   
 
2.11 cDNA Preparation 
To synthesise cDNA for PCR, 1µg of RNA, 0.5µl of oligo-dT 
(Sigma, UK) was made up to 12.5µl with H20 and left at 65oC for 10 
minutes to denature the RNA structure and then put onto ice to stop 
renaturing. To this 4µl of 5x RT buffer, 0.5µl of RNAsin (Roche, UK), 
2.5µl of 10mM dNTPs and 0.5µl RT (Roche, UK) was added and left for 
30 minutes at 65oC. To synthesise cDNA for qRT-PCR, 1µg RNA, 1µl 
random hexamers (Sigma, UK) were made up to 11µl with RNAse free 
water and left at 70oC for 10 minutes. 4µl 5x first strand buffer (Sigma, 
UK), 2µl DTT (Sigma, UK), 1µl dNTP (Roche, UK), 1µl RNAsin (Roche, 
UK) and 1µl superscript II (Sigma, UK) were added for 1 hour at 42oC. 
cDNAs were diluted 1:20 to give a final concentration of 10ng/µl. 
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2.12 PCR 
The reaction mixture was as follows; 12.5µl of Bioline Taq mix 
(Bioline, UK), 1µl cDNA as a template, 2µl of forward primer, 2µl reverse 
primer made up to 25µl with RNAse free Sigma water. The reaction 
conditions were 95oC for 3 minutes, 25-35 cycles (specific for each 
primer set) of 95oC for 30 seconds, 50-60oC temperature gradient for 1 
minute, 72oC for 2 minutes and one final 72oC for 10 minutes. 5µl 
samples were then analysed by agarose gel electrophoresis and 
visualised using ethidium bromide under UV.  
 
2.13 qRT-PCR 
The reaction mixture used was as follows; 10µl cDNA, 0.5µl of each 
primer (forward and reverse), 8.5µl SyberGreen (Applied biosystems, 
UK) and 0.5µl RNAse free water. The reaction conditions 50oC for 2 
minutes, 95oC for 10 minutes 95oC for 15 seconds cycled 40 times and 
60oC for 1 minute. Amplification curves were analysed using 7500 
sequence detection software. 
 
 2.14 Primers used 
Table 2.2 Primers used 
Name Forward primer Reverse primer 
FoxD3 TCTCTGGGGCAATCACACTC GTACATTTGTTGATAAAGGG 
Slug TCCCGCCACTGAAAATGCCACGATC CCGTCCTAAAGATGAAGGGTATTCCTG 
Sox2 GAGGATGGACACTTATGCCCAC GGACATGCTGTAGGTAGGCGA 
Brachyury GCTGGAAGTATGTGAATGGAG TTAAGTGCTGTAATCTCTTCA 
Keratin CACCAGAACACAGAGTAC CAACCTTCCCATCAACCA 
Histone 
H4 
CGGGATAACATTCAGGGTA TCCATGGCGGTAACTGTC 
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2.15 Restriction digest 
Clones within plasmids were linearised by restriction digest using 
the appropriate restriction enzyme for each plasmid. 2-10µg of plasmid 
was added to 2µl of the appropriate enzyme, 5µl of the optimal buffer for 
the enzyme and then made up to 50µl with sigma H2O. This is left at 
37oC for a minimum of 2 hours or a maximum of overnight. The cut 
plasmid can be visualised on an agarose gel.  
 
2.16 Ethanol precipitation 
Digests were purified by ethanol precipitation. 1:10 volumes of 0.3M 
sodium acetate and 250µl of absolute ethanol were added to a 50µl 
digest. This is left overnight at -20oC. This was then centrifuged for 15 
minutes at 14000 rpm. The supernatant was removed and the pellet was 
washed using 400µl of 70% ethanol and spun for 5 minutes at 14000 
rpm. The ethanol was then removed and the pellet left to air-dry at room 
temperature. The pellet was then resuspened in 20µl of sigma H2O and 
stored at -20oC. 
 
2.17 Agarose gel electrophoresis 
Agarose (Sigma, UK) gels were made at a 2% concentration. 1g of 
agarose was dissolved in 50mls of 1x TAE buffer by warming. Ethidium 
bromide (Sigma, UK) was added to the gel at a concentration of 0.5µg/ml 
to visualize DNA or RNA using a UV trans-illuminator (BiO-RAD) 
following electrophoresis. Samples were mixed with 1/10 volume of 10x 
DNA loading dye before loading onto the gel. Electrophoresis was carried 
out at 70 volts for 65 minutes.  
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2.18 Probe synthesis 
 Plasmids containing a gene of interest were linearised using the 
appropriate restriction enzymes to digest at restriction sites to give 
antisense and sense RNA probes. Linearised DNA was purified before 
probe synthesis. For probe synthesis the following reaction mixture was 
used; 4µl 5x transcription buffer (Sigma, UK), 2µl DTT (Sigma, UK), 1µl 
digoxygenin (DIG) or Fluorescein labelled UTPs (Roche, UK), 1µl 
RNAsin, 1µl linearised DNA, 2µl RNA polymerase (Roche, UK) made to a 
final volume of 20µl with dH2O. This was incubated at 37oC for 3 hours. 
Any remaining DNA template was removed by adding 1µl of DNase I 
(Roche, UK) and incubating for 30 minutes at 37oC. The probe was then 
run on a 2% agarose gel and visualised in a UV transmitter (BiO-RAD). 
Plasmids used to make probes are shown in table 2.3 
 
Table 2.3 Plasmids used to make probes  
Clone 
name 
Sense RE Antisense 
RE 
Sense 
Polyme
rase 
Antise
nse 
Polym
erase 
Source 
Sox2 Not1 EcoR1 Sp6 T7 Prof Yoshiki 
Sasai 
Slug Xho1 Bgl2 T7 Sp6 Dr Michael 
Sargent 
Sox10 Xho1 EcoR1 T7 T3 Prof Jean-Pierre 
Saint-Jeannet 
FoxD3 Not1 BamH1 Sp6 T7 Prof Yoshiki 
Sasai 
c-Myc Not1 EcoRV Sp6 T7 Image Clone 
from Source 
Bioscience 
Zic1 NS EcoR1 NS T3 Dr Jung Aruga 
Zic3 Hind III BamH1 T7 T3 Dr Jung Aruga 
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Pax3 NS NS Bgl2 Sp6 Dr Michael 
Sargent 
Sox9 Sac1 Nco1 T7 Sp6 Dr Karen 
Chambers 
Cdk9-a Not1 Sal1 Sp6 T7 Image Clone 
from Source 
Bioscience 
Cdk9-b NS Nde1 NS T7 Dr Paul Mead 
CyclinK NS Nco1 NS Sp6 Dr Paul Mead 
CyclinT2 NS Nde1 NS T7 Dr Paul Mead 
CyclinT1 Not1 EcorR1 Sp6 T7 Image Clone 
from Source 
Bioscience 
Runx1 Xho1 T3 EcoR1 T7 Prof Jean-Pierre 
Saint-Jeannet, 
 
Islet-1 Xho1 T3 EcoR1 T7 Prof Jean-Pierre 
Saint-Jeannet 
Ngnr-1 NS NS BamH1 T3 Prof Jean-Pierre 
Saint-Jeannet 
Tbx2 NS NS BamH1 T7 Prof Jin-Kwan 
Han 
Elrd NS NS Xho1 T3 Dr Michela Ori 
 
NeuroD NS NS Xho1 T3 Dr Michela Ori 
 
NS = Not synthesised 
 
2.19 Purification of probes 
Probes were purified by adding 30µl of Sigma H2O and putting it 
through an illustra MicroSpin G-50 Column (GE healthcare life sciences) 
according to manufacturers instructions. 5µl of probe was run on a 2% 
agarose gel to check probe quality. 5µg of purified probe was added to 5-
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10ml of hybridisation buffer depending on probe quality and stored at -
20oC.  
 
2.20 Whole mount in situ Hybridisation 
 Embryos were rehydrated from 100% methanol by using 100%, 
75%, 50%, 25% methanol (Sigma, UK) and phosphate buffered saline 
with 0.1% Tween (PBST) for 5 minutes each followed by 2 PBST washes 
for the same time, all with rocking at room temperature. Embryos were 
then treated with 10µg/ml Proteinase K (Sigma, UK) for varying times 
depending on the embryo stage (e.g. Xenopus stage 38-10minutes, 
stage 25-4minutes and stage 10.5-1minute). Xenopus embryos were 
then washed twice in PBST for 5 minutes and incubated in 3.7% 
formaldehyde/PBST (Sigma, UK) for 20 minutes with rocking at room 
temperature after which they were washed 3 times in PBST for 5 minutes 
and incubated in hybridisation buffer at 60oC for 2-6 hours. After this the 
embryos were placed in fresh hybridisation buffer and the appropriate 
probe and incubated overnight at 60oC.  
 Probes were removed and stored at -20oC and embryos were 
washed with fresh hybridisation buffer for 10 minutes. Xenopus embryos 
undergo 3 washes in 2x Sodium Chloride and Sodium Citrate solution 
(SSC) for 20 minutes and 2 washes in 0.2x SSC for 30 minutes, all at 
60oC. Embryos were then washed twice in Maleic acid buffer with 0.1% 
Tween (1xMABT) for 30 minutes at room temperature and then put into a 
1xMAB and 2% Boerhinger Mannhein Blocking (BMB) solution (Fischer, 
UK) for 1 hour at room temperature with rocking. BMB solution was 
replaced with antibody solution containing anti-deoxygenin (Promega, 
UK) 1:2000 and incubated overnight at 4oC with rocking.  
 Antibody solution was removed and embryos are washed in 
1xMABT 5 times for 60 minutes each at room temperature with rocking 
and incubated in a sixth MABT wash overnight at 4oC with rocking. The 
colour reaction is then carried out by firstly washing the embryos in 
freshly made alkaline phosphate buffer twice for 5 minutes at room 
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temperature with rocking. Embryos were then put in NBT/BCIP in alkaline 
phosphate buffer (67.5µl NBT, 52.5µl BCIP made up to 15ml with alkaline 
phosphate buffer) until the desired level of colour was seen. Embryos 
were then put in 5xTBST solution overnight if needed to remove 
background colour and then photographed. 
 For double in situ hybridisation after TBST washes embryos 
underwent 2x 5 minute PBST washes then embryos were fixed in 
MEMFA for 1 hour at room temperature. Embryos then underwent 2 
further 5 minute PBST washes at room temperature then a 1 hour wash 
in MABT at 65oC to deactivate any DIG antibody still present. After this 
embryos were washed twice in MABT for 5 minutes, for an hour in 2% 
BMB and then 2 hours in 2% BMB with 20% goat serum (Fischer, UK) all 
at room temperature. BMB and goat serum solution was replaced with 
antibody solution containing anti-Flourescin (Promega, UK) 1:1000 and 
incubated overnight at 4oC with rocking.  
Antibody solution was removed and embryos were washed in 
1xMABT 5 times for 60 minutes each at room temperature with rocking 
and incubated in a sixth MABT wash overnight at 4oC with rocking. The 
embryos were then washed twice for 5 minutes with alkaline phosphate 
buffer then colour reaction is carried out by adding Fast Red solution 
(Sigma, UK). When colour reaction is complete the reaction was stopped 
with a 5 minute MABT wash followed by 2 PBST washes all at room 
temperature then the embryos were left overnight in TBST. After this 
embryos were fixed in MEMFA for 1 hour at room temperature.  
 
Solutions 
• Alkaline Phosphatase Buffer: 100mM Tris (pH 9.5), 50mM MgCl2, 
100mM NaCl, 0.1% Tween 20 
• Antibody solution: 2% BMB, 20% goat serum, anti-DIG Fab 
fragment, (1:2000 dilution) in 1X MAB 
• BCIP: 50mg/ml in 100% DMF 
• Blocking solution: 2% BMB in 1X MAB 
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• BMB (Boehringer Mannheim Blocking agent) 10%: 10% (w/v) in 
BMB preheated (50oC) 1XMAB, stirred until dissolved and then 
autoclaved, aliquoted and stored at –20oC 
• Hybridisation buffer: 50% formamide, 5XSSC, 1mg/ml Torula RNA, 
100µg/ml Heparin, 1X Denharts solution, 0.1% Tween 20, 0.1% 
CHAPS, 10mM EDTA 
• MAB 1X (Maleic Acid Buffer): 100mM Maleic acid; 150mM NaCL 
(pH 7.5) 
• MEMFA: 10% MEM salts, 10% formaldehyde 
• MEM salts: 0.1M MOPS, 2mM EGTA, 1mM MgSO4, pH7.4 
• NBT (Nitro Blue tetrazolium): 75mg/ml in 70% dimethylformamide 
(DMF) 
• PBS 10X: 2.5g NaH2PO4.H2O, 11.94g NaHPO4.H2O, 102.2g NaCl, 
400ml DEPC dH2O. pH adjusted to 7.4 and volume to 1 litre 
• PBST: 1XPBS, 0.1%Tween 20 
• Proteinase K (10µg/ml): 1µl proteinase K, 1ml PTw 
• SSC 20X: 175.3g NaCL, 88.2g Sodium citrate. pH adjusted to 7.0 
and volume to 1 litre with DEPC H2O 
• TBST: 125ml 1M Tris pH 7.5 40g NaCl, 1g KCl made up to 450ml 
with dH20. Autoclave then add 50ml Tween-20 
• Fast Red Solution: SIGMAFAST™ Fast Red TR/Naphthol AS-MX 
Tablets dissolved in 10ml alkaline phosphate buffer 
 
2.21 Bleaching 
 Some embryos were bleached to effectively observe in situ 
staining. For this embryos were placed in a solution of 8.95ml DEPC 
H2O, 300µl 30% H2O2 (Sigma, UK), 500µl formamide (Fischer, UK) and 
250µl 20xSSC and incubated on a light box for 1 hour. After bleaching 
the embryos were washed twice for 5 minutes in PBS and fixed in 
MEMFA overnight at 4oC 
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2.22 Cryosectioning 
 Embryos were fixed in MEMFA for 1 hour, washed twice for 5 
minutes in PBST and then put in 30% sucrose (Fischer, UK) for 4 hours 
all at room temperature with rocking. Embryos were then transferred to 
cryomoulds filled with optimal cutting temperature (OCT) compound and 
left at 4oC overnight. After this, embryos were positioned appropriately for 
sectioning and left at -20oC overnight. Embryos were sectioned using the 
LEICA CM 1950 Cryostat and sections were placed on 5% TESPA slides 
overnight at 37oC. Slides were then washed for 5 minutes in PBST and 
for 5 minutes in PBS after which they were covered with a coverslip using 
hydromount and left overnight to dry before use. Images were taken 
using a Zeiss CCD upright microscope with colour camera.  
2.23 In vitro translation using 35S labelled probe 
 Carried out using the TNT® Coupled Reticulocyte Lysate System 
(Promega, UK) following manufacturers instructions. The reaction was 
incubated at 30oC for 90 minutes. 2.5µl of a 25µl radiolabelled protein 
reaction was added to 1x SDS loading buffer boiled at 80oC for 3 minutes 
and run on a 12% SDS-polyacridamide gel by electrophoresis in a Mini-
PROTEAM®3cell (BIO-RAD) system containing running buffer. The gel 
was fixed using a fixing buffer for 30 minutes on a shaker then put into 
drying buffer for 5 minutes. The gel was then dried for 90 minutes at 80oC 
onto whatmann paper using a Model 583 gel dryer (BIO RAD) and a 
HydroTechTM vacuum pump (BIO RAD). This was then exposed onto a 
phosphoimager screen and visualised on a phosphoimager (BIO-RAD). 
 
Solutions 
• Fixing buffer: 50% methanol, 10% glacial acetic acid, 40% dH20 
• Drying buffer: 7% acetic acid, 7% methanol, 1% glycerol, 85% 
dH20 
• TG buffer: 30g Tris, 144g Glycine make up to 1L with dH2O pH to 
8.3 
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• Runnning buffer: 100ml TG buffer, 10ml 10% SDS, 890ml dH2O 
• 5x SDS loading buffer: 20.83ml 1.5M Tris pH 6.8, 10g SDS 
powder, 25ml Glycerol, 750µl 2% Bromophenol blue (in EtoH), 5ml 
0.1M DTT, make up to 100ml with dH20. Dilute with sigma H20 to 
1x concentration when needed.  
 
2.24 Microinjection, morpholinos used and β-galactosidase 
detection 
 Embryos undergoing microinjection were placed in 3% Ficoll 
PM400 (Sigma, UK). One or both blastomeres were injected into the 
animal pole at the 2-cell stage using a 10nl calibrated needle and oxygen 
free nitrogen was used with a Harvard apparatus injector (Medical 
Systems Research products). The injector is set up at Pout =90 
Pbalance=0.6 and Pinject=16. For rescue experiments embryos were injected 
twice into the animal pole of one blastomere to obtain the correct 
amounts of morpholino and mRNA injected. 2 hours after injection the 
Ficoll was removed from the embryos and replaced with 0.1x 
MMR/gentamycin (1:1000) and left to develop at 18oC.  
 Antisense morpholino oligonucleotides (MOs) used in these 
studies were designed and synthesised by Gene Tools. The sequence of 
the morpholinos are shown in table 2.4. Morpholinos underwent in vitro 
translation before use to confirm activity and specificity.  
 
Table 2.4 Morpholino target sequences 
Morpholino name Target sequence 
Standard control (CMO) 5’-CCTCTTACCTCAGTTACAATTTATA-3’ 
Cdk9-a 5’-ATGGCCAAGAACTACGACTCGGTGG-3’ 
Cdk9-b 5’-ATGGTAAAGAACTACGACTCTGTTG-3’ 
CyclinT1 5’-GACATCGTACTTTATGGCAACAAAC-3’   
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Morpholino stocks and working stocks are stored at room 
temperature. If frozen they must be heated at 65oC before use for 10 
minutes. If lineage tracing is required morpholinos are placed on ice and 
1µl Lac-Z capped RNA was added and these samples were stored on 
ice. MOs were coinjected with 300pg of Lac-Z mRNA. β-galactosidase 
activity was detected using Red-gal (Sigma, UK) as a substrate. For this 
embryos were washed 3 times in 1x PBS for 5 minutes then fixed for no 
more than 1 hour at RT in MEMFA. Embryos were rinsed 3 times in 1x 
PBS then Red-gal solution is added at 37oC until red staining is seen. 
When staining is complete embryos were fixed again in MEMFA for 1 
hour at room temperature.  
 
Solutions 
• 3% Ficoll: 6g Ficoll PM400, 60ml 1xMMR, 140ml dH2O 
• Red-gal: 2.5ml 0.1mM K3Fe(CN)6, 2.5ml 0.1mM K4Fe(CN)63H20, 
2.5ml 20mg/ml Red-gal solution, 0.1ml of 1M MgCl2 made up to 
50ml with 1x PBS 
2.25 RNA sequencing 
 RNA sequencing was carried out on 6 animal cap samples. RNA 
was extracted by TRIzol method and DNAse treated as mentioned 
previously. Each of the 6 samples contained 3 biological replicates tested 
individually by PCR to detect expected gene expression. Samples 
contained 2-4µg of RNA in 30µl of RNase free H20. RNA samples were 
sent to the High-Throughput Genomics Group at the Wellcome Trust 
Centre for Human Genetics Oxford, for library preparation.  
 Total RNA was fragmented before undergoing cDNA library 
preparation. cDNA was end-repaired, A-tailed and adapter-ligated before 
amplification and size selection. The prepared libraries undergo quality 
control by running on a gel and using a bioanalyser to check library 
fragment size distribution before 100bp paired end sequencing over one 
lane of a flow cell. Samples were multiplexed 2 x 3 and run on one lane 
each to yield approximately 25 million paired reads per sample. Data 
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were aligned to the reference genome of Xenopus laevis to be quality 
checked. 
Samples were aligned to the Xenopus laevis transcriptome 
(xlaevisMRNA.fasta) downloaded from Xenbase. Mapping was carried 
out with bowtie2 on paired-end samples using default parameters. A 
custom Perl script was used to parse the bowtie results and count the 
number of sequences in each sample mapping to every mRNA sequence 
in the transcriptome file. The table of raw abundances for each mRNA 
was then read into R and differential expression between untreated and 
leflunomide treated samples was calculated using the Deseq package. 
Any mRNA with a p-value of <= 0.05 was classed as being differentially 
expressed between untreated and leflunomide treated samples. 
 
2.26 Site directed mutagenesis 
 
 Mutagenesis primers were designed for Cdk9a, Cdk9b and 
CyclinT1. The sequences for these are shown in table 2.5. Mutations are 
highlighted in yellow. All primers were FPLC purified. 
 
Table  2.5  Mutagenesis primers 
Name Mutagenesis Primer 
Cdk9a 
Forward 
5'-ccccctccttccgccatggccaaaaattatgattcggtggaattcc-3' 
 
Cdk9a 
Reverse 
5'-ggaattccaccgaatcataatttttggccatggcggaaggaggggg-3' 
Cdk9b 
Forward 
5'-agccccctccttccgccatggtaaaaaattatgattctgttgaattcccttattg-3' 
 
Cdk9 
Reverse 
5'-caataagggaattcaacagaatcataattttttaccatggcggaaggagggggct-3' 
 
CyclinT1 
Forward 
5'-gcaaggacttggcacagacatcatatttcatggcgacaaacagcttacatttgacca-3' 
CyclinT1 
Reverse 
5'-tggtcaaatgtaagctgtttgtcgccatgaaatatgatgtctgtgccaagtccttgc-3' 
 
 Mutations marked in yellow 
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The mutagenesis PCR reaction was set up as follows; 5µl 10 x Pfu 
polymerase buffer (Agilent technologies, UK), 4µl 10mM dNTPs, 0.2µl 
forward primer, 0.2µl reverse primer, 10µg plasmid DNA, 2µl Pfu 
polymerase (Agilent technologies, UK) make up to 50µl with Sigma H2O. 
The PCR reaction conditions used were 94oC for 60 seconds then 12 
cycles of 94oC for 30 seconds, 55oC for 30 seconds and 68oC for 12 
minutes. The PCR reaction was cooled to room temperature and 1µl of 
DpnI (Agilent technologies, UK) restriction enzyme was added. This will 
cut all parental methylated DNA leaving only the PCR reaction. 5µl of the 
PCR product is transformed (following section 2.4) into competent E.coli 
cells and DNA was obtained using a DNA midi prep (following section 
2.5). This DNA was sequenced at the University of Dundee sequencing 
service 
2.27 Alcian blue staining 
 Embryos were fixed for 1 hour at room temperature, dehydrated 
with 5 washes of 100% ethanol (Sigma, UK) for 5 minutes each at RT 
and then left in Alcian blue (Fischer, UK) staining solution for 3 nights. 
After this they were washed 3 times for 15 minutes in 95% ethanol 
(Sigma, UK) at RT then rehydrated in 2% KOH. This was done gradually 
using 10 minute washes of 75% EtoH in 2% KOH, 50% EtoH in 2% KOH, 
25% EtoH in 2% KOH then 3 2% KOH washes. Embryos were then 
stored in glycerol to make embryos more transparent. This was done by 1 
hour washes of 20% glycerol in 2%, 40%glycerol in 2% KOH, 60% 
glycerol in 2% KOH and finally stored in 80% glycerol in 2% KOH. Facial 
cartilage was then dissected out before imaging.  
 
Solutions 
• Alcian Blue solution: 20mg Alcian blue, 15ml acetic acid, 35ml 
100% ethanol 
• 2% KOH: 1g KOH tablets in 500ml dH20 
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2.28 Statistical analysis 
 
 All statistical tests were carried out using Graph Pad Prism 6 
software. Suitable statistical tests were chosen for each data set to suit 
the type of data analysed. Tests used in this thesis include Kruskall 
Wallis, Mann Whitney U and students T-tests.  
 
2.28 Determining pigment loss 
 
 Throughout this thesis the neural crest derivative melanophores 
are phenotypically assayed by eye based on whether the embryos are 
displaying a reduced number in this cell type. Those embryos displaying 
this phenotype are termed as having pigment loss. Embryos showing a 
normal phenotype are described as wild type. Examples of what is 
considered pigment loss is shown in figure 2.2A-D and what is 
considered wild type is shown in figure 2.2E-H. Pigment loss was 
achieved throught the addition of compounds in a chemical genetic 
screen. These compunds are leflunomide (Sigma, UK), 5,6-dichloro-1-
beta-D-ribofuranosylbenzimidazole (Sigma, UK) and Cdk9 inhibitor II 
(Merck Millipore). 
Figure 2.2 Examples of pigment loss and wild type embryos. (A-D) Examples of 
embryos displaying a pigment loss phenotype. (E-H) Examples of embryos displaying a 
wild type phenotype.  
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Chapter III 
Using leflunomide as a tool to 
investigate transcription elongation in 
neural crest cells 
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3.1 Introduction 
 To investigate the role of transcriptional elongation in neural crest 
cells the drug leflunomide was used to treat Xenopus embryos. 
Leflunomide is a compound identified within our lab in collaboration with 
the Zon lab, which inhibited pigment cell development. Its mechanism of 
action was suggested to inhibit transcriptional elongation [3]. We are 
interested in the role of transcription elongation in neural crest cells so 
the first experiments carried out here further analyse the leflunomide 
phenotype. The expected phenotypes would be those showing defects in 
the neural crest derivatives such as melanophores, cranio-facial cartilage 
and sensory neurons. One advantage of using a small molecule 
compound to inhibit transcription elongation is that it can be applied to 
the embryos at different stages therefore allowing for experiments to be 
carried out analysing the effect of blocking transcriptional elongation at 
different stages. 
 There are many other small molecule compounds readily 
available which have been commonly used in studies investigating 
transcriptional elongation. These include 5,6-dichloro-1-beta-D 
ribofuranosylbenzimidazole (DRB), flavopiridol and many CDK9 inhibitors 
with varying degrees of specificity. Some of these compounds will also be 
tested to verify the phenotype given by leflunomide and also to assess 
the efficiency of leflunomide.  
 Finally, different genes at various stages of neural crest 
development will be assayed for their levels of gene expression after 
leflunomide treatment using in situ hybridisation. Neural crest cells initially 
undergo induction at the neural plate border and so neural plate border 
markers should be looked at first. After this they will undergo specification 
and differentiation and so markers of these phases of crest development 
will also be looked at. The aims of these experiments are to ascertain 
whether transcriptional elongation is important for neural crest cell 
development and if so at what stage of their development. 
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3.2 The phenotype obtained from leflunomide treatment 
3.2.1 The phenotype seen after leflunomide treatment of stage 38 
Xenopus laevis 
3.2.1.1 Phenotypic analysis 
X.laevis embryos were put into 20, 40 and 60μM leflunomide or 
DMSO as a control, at stage 15. The leflunomide and DMSO were added 
at the desired concentration to the embryos media, 0.1xMMR. These 
embryos were left to develop at 18oC until they had reached stage 38.  At 
this stage they were fixed and phenotypically scored for defects in their 
melanophore formation and migration. Leflunomide acts to inhibit 
transcriptional elongation and as we are interested in the role this plays in 
neural crest development we are using the neural crest derivative, 
melanophores as a read out of the impact inhibiting this process has on 
neural crest cell specification. 
Leflunomide was shown to have a dose-dependent effect on 
X.laevis embryos. A gradual decrease in the number of melanophores 
present can be seen from the DMSO control to the 20, 40 and 60μM 
treated samples (figure 3.1A-D). A clear loss of melanophore formation 
can be seen after 60μM leflunomide treatment (figure 3.1D) compared to 
DMSO treated control embryos (figure 3.1A). Less melanophores were 
seen in the head region (figure 3.1E and F), the lateral stripe (figure 
3.1G and H) and the tail region (figure 3.1I and J) of 60μM leflunomide 
treated embryos when compared to DMSO-treated controls. The 
melanophores in the head region of leflunomide treated embryos (figure 
3.1F) appear more rounded in shape compared to the dendritic wild type 
cells seen in the DMSO control (figure 3.1E). Melanophores also seem 
unable to migrate into the underside of the tail after 60µM leflunomide 
treatment (figure 3.1J) when compared to the DMSO control (figure 
3.1I).
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Figure 3.1: The effect of leflunomide on Xenopus laevis. (A-D) Dose response gradient 
of leflunomide on stage 38 X.laevis embryos. (A) DMSO control. (B) 20μM leflunomide. (C) 
40μM leflunomide. (D) 60μM leflunomide (E) Head region of WT embryo shows normal 
melanophores. (F) Head region of leflunomide treated embryo shows less melanophores 
which have a rounded morphology (black arrow head). (G) Lateral pigment of WT embryo 
appears normal. (H) Lateral pigment of leflunomide treated embryo. Melanophores are 
much fewer in number (black arrow head). (I) Tail of WT embryo shows normal 
melanophores in the normal position. (J) Tail of leflunomide treated embryo has much fewer 
melanophores none of which have migrated into the underside of the tail (black arrow head).  
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3.2.1.2 Quantitative analysis 
The number of embryos showing wild type and pigment loss 
phenotypes were counted after both DMSO, 20μM leflunomide, 40μM 
leflunomide and 60μM leflunomide treatment and plotted as a graph of 
the percentage of embryos showing these phenotypes (figure 3.2). The 
percentage of embryos showing a pigment loss phenotype gradually 
increases in a dose dependent manner from 12%, 16%, 24% up to 33% 
from DMSO up to 60μM leflunomide. This is to be expected as 
demonstrated in figure 3.1, increasing the dose of leflunomide results in 
a more dramatic phenotype and as shown by the graph is figure 3.2, the 
phenotype is also more commonly seen. 
 The graph in figure 3.2 represents the percentage of embryos 
showing a pigment loss phenotype. There are also other phenotypes 
commonly seen in Xenopus embryos which are considered general 
developmental defects as they can occur randomly even in control 
samples as part of poor quality development. These defects include 
oedemas, stunting of growth (embryos appear shorter than normal) and 
abnormalities to the eye, which can include retinal pigment loss. The 
results shown in table 3.1 demonstrate that a very low percentage (2%) 
of embryos have developmental defects in the DMSO control sample. 
This percentage gradually increases from 5%, 8% up to 26% as the 
concentration of leflunomide increases. This reflects an increase in the 
general toxicity of the drug. 
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Figure 3.2: The percentage of X.laevis embryos showing a pigment loss 
phenotype after leflunomide treatment. Graph showing the percentage of 
embryos showing pigment loss phenotype and wild type phenotype for DMSO 
control (n=155), 20µM leflunomide (n=158), 40µM leflunomide (n=164) and 60µM 
leflunomide (n=141). *=p<0.05 by Kruskall Wallis statistical test. 
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3.2.2 Applying leflunomide at different stages 
3.2.2.1 Phenotypic analysis 
 To analyse the effect of leflunomide at different stages of 
development, embryos were added to 60µM leflunomide or DMSO 
containing media at stages 1, 8 and 12. 60µM leflunomide was 
established as an effective dose from the previous dose response 
experiments. It was hypothesised that adding leflunomide earlier before 
neural crest cell specification starts at stage 12, would give a stronger 
pigment cell loss phenotype. This was seen to be the case however the 
drug also appeared to affect the general development of the embryos. 
Adding the drug before gastrulation i.e. stage 1 and 8 caused the 
embryos to have a stunted phenotype and display improper eye 
development. Adding it to the embryos at stage 12 appeared to give a 
similar phenotype to that seen when added at stage 15, embryos 
displayed fairly normal development but appeared to have less 
melanophores. 
 Embryos added to DMSO at stage 1 displayed a wild type 
phenotype (figure 3.3A). Embryos added to 60µM leflunomide at stage 1 
(figure 3.3B) had an almost complete loss of melanophores however 
they appeared much shorter in length due to stunted growth. They also 
appeared to be much shorter and wider than the wild type embryos and 
displayed a loss of retinal pigment in the eye suggesting improper eye 
development. Embryos added to DMSO at stage 8 displayed a wild type 
phenotype (figure 3.3C). Embryos added to 60µM  leflunomide at stage 
8 (figure 3.3D) also show an almost complete loss of melanophores 
however these too appear stunted and display eye development defects. 
Embryos added to DMSO post gastrulation at stage 12 show a wild type 
phenotype (figure 3.3E). Embryos added to 60µM  leflunomide at stage 
12 (figure 3.3F) show fewer melanophores in the head lateral stripe and 
tail regions of the embryos. The embryos also appear normal in shape 
and display fewer general developmental defects. Melanophores in the 
tail again seem unable to migrate into the underside of the tail.
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Figure 3.3: Applying leflunomide at different stages of development. (A) Embryos 
added to DMSO at stage 1 showing wild type phenotype. (B) Embryos added to 60µM 
leflunomide at stage 1 show loss of melanophores (black arrow head) and also stunting 
and eye defects. (C) Embryos added to DMSO at stage 8 show wild type phenotype. (D) 
Embryos added to 60µM at stage 8 show loss of melanophores (black arrow head) and 
also stunting and eye defects. (E) Embryos added to DMSO at stage 12 show wild type 
phenotype. (F) Embryos added to 60µM at stage 12 show a loss of melanophores in the 
lateral stripe and tail (black arrow heads).  
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3.2.2.2 Quantitative analysis 
The number of embryos showing wild type and pigment loss 
phenotypes were counted after DMSO treatment at stage 1, 8 and 12 
and also 60μM leflunomide treatment at the same stages and plotted as 
a graph of the percentage of embryos showing these phenotypes (figure 
3.4). The percentage of embryos showing a pigment loss phenotype 
starts off very high at 51% when 60μM leflunomide is added at stage 1. 
This number gradually decreases as the drug is added at later stages 
showing 47% of embryos with pigment loss when leflunomide is added at 
stage 12. This is to be expected as administering the drug earlier before 
neural crest specification ensures that the drug is taking effect at a point 
which will sufficiently block neural crest development. This results in a 
higher frequency of the pigment cell loss phenotype.  
 The graph in figure 3.4 represents the percentage of embryos 
showing a pigment loss phenotype. Other phenotypes commonly seen 
include oedemas, stunting of growth (embryos appear shorter than 
normal) and abnormalities to the eye such as retinal pigment loss. The 
results shown in table 3.2 demonstrate that a low percentage (5-7%) of 
embryos have developmental defects in the DMSO control samples. This 
percentage was relatively high (34%) in the embryos treated with 60μM 
leflunomide at stage 1 however what is not reflected by this is that all of 
the pigment loss embryos in this category also show many other defects 
including stunting and eye abnormalities shown in figure 3.3. This is also 
the case for embryos added to 60μM leflunomide at stage 8, 25% of this 
category show developmental defects however all of the pigment loss 
embryos also have stunting and eye abnormalities. This may arise to due 
off target effects of the drug preventing the embryos undergoing normal 
gastrulation. This is a common effect seen in chemical screens when the 
compound is added before gastrulation. Pigment loss embryos added to 
leflunomide at stage 12 show no other developmental defects and only 
18% of the total embryos in this category show such defects (table 3.2).  
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Figure 3.4: The percentage of embryos showing a pigment loss phenotype 
after leflunomide addition at different stages. Graph showing the percentage 
of embryos showing pigment loss phenotype and wild type phenotype for 
DMSO control added at stage 1 (n=60), stage 8 (n=67) , stage 12 (n=63) and 
60µM leflunomide added at stage 1(n=72), stage 8 (n=73) and stage 12 (n=67). 
*=p<0.05 by Kruskall Wallis statistical test 
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3.2.3 The phenotype seen after leflunomide treatment of stage 38 
Xenopus tropicalis 
3.2.3.1 Phenotypic analysis 
After looking at the phenotype given by leflunomide in Xenopus 
laevis, we looked at the phenotype given in Xenopus tropicalis. This 
experiment was carried out as it would be interesting to see whether the 
chemical genetic experiment of adding leflunomide to the embryos 
media, would have a stronger effect on the diploid X.tropicalis species 
over the tetraploid X.laevis. Being diploid it would be logical to observe a 
stronger phenotype as fewer copies of the same gene are present in the 
embryos to provide redundancy. X.tropicalis embryos were put into either 
60μM leflunomide or DMSO as a control at stage 15. The leflunomide 
and DMSO are added straight to the embryos media, 0.1xMMR. These 
embryos were left to develop at 26oC until they had reached stage 38.  At 
this stage they were fixed and phenotypically scored for defects in their 
melanophore formation and migration.  
Leflunomide was shown to have a much stronger effect on the 
X.tropicalis embryos then X.laevis embryos. Clear defects were seen in 
melanophore formation after 60μM leflunomide treatment compared to 
DMSO treated control embryos (figure 3.5A). The loss of melanophores 
seen in X.laevis is much less obvious. Less melanophores were seen in 
the head region (figure 3.5B and C), the lateral stripe (figure 3.5D and 
E) and the tail region (figure 3.5F and G) of 60μM leflunomide treated 
embryos when compared to DMSO treated controls. On closer 
examination the melanophores themselves appear to have lost their 
dendritic morphology and adopted a more rounded one (figure 3.5D and 
E).  
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Figure 3.5: The effect of leflunomide on Xenopus tropicalis. (A) Top embryo is a 
wild type embryo which has undergone DMSO treatment as part of a control group. Its 
melanophore morphology appears normal. The three beneath this developed in 60µM 
leflunomide and they appear to have fewer melanophores with no dendritic morphology. 
(B) Head region of WT embryo shows normal melanophores. (C) Head region of 
leflunomide treated embryo shows less melanophores which have a rounded 
morphology (black arrow head). (D) Tail of WT embryo shows normal melanophores in 
the normal position. (E) Tail of leflunomide treated embryo has no melanophores (black 
arrow head). (F) Lateral pigment of WT embryo appears normal. (G) Lateral pigment of 
leflunomide treated embryo. Melanophores are fewer in number and appear rounded 
(black arrow head).  
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3.2.3.2 Quantitative analysis 
The number of embryos showing wild type and pigment defect 
phenotypes were counted after both DMSO and 60μM leflunomide 
treatment and plotted as a graph of the percentage of embryos showing a 
pigment loss phenotype (figure 3.6). 47% of embryos after leflunomide 
treatment were seen to have the pigmentation defects seen in figure 3.5 
compared to only 9% of embryos showing pigmentation defects in the 
DMSO control (table 3.3). This is greater than the number of X.laevis 
showing a pigment loss (33% shown in figure 19). Suggesting that the 
tropicalis phenotype is stronger and occurs more frequently.  
Figure 3.6: The percentage of X.tropicalis embryos showing a 
pigment loss phenotype after leflunomide treatment. Graph showing 
the percentage of embryos showing pigment loss phenotype and wild 
type phenotype for DMSO control (n=302), and 60µM leflunomide 
(n=252). *=p<0.05 by Mann-Whitney U statistical test 
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3.2.4 Affect of leflunomide treatment on craniofacial development 
 Craniofacial cartilage is derived from cranial neural crest cells 
and can easily be stained using an alcian blue stain. Alcian blue will stain 
glycosaminoglycans specific to cartilage leaving the cartilage of the 
embryo stained blue and the rest of the embryo unaffected. Observing 
the structure of cranio-facial cartilage is a commonly used method to 
analyse the development of cranial neural crest cells. Here Xenopus 
laevis embryos were added to DMSO and a gradient of leflunomide 
concentrations at stage 15 and left to develop until stage 45 when they 
were fixed and underwent alcian blue staining to visualise the 
development of cranio-facial cartilage. Embryos were visualised in 
glycerol to increase the transparency of the head region.  
 DMSO treated embryos (figure 3.7A) show normal cranio-facial 
cartilage development. The alcian blue stains dark blue in all of the 
cranio-facial cartilage present in the head region of the embryo. 20μM 
leflunomide treated embryos (figure 3.7B) also show a wild type 
phenotype. Their cranio-facial cartilage appears normal and stains dark 
blue. 40μM leflunomide treated embryos (figure 3.7C) show some 
defects in their cranio-facial cartilage development. Cartilage starts to 
appear disorganised and a paler blue. 60μM leflunomide treated embryos 
(figure 3.7D) show clear cranio-facial cartilage defects. Cartilage and 
head region is clearly not properly developed and alcian blue staining 
appears pale blue.  
 To further analyse the organisation of the embryos craniofacial 
cartilage it was removed by dissection. The DMSO treated cartilage 
(figure 3.7E) shows normal organisation comparable to the diagram in 
figure 3.7G. The 60μM leflunomide treated cartilage (figure 3.7F) has 
small, disorganised branchial cartilage regions compared to the DMSO 
control. It also appears paler in colour suggesting that less cartilage has 
been formed.  
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Figure 3.7: The effect of leflunomide on cranio-facial cartilage. (A-D) DMSO, 20µM, 
40µM, and 60µM leflunomide treated embryos at stage 45 after alcian blue staining. (E) 
Dissected cranio-facial cartilage of a DMSO treated embryo. (F) Dissected cranio-facial 
cartilage of a 60µM leflunomide treated embryo. Embryos show a disorganisation in the 
development of the branchial cartilage (black arrow heads). (G) Diagram representing 
normal cranio-facial cartilage development. M=Meckels cartilage, C=Ceratohyal, 
B=Branchial cartilage.  
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3.2.5 Affect of leflunomide treatment on sensory neuron development 
 Sensory neurons are another neural crest cell derivative with 
simple assays used to test their development. They can be tested simply 
by poking the embryo with a pipette tip and observing the reaction of the 
embryo. Here the embryos were treated with 60μM leflunomide before 
and after gastrulation (at stages 8 and 12 respectively) then left to 
develop at 18oC until reaching stage 37 when they would be taken out of 
leflunomide and washed overnight in clean media (0.1xMMR). These 
were left to develop until stage 38 when embryos have a full sensory 
response. Washing the embryos is important to ensure any phenotype 
seen is due to neural crest defects and not a side effect of the compound. 
Embryos then underwent a poke from a pipette tip straight to the back of 
the embryo or a stroke, which involves running the pipette tip from the 
head to the tail of the embryo. If the embryos swim away they are scored 
1, if they twitch on the spot they are scored 0.5 and if they fail to react 
they are scored 0. For each treatment type, 30 embryos were tested in 3 
rounds of 10 and the average score for these 3 lots of ten is displayed.  
 Embryos treated with DMSO from stage 8 and stage 12 both show 
a normal response from poking (figure 3.8 top panel) and stroking 
(figure 3.8 bottom panel). Most of these embryos responded normally 
and swam away in response to the external stimulus. After 60μM 
leflunomide treatment at stage 8, the embryos show a significant 
decrease in their ability to respond to both poking (figure 3.8 top panel) 
and stroking (figure 3.8 bottom panel) indicating a loss of sensory 
neuron development. Similarly, embryos treated with 60µM leflunomide 
at stage 12 show a significant decrease in their ability to respond to both 
poking (figure 3.8 top panel) and stroking (figure 3.8 bottom panel) 
when compared to the DMSO control. There was a slight increase seen 
in the response ability observed between embryos added to leflunomide 
at stage 12 compared to stage 8 however this difference is not 
statistically significant. DMSO treated and stage 12 leflunomide treated 
embryos were filmed undergoing a poke response. This video can been 
seen in appendix 1. 
  95 
 
 
Figure 3.8: Poke and stroke analysis of senory neuron development. (Top 
panel) Embryos undergo poking to the dorsal side and their response is tallied 
as follows. Swim=1, twitch=0.5 no response=0. The average of 30 embryos (3 
experiments using 10 embryos) is shown. (Bottom panel) Embryos undergo 
stroking of a pipette tip from the head region to the tail and their response is 
tallied as follows. Swim=1, twitch=0.5 no response=0. The average of 30 
embryos is shown. For both conditions embryos were treated with DMSO and 
60µM leflunomide from stages 8 and 12. *=p<0.05 by students t-test.  
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3.3 Other small molecule compounds affecting transcription 
elongation 
3.3.1 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) 
3.3.1.1 Phenotypic analysis 
 To confirm the phenotype seen from leflunomide treatment 
embryos were treated with other small molecule compounds, which have 
the same function. 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole 
(DRB) has been commonly used in studies analysing the effect of 
inhibiting transcriptional elongation. It is from this compound that the 
transcriptional elongation complex component DSIF gets its name (5,6-
dichloro-1-beta-D-ribofuranosylbenzimidazole sensitivity inducing factor). 
This experiment will also suggest whether leflunomide is an appropriate 
drug to carry out further experiments with or whether other compounds 
are able to give the same phenotype more effectively.  
 Embryos treated with DMSO (figure 3.9A) show a wild type 
phenotype. Embryos treated with DRB show high concentrations needed 
in a dose response before any phenotype is seen (figure 3.9B-D). 
100µM DRB treated embryos (figure 3.9B) also appear wild type. After 
140µM DRB treatment (figure 3.9C), a small percentage of embryos 
show a loss of melanophores similar to the phenotype seen from 60µM 
leflunomide treatment. After 170µM DRB treatment (figure 3.9D), 
embryos show a clear loss of melanophores in the head, lateral stripe 
and tail however many embryos also show other developmental defects 
such as bent tails and abnormal eye development, probably due to 
toxicity of the drug used at such high concentrations. Because 
leflunomide gives a pigment loss phenotype at lower concentrations and 
without general development side effects it was deemed a more effective 
drug to use to analyse transcriptional elongation inhibition than DRB.  
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Figure 3.9: Dose response of 5,6-dichloro-1-beta-D-
ribofuranosylbenzimidazole (DRB). (A) DMSO treated embryo showing a wild 
type phenotype. (B) 100µM DRB treated embryo shows wild type phenotype. (C) 
140µM DRB treated embryo shows some loss of melanophores in the lateral stripe. 
(D) 170µM DRB treated embryo shows loss of pigment in the eye and lateral stripe 
(black arrow heads). Less melanophores in the tail however tail appears bent 
(arrow).  
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3.3.1.2 Quantitative analysis 
The number of embryos showing wild type and pigment loss 
phenotypes were counted after DMSO, 100μM DRB, 140μM DRB and 
170μM DRB treatment. These data were then plotted as a graph of the 
percentage of embryos showing pigment loss phenotype (figure 3.10). 
The percentage of embryos showing a pigment loss phenotype increases 
dose dependently from 12%, 15%, 25% up to 35% from DMSO up to 
170μM DRB. This is to be expected as demonstrated in figure 3.9, 
increasing the dose of DRB resulted in a stronger phenotype and as 
shown by the graph in figure 3.10 it is more commonly seen. At 170μM 
DRB the percentage of embryos showing a pigment loss phenotype 
(35%) is similar to that of 60µM leflunomide treated embryos (33%). 
Using leflunomide over DRB could be considered advantageous as it is 
more efficient and reliable to use compounds at the lowest possible 
concentration to avoid off target effects.  
The graph in figure 3.10 represents the percentage of embryos 
showing just a pigment loss phenotype. Other phenotypes seen include 
oedemas, stunting of growth (embryos appear shorter than normal) and 
abnormalities to the eye including a complete loss of the eye. The results 
shown in table 3.4 demonstrate that a relatively high percentage (22%) 
of embryos have developmental defects in the DMSO control samples. 
This higher than normal percentage can be explained by the increased 
amount of DMSO in the embryos media. As the highest concentration of 
compound used in these experiments was 170μM the percentage of 
DMSO used in the control was increased to reflect this. 1.7% of the 
media was DMSO which is high considering 2% is the highest 
concentration a Xenopus embryo will tolerate [270]. It is for such reasons 
as this that using high drug concentrations is not good practice. The 
amounts of general developmental defects appear to stay constant with 
the equivalent DRB concentration i.e. 23% at 170μM (table 3.4), 
however this is because this does not reflect how all of the pigment loss 
embryos display defects including loss of eye pigment and a kinked tail 
(figure 3.9). 
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Figure 3.10: Percentage of embryos showing a pigment loss phenotype after 
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) treatment. Graph 
showing the percentage of embryos showing a pigment loss phenotype after 
DMSO (n=50), 100µM DRB (n=54), 140µM DRB (n=52) and 170µM DRB (n=52). 
*=p<0.05 by Kruskall Wallis statistical test 
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3.3.2 Cyclin dependent kinase 9 (CDK9) inhibitor 
3.3.2.1. Phenotypic analysis 
  
 Another type of compound commonly used to inhibit 
transcriptional elongation are those which inhibit the enzyme CDK9, the 
active component of the P-TEFb complex which allows transcription 
elongation to occur. General CDK9 inhibitors have many off target effects 
such as inhibiting CDK2, an enzyme structurally similar to CDK9. The 
CDK9 inhibitor used in this screen claims to be specific for CDK9. Again 
this screen allows the efficiency of leflunomide to be compared to other 
compounds, which carry out the same function. 
 The DMSO treated embryos (figure 3.11A) show a wild type 
phenotype with normal amounts of melanophores in the head, lateral 
stripe and tail. Similarly to DRB, the CDK9 inhibitor required very high 
concentrations before a phenotype was observed (figure 3.11B-D). After 
treatment with 100µM CDK9 inhibitor (figure 3.11B) the embryos still 
appear wild type. At 140µM of CDK9 inhibitor (figure 3.11C) the embryos 
show a clear pigment cell loss phenotype. Pigment cell loss can be seen 
in the eye, lateral stripe and tail. At 170µM of CDK9 inhibitor (figure 
3.11D) the embryos show a loss of pigment cells in the eye, lateral stripe 
and tail. At this concentration all of the embryos also displayed 
developmental defects such as stunting and bent tails. These are side 
effects often seen when compounds a added to embryos at very high 
concentrations and so are considered off target effects.  
 Similarly to DRB the CDK9 inhibitor is only effective at very high 
concentrations. This is not optimal as demonstrated using high 
concentrations of a compound tends to give off target general 
developmental defects. In comparison to leflunomide both DRB and the 
CDK9 inhibitor use very high concentrations of compound, which is not 
ideal for specific genetic experiments. They did however both give the 
same melanophore loss phenotype seen from leflunomide treatment. 
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Figure 3.11: Dose response of CDK9 inhibitor. (A) DMSO treated embryo 
showing a wild type phenotype. (B) 100µM CDK9 inhibitor treated embryo shows 
wild type phenotype. (C) 140µM CDK9 inhibitor treated embryo shows loss of 
melanophores in the lateral stripe, eye and tail (black arrow heads). (D) 170µM 
CDK9 inhibitor treated embryo shows loss of pigment in the eye and lateral stripe 
(black arrow heads). Less melanophores are found in the tail however tail appears 
bent (arrow) and embryos are stunted.  
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3.3.2.2 Quantitative analysis 
 
 The number of embryos showing wild type and pigment loss 
phenotypes were counted for DMSO, 100µM CDK9 inhibitor, 140µM 
CDK9 inhibitor and 170µM CDK9 inhibitor treatment. These data were 
plotted as a graph of the percentage of embryos showing these 
phenotypes (figure 29). The percentage of embryos showing a pigment 
loss phenotype gradually increases in a dose dependent manner from 
16%, 15%, 34% up to 36% from DMSO up to 170µM CDK9 inhibitor. 
Increasing the dose of CDK9 inhibitor results in a stronger phenotype 
(figure 3.11) and as shown by the graph in figure 3.12, the general 
phenotype is also more commonly seen. At 140µM CDK9 inhibitor the 
percentage of embryos showing a pigment loss phenotype (36%) is 
similar to that of 60µM leflunomide treated embryos (33%). This is 
however a similar problem to using DRB, it is inefficient and unreliable to 
use compounds at high concentrations as off target effects arise and so 
leflunomide would be a better alternative to use in further experiments. 
 The graph in figure 3.12 represents the percentage of embryos 
showing either a pigment loss phenotype. Similarly to previous 
experiments, other phenotypes are seen including oedemas, stunting of 
growth and abnormalities to the eye. The results shown in table 3.5 
indicate that the amounts of general developmental defects appear to 
increase drastically with increasing CDK9 inhibitor concentration i.e. 31% 
of embryos have such defects at 170µM (table 3.5), this also does not 
reflect that all of the pigment loss embryos display defects including loss 
of eye pigment and stunting (figure 3.9D). Overall this compound 
appeared to have many off target side effects causing many 
developmental defects to occur and therefore would not be as efficient for 
further genetic experiments when compared to leflunomide.  
 
 
 
 
 
  103 
Figure 3.12: Percentage of embryos showing a pigment loss phenotype after 
CDK9 inhibitor treatment. Graph showing the percentage of embryos showing a 
pigment loss phenotype after DMSO (n=43), 100µM CDK9 inhibitor (n=47), 
140µM CDK9 inhibitor (n=56) and 170µM CDK9 inhibitor (n=69) *=p<0.05 by 
Kruskall Wallis statistical test 
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3.4 Analysis of genes affected by leflunomide using in situ 
hybridization on whole embryos 
3.4.1 Neural plate and neural plate border specifiers 
The previous experiments shown indicate that treatment of 60µM 
leflunomide causes Xenopus embryos to show a loss of neural crest 
derivatives such as melanophores, cranio-facial cartilage and sensory 
neurons. The reduction in this variety of derivatives suggests that the 
neural crest cells themselves are not forming or are not being specified 
into neural crest cells and therefore not undergoing differentiation into the 
different cell types they are able to form. Neural crest cells are initially 
induced at the neural plate border at stage 12 due to the upregulation of 
neural plate border specific genes such as Zic1, Zic3 and Pax3. To 
investigate the stage of neural crest development in which transcriptional 
elongation is important, stage 3 embryos were added to 60µM 
leflunomide and left to develop until stage 12 when they were fixed to 
undergo in situ hybridisation for neural plate border markers. Some were 
also fixed at stage 15 to investigate any possible effect leflunomide might 
have on general neural plate development by carrying out in situ 
hybridisation for the pan neural plate marker Sox2. 
In situ hybridisation for the neural plate border markers Zic1, Zic3 
and Pax3 after DMSO treatment (figure 3.13A, C and E) show wild type 
expression in the neural plate border of stage 12 embryos. After 
leflunomide treatment (figure 3.13B, D and F) there appears to be no 
change to the expression of these neural plate border genes and their 
expression resembles that of the wild type expression seen in the DMSO 
treated embryos. This suggests that leflunomide is not having an effect 
on early neural crest induction at the neural plate border. Similarly the 
neural plate marker Sox2 shows wild type expression in both the DMSO 
treated (figure 3.13G) and leflunomide treated embryos (figure 3.13H) 
indicating that leflunomide has no effect on general neural development.  
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Figure 3.13: The affect of leflunomide on neural plate and neural plate border 
specifiers. (A,C and E) DMSO treated embryos at stage 12 showing wild type 
expression of Zic1, Zic3 and Pax3 respectively. (B, D and F) 60µM leflunomide 
treated embryos at stage 12 also showing wild type expression of neural plate 
border markers Zic1, Zic3 and Pax3 respectively. (G) DMSO treated embryo at 
stage 15 showing wild type Sox2 expression. (H) 60µM leflunomide treated embryo 
showing wild type Sox2 expression.  
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3.4.2 Neural crest specifiers 
Following induction at the neural plate border the neural crest cells 
undergo specification. There are many genes shown to be involved in 
this process. To analyse the effect of leflunomide on neural crest 
specification in situ hybridisation experiments were carried out using a 
range of neural crest specifying genes. Embryos were treated with 60µM 
leflunomide and left to develop until stage 15 (or 13 for c-Myc) when they 
were fixed for in situ hybridisation of neural crest specifier genes. 
The most striking downregulation for these neural crest specifiers 
was seen after in situ hybridisation of c-Myc and Sox10. Other neural 
crest specifiers showed some downregulation of expression but not as 
frequently as c-Myc and Sox10. c-Myc is an early neural crest specifier 
and starts to be expressed in the neural crest at stage 13. DMSO treated 
embryos showing wild type c-Myc expression (figure 3.14A) show 
expression in the early neural crest cells in the anterior of the embryo and 
also dorsal neural tissues. It is not specific for neural crest and plays a 
role in determining other tissue types. After treatment with leflunomide, 
the anterior patches of expression appear downregulated (figure 3.14B), 
leaving the dorsal neural expression unaffected. Sox10 wild type 
expression shown in figure 3.14C is specific for the neural crest cells at 
stage 15 and continues to be expressed in migrating crest cells where it 
plays a key role in neural crest differentiation. Along with c-Myc this 
neural crest specifier showed a striking downregulation of expression 
after leflunomide treatment (figure 3.14D), which was frequently detected 
in 47% of embryos (figure 3.15).  
Other neural crest specifier genes tested include Slug (figure 
3.14E), Sox9 (figure 3.14G) and FoxD3 (figure 3.14I). These all show 
specific expression in the neural crest cells. After leflunomide treatment 
these three neural crest specifiers show some downregulation of 
expression (figure 3.14F, H and J) however it is seen much less 
commonly, 14%, 7% and 6% of embryos displayed a loss of their 
expression pattern (figure 3.15). These results suggest that leflunomide 
is acting on neural crest cells during their specification and differentiation. 
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Figure 3.14: The effect of leflunomide of neural crest specifiers. (A) DMSO treated 
embryo at stage 13 showing wild type c-Myc expression. (B) 60µM leflunomide treated 
embryo showing specific downregulation of c-Myc in the neural crest cells (black arrow 
heads). (C,E,G and I) DMSO treated embryos at stage 15 showing expression of 
Sox10, Slug, Sox9 and FoxD3 respectively. (D, F, H and J) 60µM leflunomide treated 
embryos showing downregulation of expression of Sox10, Slug, Sox9 and FoxD3 
respectively.  
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3.4.3 Quantitative analysis 
 
 Embryos undergoing in situ hybridisation after either DMSO (figure 
3.13 and figure 3.14) or 60µM leflunomide treatment (figure 3.13 and 
figure 3.14) were scored as to whether the expression pattern seen 
appeared wild type, a partial loss of expression or a loss of expression. 
Examples of this are shown for FoxD3 expression in figure 3.15 A, B and 
C. Once all of the embryos had been counted and placed into these 
categories a graph can be plotted of the percentage of embryos showing 
these expression levels for each gene of interest (figure 3.15). The graph 
representing the results obtained after DMSO treatment (figure 3.15 top 
panel) shows that mostly the expression patterns seen are wild type. 
This was true for all of the genes tested. This is to be expected as this is 
the control group and so there is no reason for there to be any loss of 
expression. This is also reflected in table 3.6, which shows all genes to 
have above 90% wild type expression. Some partial loss is seen in below 
10% of embryos, which is a result of embryo quality or in situ 
hybridisation efficiency.  
 The gene showing the highest frequency of expression loss is 
Sox10 (figure 3.15 bottom panel). Table 3.7 shows that 47% of these 
embryos had a loss of gene expression and 39% showed a partial loss. 
This is a very large proportion of these embryos. c-Myc also 
demonstrated a very high frequency of expression loss (figure 3.15 
bottom panel) this gene saw a 30% loss of expression and a 37% partial 
loss (table 3.7). These two genes showed the clearest knockdown of 
expression. Other Neural crest specifiers (Sox9, FoxD3 and Slug) show 
some loss but always below a 10% frequency. Neural plate and neural 
plate border markers (Zic1, Zic3 and Sox2) showed 0% loss of 
expression (table 3.7) suggesting that leflunomide does not affect these 
areas of development. 5% of the Sox2 in situ embryos showed an 
expansion of expression, this is sometimes seen for neural plate markers 
when development of the neural plate border is disrupted. These results 
would suggest that leflunomide is having an effect on neural crest 
specifiers, predominantly c-Myc and Sox10. 
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Figure 3.15: The percentage of embryos showing a loss or partial loss of neural 
plate, neural plate border or neural crest specifying genes. (A) Wild type 
expression. (B) Partial loss of expression. (C) Loss of expression. (Top panel) DMSO 
treated embryos are scored for wild type, partial loss, loss and expansion of 
expression after in situ hybridisation of Sox10 (n=49), c-Myc (n=106), Sox9 (n=39), 
FoxD3 (n=47), Slug (n=54), Zic1 (n=40), Zic3 (n=45) and Sox2 (n=43). (Bottom panel) 
60µM leflunomide treated embryos are scored for wild type, partial loss, loss and 
expansion of expression after in situ hybridisation of Sox10 (n=56), c-Myc (n=108), 
Sox9 (n=47), FoxD3 (n=50), Slug (n=62), Zic1 (n=37), Zic3 (n=43) and Sox2 (n=39). 
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Table 3.6 Qualitative expression levels after DMSO treatment 
 
 
Table 3.7 Qualitative expression levels after 60µM leflunomide treatment 
 
 
 
 
 
 
 
 
 
 Total 
embryos 
Wild type Partial 
loss 
Loss Expansion 
Sox10 49 45 (92%) 4 (8%) 0 (0%) 0 (0%) 
c-Myc 106 103 (97%) 3 (3%) 0 (0%) 0 (0%) 
Sox9 39 36 (92%) 3 (8%) 0 (0%) 0 (0%) 
FoxD3 47 46 (98%) 1 (2%) 0 (0%) 0 (0%) 
Slug 54 50 (93%) 4 (7%) 0 (0%) 0 (0%) 
Zic1 40 40 (100%) 0 (0%) 0 (0%) 0 (0%) 
Zic3 45 45 (100%) 0 (0%) 0 (0%) 0 (0%) 
Sox2 43 43 (100%) 0 (0%) 0 (0%) 0 (0%) 
 Total 
embryos 
Wild type Partial 
loss 
Loss Expansion 
Sox10 56 8 (14%) 22 (39%) 26 (47%) 0 (0%) 
c-Myc 108 36 (33%) 40 (37%) 32 (30%) 0 (0%) 
Sox9 47 18 (38%) 26 (55%) 3 (7%) 0 (0%) 
FoxD3 50 18 (36%) 29 (58%) 2 (6%) 0 (0%) 
Slug 62 19 (31%) 34 (55%) 3 (14%) 0 (0%) 
Zic1 37 37 (100%) 0 (0%) 0 (0%) 0 (0%) 
Zic3 43 43 (100%) 0 (0%) 0 (0%) 0 (0%) 
Sox2 39 34 (87%) 3 (8%) 0 (0%) 2 (5%) 
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3.5 Discussion 
 The aim of this chapter was to use leflunomide to investigate the 
role of transcriptional elongation in neural crest cell development. Initial 
experiments showed that treating Xenopus embryos with leflunomide 
reduced neural crest derivatives seen in tadpole stage Xenopus 
embryos. Embryos treated with leflunomide showed a reduction in the 
number of neural crest derived melanophores present in both Xenopus 
laevis and Xenopus tropicalis. The diploid X.tropicalis species 
demonstrated a more pronounced phenotype than the tetraploid X.laevis 
species. X.tropicalis showed much fewer melanophores and the ones 
that did form appeared rounded in shape unlike the wild type dendritic 
shape usually adopted by fully differentiated melanophores. This 
difference between species is likely to arise due to redundancy occurring 
in the tertraploid laevis species. If leflunomide is targeting certain neural 
crest specification genes, having 4 copies of each means leflunomide 
has twice as many to knockdown and so would therefore inherently be 
less efficient. Alternatively the phenotype seen in tropicalis may be more 
striking simply because this species are smaller and so the compound 
may penetrate easier. The phenotype seen in Zebrafish is also more very 
striking and these are very small diploid organisms.   
To test the time at which leflunomide is having an effect, the 
compound was added at stage 1, stage 8 and stage 12. These time 
points were chosen as stage 1 gives the longest possible time in the 
drug. Stage 8 is just before gastrulation to highlight any general 
developmental issue, which may arise during gastrulation. Stage 12 is 
when neural crest cells start to be specified and so this is the time at 
which we want to target these cells. Adding the drug at stage 1 and 8 
caused many general developmental defects. A very high percentage of 
embryos were shown to exhibit a loss of melanophores suggesting that 
adding at these early stages could prevent a large proportion of neural 
crest specification. However all of these embryos also appeared stunted 
and so it is difficult to assume if the loss of melanophores is due to loss of 
neural crest or general developmental delay or secondary effect. Adding 
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leflunomide at stage 12 gave a similar phenotype when added at stage 
15 which would otherwise appear normal in shape and size whilst 
displaying few general development defects. This suggests that 
transcriptional elongation is important for neural crest development 
around the time of induction/specification.  
 Other experiments carried out in X.laevis confirmed that a reduced 
amount of neural crest derivatives are seen after leflunomide treatment. 
These included testing sensory neurons, after leflunomide treatment 
embryos underwent a ‘poke or stroke’ test to monitor their ability to 
respond to external stimulus. These embryos showed a statistically 
significant reduction in their ability to react. This could suggest that fewer 
sensory neurons are present in the embryo potentially due to a reduced 
amount of neural crest cells or an inability for them to differentiate 
properly. Similarly, there was seen to be a reduction in the amount of 
neural crest derived branchial cartilage in leflunomide treated embryos. 
This cartilage appeared disorganised after alcian blue staining 
suggesting a defect in the cranial neural crest development. It is clear 
from these experiments that treating with leflunomide causes a reduction 
in neural crest derivatives. The fact that there is a reduction seen and not 
a failure to migrate would suggest that the neural crest cells are not being 
induced, specified or differentiating properly.  
 Functional experiments looking at particular gene expression must 
be carried out in order to answer the question of how leflunomide is 
acting. Before these were carried out it was important to confirm the 
phenotype seen from leflunomide treatment with other drugs known to 
inhibit transcriptional elongation. This would also allow us to verify 
whether leflunomide was a good drug to use for further experiments in 
terms of its relative toxicity levels. So far leflunomide has shown not to 
cause excessive levels of developmental defects and the concentration 
at which it is used is not so high that it would be considered to be causing 
off target effects. To conduct these experiments chemical tests were 
carried out using the compound DRB, a drug used in many initial 
experiments characterising transcriptional elongation and pausing in 
various cell lines and also a CDK9 inhibitor with a high specificity for 
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CDK9 and not other kinases. One problem commonly seen with kinase 
inhibitors is that they target many different kinases inadvertently causing 
many unexpected off target effects. Both of these compounds 
demonstrated a loss of melanophores confirming the phenotype seen for 
leflunomide treatment and therefore provides further evidence for the 
action of leflunomide to be blocking transcriptional elongation rather than 
inhibiting DNA replication. They also however only gave a phenotype at 
very high concentrations and with many off target side effects. This 
rendered these compounds to be not as efficient as leflunomide and so 
leflunomide was considered appropriate to use in further experiments. 
 To assess the stage at which transcriptional elongation is important 
in neural crest development, leflunomide treated embryos were fixed and 
underwent in situ hybridisation for various neural plate border, neural 
plate and neural crest specifying genes. No effect was seen to the neural 
plate border genes Zic1, Zic3 and Pax3 suggesting that neural crest are 
induced at the neural plate border and do not require transcriptional 
pausing and subsequent elongation at this stage. Similarly the neural 
plate marker Sox2 was unaffected suggesting that regulation of 
transcriptional elongation is not important for general neural 
development. Differences in genes expression were only seen in genes 
involved in the specification and differentiation of neural crest cells.  
 Firstly c-Myc was shown to be drastically knocked down in 
leflunomide treated embryos but only in the specific neural crest regions 
at the anterior and of the embryos. c-Myc expressed in the dorsal neural 
tissues appeared unaffected. This could potentially make sense as 
discussed in the introduction, c-Myc is known to play a role in neural crest 
specification and is also implicated in transcriptional elongation. Studies 
which have knocked down Med26, the SEC component, have shown 
there to be a loss of c-Myc expression in embryonic stem cell lines [199]. 
Neural crest cells are a highly synchronous cell type and c-Myc is at the 
forefront of the specification of this cell type expressed very early on in 
neural crest specification.  
 Sox10 was also shown to be severely downregulated after 
leflunomide treatment. Sox10 is also a neural crest specifier and has 
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been shown to function directly downstream of c-Myc in the neural crest 
gene regulatory network [2]. It is also at the forefront of neural crest 
differentiation and continues to be expressed after specification in the 
differentiating crest. It is responsible for the differentiation of several cell 
types including melanophores and sensory neurons, which would explain 
the loss of these neural crest derivatives after leflunomide treatment. 
Other neural crest specifying genes were shown to have some 
downregulation or alteration to their expression pattern. These included 
Sox9, which is key for the differentiation of cranio-facial cartilage 
development. This slight knockdown and alteration of Sox9 expression 
could explain why the Xenopus craniofacial cartilage is present but 
appears disorganised. Partial knockdown and alteration of the expression 
of Slug, FoxD3 and Sox9 could be an indirect effect of the knockdown of 
c-Myc as these genes lie downstream of this in the neural crest gene 
regulatory network however there are many other signal which feed into 
them to regulate their expression such as BMP and FGF signals [2].  
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Chapter IV 
RNA sequencing of animal caps  
treated with leflunomide 
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4.1 Introduction 
The results obtained in chapter 3 suggests that leflunomide is 
acting on neural crest cells during the specification stage of their 
development. To analyse this further the following experiments were 
designed which will utilise the Xenopus animal cap assay to separate out 
neural crest tissue from neuro-ectoderm, ectoderm and mesoderm.  The 
animal cap assay makes Xenopus an excellent model for neural crest 
development. This assay involves injecting the early one or two cell stage 
embryo with different RNAs into the animal pole to induce certain cell 
types and tissues. Injecting Noggin will induce neuro-ectoderm. Injecting 
Wnt and Noggin induces neural crest and leaving the embryos uninjected 
allows ectoderm to form. After injecting, embryos are left until stage 9 
when the cells of the animal pole are removed and placed in media to 
grow to their desired stage, in this case stage 15 the time of neural crest 
specification.  
 In this chapter an assay has been adapted so that animal caps are 
placed in media containing DMSO as a control or 60µM leflunomide to 
dertermine by unbiased RNA sequencing which genes are affected by 
leflunomide treament. Animal caps first underwent PCR and in situ 
hybridisation experiments to test whether this approach would work. 
Firstly we wanted to insure that neural crest is sufficiently induced and 
secondly that leflunomide was able to knock down gene expression of 
neural crest specifiers. Based on these experiments working the main 
aim of this chapter was to send off RNA from these animal caps for RNA 
sequencing to enable us to analyse changes in RNA expression on a 
whole genome scale. From this we hoped to confirm some of the results 
already obtained, identify other genes involved in the process to give a 
better idea of the mechanism behind inhibiting transcriptional elongation, 
and finally to try to identify some novel genes potentially involved in 
neural crest specification and confirm these by in situ hybridisation.  
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4.2 Xenopus animal cap experiments 
4.2.1. Determining amounts of Noggin and Wnt to inject. 
 Before animal cap experiments could be carried out it must first be 
determined how much of the neural crest inducing factors Noggin and 
Wnt should be injected to obtain neural crest tissue. For this an optimal 
amount is required which will allow the induction of neural crest and 
would also show the knock down of neural crest specific genes, which is 
to be expected after leflunomide treatment. Initially we tested 500pg of 
Noggin capped RNA and varying amounts of Wnt capped RNA, 50pg, 
100pg and 150pg injected together into the animal pole of a one-cell 
stage embryo. After injection the embryos were left to reach stage 9 
when an ectodermal animal cap explant was removed and placed in 
60µM leflunomide or DMSO. This was also done for whole embryos and 
non-injected animal caps, which will go on to form default ectodermal cell 
types. To observe the induction of neural crest in these explants they 
underwent RNA extraction at stage 15 and subsequent cDNA synthesis 
which was used to carry out a PCR reaction with Slug, a commonly used 
marker for neural crest specification (figure 4.1).  
 
From this result it could be determined that 500pg of Noggin and 
50pg of Wnt was not sufficient to induce neural crest. 500pg of Noggin 
and 100pg of Wnt was sufficient to induce neural crest in the ectoderm 
Figure 4.1: Testing the amounts of Wnt and Noggin to induce animal caps to give rise 
to neural crest. Animal caps were treated with or without leflunomide. cDNA made from 
these underwent a PCR reaction using Slug primers. When 500pg of Noggin and 50pg of 
Wnt were injected into one cell stage embryos the animal caps produced did not form neural 
crest. Using 500pg of Noggin and 100pg of Wnt induced neural crest and was knocked 
down by leflunomide treatment. 500pg of Noggin and 150pg of Wnt induced neural crest but 
no knock down was observed after leflunomide treatment. Non-injected animal caps show 
no slug expression. The whole embryo shows Slug expression but less than the induced 
caps and a small amount of knock down after leflunomide treatment.  
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explants at a level that allowed the knockdown of Slug after leflunomide 
treatment. These amounts are therefore used for all experiments to 
follow. When the amount of Wnt was increased to 150pg no knockdown 
of Slug could be identified after leflunomide treatment suggesting that 
Wnt upregulation may rescue the action of leflunomide (figure 4.1). This 
is discussed further later. As expected the non-injected animal caps 
showed no slug expression indicating that animal caps had been cut 
successfully with no mesoderm contamination which would result in the 
formation of neuroectoderm or neural crest cell fates. After leflunomide 
treatment the whole embryo samples show some knockdown of Slug but 
not entirely indicated by the presence of a small band (figure 4.1). This is 
in keeping with the in situ hybridisation results obtained which suggest 
only a partial knockdown of Slug in the whole embryo. This form of PCR 
is only semi quantitative and so quantitative PCR should be carried out 
before conclusions are drawn about the levels of expression.  
 
4.2.2. The effect of leflunomide on gene expression in animal caps 
induced to become neural crest, neuroectoderm and ectoderm 
 
4.2.2.1. PCR results for Slug, Sox2, Keratin and Brachyury 
 
 Initial experiments were carried out using the same animal cap 
assay described. Embryos were injected at the one cell stage with 500pg 
of Noggin and 100pg of Wnt to induce neural crest, 500pg alone to 
induce neuroectoderm and non-injected to give default ectoderm cell 
fates. Whole embryos and all animal cap variants were added to either 
DMSO as a control or 60µM leflunomide from stage 9 when explants 
were removed until stage 15. cDNA synthesised from the RNA of these 
embryos were used to carry out PCR (figure 4.2) and Q-PCR (figure 
4.3) for neural crest markers Slug and FoxD3, neuroectoderm marker 
Sox2, mesoderm marker Brachyury and housekeeping control gene 
histone H4.  
The results from this showed that Slug is expressed in the animal 
caps induced to become neural crest after DMSO treatment however 
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when leflunomide is present Slug expression is seen to be knocked down 
(figure 4.2). As expected caps induced to become neuroectoderm and 
ectoderm show very little Slug expression (figure 4.2). The whole embryo 
shows Slug expression with some knockdown of Slug after 60µM 
leflunomide treatment (figure 4.2). The same was seen for FoxD3 
expression using Q-PCR. FoxD3 is expressed in the neural crest caps 
but this is significantly reduced after leflunomide treatment (figure 4.3A). 
FoxD3 expression is low in the neuroectoderm and ectoderm caps which 
is expected as FoxD3 is a neural crest specifying gene (figure 4.3A). It is 
highly expressed in the whole embryo and shows a reduction after 
leflunomide treatment (figure 4.3A) comparable to the partial knockdown 
seen using in situ hybridisation on whole embryos.  
Sox2, the neuroectoderm marker predominantly showed 
expression in the animal caps injected with Noggin fated to become 
neuroectoderm (figure 4.2 and 4.3B). A small amount of expression is 
also present in the caps injected with both Noggin and Wnt. Both of these 
cap types showed no significant reduction in Sox2 expression after 
leflunomide had been administered (figure 4.2 and 4.3B). Sox2 was not 
expressed in the non-injected animal caps as was to be expected and 
was found to be expressed in the whole embryo with no effect after 
leflunomide treatment (figure 4.2 and 4.3B).  
The mesodermal marker Brachyury was found to be expressed in 
none of the animal cap explants (figure 4.2). This is to be expected as 
these explants should only contain tissue from the upper ectoderm layer 
of the embryo and not the mesoderm layer. This lack of Brachyury 
expression indicated that the animal caps in this experiment were cut 
cleanly and therefore any expression of neural crest or neuroectoderm 
markers seen is due only to prior injection and not signals from 
contaminating mesoderm. Expression was seen in the whole embryo with 
no knockdown was caused by leflunomide treatment (figure 4.2). Finally, 
histone H4 was used as a positive control gene. Its expression is seen to 
be constant for all animal cap variant groups and the whole embryo and 
is not affected by the presence of leflunomide (figure 4.2 and 4.3C). This 
suggests that the same amount of RNA was used to make cDNA for each 
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sample and that the same amount of cDNA was loaded into each 
reaction making the results comparable. Water is used instead of cDNA 
for negative control groups and so no amplification of gene expression is 
seen in these PCR reactions (figure 4.3).  
 
 
 
Figure 4.2: Animal cap experiments to observe the effect of leflunomide on 
Slug, Sox2 and Brachyury using PCR. Slug, Sox2, Brachyury and Histone H4 
expression for Noggin and Wnt injected animal caps, Noggin injected animal 
caps, non-injected animal caps and whole embryos with DMSO (-) or leflunomide 
treatment (+). Histone H4 was used as a housekeeping gene. The expression of 
this is constant in all sample types. Concentrations used are 500pg Noggin and 
100pg Wnt.  
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Figure 4.3: Q-PCR results showing the effect of leflunomide on FoxD3, Sox2 and 
Histone H4. (A) FoxD3 expression for neural crest animal caps, neuroectoderm animal 
caps, ectoderm animal caps and whole embryos with DMSO or leflunomide treatment. (B) 
Sox2 expression for neural crest animal caps, neuroectoderm animal caps, ectoderm animal 
caps and whole embryos with DMSO or leflunomide treatment (C) Histone H4 is used as a 
housekeeping gene, the expression levels for this are constant for all sample types to 
ensure the same amount of cDNA is present in each sample. This shows H4 expression for 
neural crest animal caps, neuroectoderm animal caps, ectoderm animal caps and whole 
embryos with DMSO or leflunomide treatment. For all genes analysed sigma water is used 
instead of cDNA as a negative control. Concentrations used are 500pg Noggin and 100pg 
Wnt. n=3 for all samples. *= p<0.05 using ANOVA 
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4.2.2.2. in situ hybridisation of leflunomide treated animal caps 
 
 Animal caps were injected and treated in the same way as the 
PCR experiments only once they had reached stage 15 they were fixed 
and underwent in situ hybridisation for the neural crest marker Slug. This 
experiment is another way of determining the effect of leflunomide on the 
transcription of neural crest specifying genes and can be used to back up 
PCR results. The result obtained was the same as that seen for the PCR 
experiment. Slug expression was detected in the animal caps induced to 
become neural crest (figure 4.4A) but this was abrogated due to the 
administration of leflunomide (figure 4.4B). No Slug expression was 
detected in the animal caps fated to become neuroectoderm or ectoderm 
as expected (figure 4C-F). Whole embryos were left to reach stage 15 to 
gauge the stage of the animal caps and then underwent a Slug in situ to 
show the probe used is specific for neural crest (figure 4.4G and H).  
 To verify that neural crest have been induced in the animal caps, 
some of the Noggin and Wnt injected caps were left to develop until the 
equivalent of stage 38 when neural crest derived melanophores are fully 
differentiated in the Xenopus tadpole. These animal caps should show 
expression of the melanophore marker dopachrome tautomerase (DCT) if 
they have been sufficiently induced to become neural crest. The DCT in 
situ carried out on these animal caps is shown in figure 4.5. The 
expression pattern appears speckled indicating many melanophores 
present on the caps (figure 4.5A). The melanophores may appear 
clumped together and densely compacted or they may appear 
individually as single melanophores (figure 4.5B). Expression of Slug 
and DCT in the animal caps confirms that neural crest cell fate has been 
sufficiently induced.   
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Figure 4.4: The effect of leflunomide on Slug expression detected by in situ 
hybridisation. Animal caps underwent in situ and were subsequently bleached to observe 
expression (A) DMSO control animal caps injected with Noggin and Wnt show Slug 
expression. (B) Leflunomide treated Noggin and Wnt injected animal caps show very little 
Slug expression. (C) DMSO control Noggin injected caps show no Slug expression. (D) 
Leflunomide treated Noggin injected caps show no Slug expression. (E) DMSO control 
non-injected animal caps show no Slug expression. (F) Leflunomide treated non-injected 
animal caps show no Slug expression. (G) Collective picture of whole embryo control 
illustrating the normal position of Slug expression and confirming the efficiency of the 
probe used. (H) Close view of one control whole embryo displaying Slug expression.  
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4.3 Quality control of RNA sequencing 
 
4.3.1 Samples sent for RNA sequencing 
 
 Once it had been established that the leflunomide experiment 
would work in animal cap explants it was decided that some of these 
samples should be sent for RNA sequencing. In order to make RNA 
sequencing libraries a minimum of 2µg of RNA is required. To be safe it 
was deemed advantageous to collect RNA in excess of this to ensure all 
of the libraries were made efficiently. RNA extraction of 40 animal caps 
on average yielded 1.5µg of RNA. 0.5µg of this was used to produce 
cDNA to test the samples for the correct gene expression by Q-PCR i.e. 
neural crest markers in the Noggin and Wnt injected samples. RNA was 
collected from Noggin and Wnt injected caps, Noggin injected caps and 
non-injected caps all with DMSO treatment or 60µM leflunomide 
treatment giving 6 sample types. Each experiment was carried out 3 
times and the RNA remaining after confirmation by Q-PCR was pooled 
together to give the required amount of RNA to produce sequencing 
libraries.  The quality of this RNA was tested by running on an agarose 
Figure 4.5: DCT expression in Noggin and Wnt injected animal caps. (A) 
Noggin and Wnt injected animal caps at stage 38 show DCT expression in 
melanophores. (B) An inlarged image of one animal cap shows DCT expression 
in individual melanophores (black arrows) and also clumps of melanophores 
expressing DCT.  
  125 
gel and by nanodrop. The sample types including the amounts of RNA 
obtained and the nanodrop readings for each are shown in table 4.1.  
 
Table 4.1 Samples sent for RNA sequencing 
Sample Treatment Total 
RNA/µg 
260/280 260/230 
Noggin and Wnt  
(Neural crest) 
DMSO 4.6 1.81 2.10 
Noggin and Wnt 
(Neural crest) 
60µM 
leflunomide 
2.7 1.86 1.67 
Noggin 
(Neuroectoderm) 
DMSO 3.1 1.77 2.13 
Noggin 
(neuroectoderm) 
60µM 
leflunomide 
3.9 1.82 2.00 
Non-injected 
(Ectoderm) 
DMSO 5.2 1.85 1.89 
Non-injected 
(Ectoderm) 
60µM 
leflunomide 
6.1 1.86 1.85 
 
 
 
4.3.2 Quality of cDNA libraries 
 
 RNA samples were sent to the high throughput genomics centre at 
the Wellcome Trust Centre for Human Genetics in the University of 
Oxford for library preparation and sequencing. One of the most important 
factors of obtaining reliable next generation sequencing data is having 
good quality libraries. Sequencing platforms require shearing of cDNA 
libraries by focused ultra-sonicators which will mechanically shear the 
DNA to give fragments of around 300bp which will undergo size selection 
and adapter ligation for use on the specific sequencing platform. For 
quality control the quantitiy and fragment size of these libraries was 
analysed using an Agilent 2100 bioanalyzer to give a smear analysis 
(figure 4.6) and an electropherogram (figure 4.7). These were carried 
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out by the Wellcome Trust Centre for Human Genetics at the University 
of Oxford.  
  
 Smear analysis is considered the most accurate method for 
analysing library quality, however it is good practice to compare smear 
analysis results to those obtained by electropherogram. For smear 
analysis 1µl of each cDNA library is run on a gel and from this the 
average fragment size can be determined by the darkest region of the 
smear. Here each library shows an average fragment size of around 
300bp (figure 4.6), which is ideal for adapter ligation for next generation 
sequencing platforms. Also shown are the upper (purple line) and lower 
(green line) markers which are added to the samples to better gauge the 
library size.  
Figure 4.6 Smear analysis of sequencing libraries. Each lane 
represents a different cDNA library. 1 = Noggin and Wnt DMSO treated, 2 
= Noggin and Wnt leflunomide treated, 3 = Noggin DMSO treated, 4 = 
Noggin leflunomide treated, 5 = Non-injected DMSO treated, 6 = Non-
injected leflunomide treated. Purple lines show the upper marker. Green 
lines show the lower marker. Black arrow heads show average fragment 
size for each library at approximately 300bp.  
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 The cDNA libraries were also loaded onto a bioanalyzer chip, 
which gives a read out as an electropherogram (figure 4.7). Library 
samples were loaded with a fluorescent dye, which incorporates into 
double stranded DNA to give a readout in fluorescent units representing 
the size of the library fragments. Each library shows an average fragment 
size of approximately 300bp measured from the peak representing the 
library fragments (figure 4.7A-F). This confirms what was seen by smear 
analysis (figure 4.6). This again suggests good library quality as 300bp is 
an ideal size for sequencing platforms. The upper and lower markers 
(figure 4.7) were added as a control to library samples to give a relative 
view of library fragment sizes and to ensure the electrophoresis chip has 
run efficiently.  
Figure 4.7 Electropherogram representing fragment sizes of sequencing libraries. (A) 
Noggin and Wnt DMSO treated average fragment size 265bp. (B) Noggin and Wnt 
leflunomide treated average fragment size 280bp. (C) Noggin DMSO treated average 
fragment size 276bp. (D) Noggin leflunomide treated averge fragment size 307 bp. (E) Non-
injected DMSO treated average fragment size 325bp. (F) Non-injected leflunomide treated 
average fragment size 328bp. FU=fluorescent units. MW=molecular weight. Lower=lower 
marker. Upper=upper marker.  
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4.3.3. Quality of RNA sequencing  
 
 Analysis of the RNA sequencing results was done with Dr Simon 
Moxon, a bioinformatician in our lab. To assess the quality of the RNA 
sequencing results the amount of reads obtained for each gene in the 
X.laevis genome was plotted for the leflunomide treated samples against 
the untreated samples. The log of these values were plotted in a read 
distribution graph using R (figure 4.8) and assigned a colour based on 
the fold change found when comparing the treated against the untreated 
samples. Those genes showing no difference in fold change or very little 
difference are shown in yellow and red. Those that show differences in 
gene expression appear purple or blue depending on how great the fold 
change is. The ideal situation is to have most of your genes aligning well 
along the midline with a small percentage of genes deviating from this 
midline. If the graph displayed most of the genes deviating from the 
midline it would suggest that a large proportion of the expressed genes in 
the genome are affected by leflunomide treatment, which would not be 
specific or interesting.  
 Treated against untreated analysis was carried out for the three 
tissue types sent for sequencing (neural crest, neuroectoderm and 
ectoderm) and plotted as read distribution graphs shown in figure 4.8A B 
and C. All three graphs show little deviation from the midline of the plots. 
This is good as it indicates specific changes in gene expression across 
the genome and not general changes to the whole genome. The neural 
crest samples (figure 4.8A) shows the most points appearing blue in 
colour indicating a difference in gene expression of certain genes. This 
could either be genes upregulated (those appearing above the midline) or 
downregulated (those appearing below the midline). This was to be 
expected as previous experiments indicate that leflunomide treatment is 
mostly affecting neural crest development. A few changes in gene 
expression are also seen in the neuroectoderm sample (figure 4.8B). 
Interestingly there are almost no differences between the ectoderm 
samples, which shows very few blue points on the plot (figure 4.8C).  
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Figure 4.8 RNA sequencing read distribution plots. (A) Neural crest read 
distribution. (B) Neuroectoderm read distribution. (C) Ectoderm read distribution. 
The log of leflunomide treated reads are plotted against the log of DMSO treated 
reads. Red and Yellow indicates little to no fold change in expression. Purple and 
blue indicates some change and large changes in fold of gene expression.   
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4.4 Results of RNA sequencing  
 
4.4.1 Genes downregulated in the neural crest samples 
  
 The RNA sequencing data were analysed and listed in order of 
genes showing the most significant downregulation or upregulation of 
expression after leflunomide treatment for each sample type. For this 
analysis only genes showing the most significant differences in 
expression based on their p value have been analysed and so the first 
100 genes on the list were separated into two groups, those 
downregulated and those upregulated. These groups were then 
separated into categories based on gene function. The result of those 
genes found to be downregulated after leflunomide treatment are shown 
as a pie chart in figure 4.9, which shows the percentage of the overall 
genes analysed each category takes up. These categories are then 
broken down into a list of the individual genes comprising them, which 
can be seen in table 4.2 and a full list in appendix 2.  
 The category which occupies the majority of genes 
downregulated in the neural crest animal cap samples are genes 
involved in neural crest development. This was to be expected as 
previous experiments have suggested that neural crest cells are very 
sensitive to leflunomide treatment and we have hypothesised that 
transcriptional elongation is important for neural crest development.  40% 
of the genes downregulated in the neural crest animal cap samples were 
involved in neural crest development (figure 4.9). Most of these were 
well-known neural crest specifiers such as Sox10, FoxD3 and Sox9. 
Some were genes shown to be involved in neural crest cell migration 
such as Myosin10, which very recently has been identified to promote 
cranial neural crest migration in the branchial arches [271].  
 Other migration genes downregulated include CXCR4 and Cd44 
receptors. These are expressed by the neural crest cells and their ligands 
(Sdf1 and Hyaluronan) are expressed on the ventral ectoderm where 
chemotaxis promotes the movement of the neural crest cells into the 
branchial arches [59, 272]. Some of the genes put into the neural crest 
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development category are implicated to be involved in neural crest 
development in the literature however further investigation should be 
carried out to confirm this. Crisp2 has been shown to be upregulated in 
animal caps injected with Noggin and Wnt [273]. Riddle3/4 have been 
shown to be expressed in Xenopus stem cells so they may be present in 
the neural crest [274]. To further investigate these potentially novel 
neural crest genes, in situ hybridisations will be carried out to investigate 
the temporal and spatial expression of these.  
 Another category of genes seen to be downregulated in this 
sample type are heat shock proteins. This is interesting as previously 
described, the genes encoding heat shock proteins are classic examples 
of genes which will undergo polymerase pausing. These genes are 
thought to be primed in a paused state until heat shock occurs before 
undergoing transcriptional elongation. Many examples of paused heat 
shock proteins can be found in the literature and so this gives some 
support to the suggestion that leflunomide is predominantly targeting 
those genes, which are undergoing pausing and transcriptional 
elongation. In this sample type there are three different heat shock 
proteins, Hsp90aa1.1, Hsp105 and Hsp110, which are all seen to be 
sensitive to leflunomide.  
 Other genes downregulated include proteases normally 
expressed by neural crest cells to help them migrate through the 
extracellular matrix; genes such as Vimetin, which are associated with 
epithelial to mesenchymal transition; cell adhesion and signalling 
molecules which may normally allow the neural crest cells to 
communicate with each other; a purine synthesis enzyme is seen to be 
downregulated. This is potentially interesting as leflunomide is usually 
associated with the inhibition of pyrimidine synthesis. Finally BMP 
antagonists were downregulated. These are normally present to 
attenuate BMP signals allowing neural crest cells to form. Without such 
signals BMP is fully expressed which will not promote the induction of 
neural crest cells [12].  
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Figure 4.9 Pie chart showing the categories of genes down regulated in the neural 
crest animal cap sample after leflunomide treatment. Each gene downregulated in 
this sample type was put into a category and is displayed based on what percentage of 
the total genes looked at that category represents. Each slice of the pie chart represents 
a different category.  
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Table 4.2 Genes downregulated in neural crest animal cap sample after 
leflunomide treatment 
Category Gene name Description p-value 
Involved in 
neural crest 
development 
FoxD3 Neural crest 
specifier 
2.20E-17 
 
Sox10 Neural crest 
specifier 
3.48E-08 
 
Nr2f5 Wnt antagonist. 
Knockdown 
leads to loss of 
Sox9 
3.39E-08 
 
p63 Wnt antagonist. 
Knockdown 
leads to loss of 
Sox9 
1.22E-07 
 
Crisp2 Shown to be 
expressed in 
Wnt and Noggin 
injected animal 
caps. Needs 
further 
investigation.  
9.81E-07 
 
Sox9 Neural crest 
specifier 
0.000320735 
 
Sox8 Neural crest 
specifier 
0.000417912 
 
Snail Neural crest 
specifier 
0.000501486 
 
Riddle4 Differentiation 
and migration of 
Xenopus 
embryonic stem 
0.00064359 
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cells. Needs 
further 
investigation 
Tiarin D-V patterning. 
Knockdown 
leads to 
upregulated 
FoxD3 and Twist 
0.000713025 
 
Cd44 Neural crest 
migration 
0.000710453 
 
CXCR4 Neural crest 
migration 
0.000788999 
 
Slug Neural crest 
specifier 
0.001397235 
 
Myosin10 Neural crest 
migration 
0.001393705 
 
Riddle3 Differentiation 
and migration of 
Xenopus 
embryonic stem 
cells. Needs 
further 
investigation 
0.002592028 
 
Hoxa2b Neural crest AP 
patterning 
0.002949001 
 
Ap2-b Neural crest 
specifier 
0.003003123 
 
Tshirt1 Neural crest AP 
patterning 
0.004662415 
 
Tshirt3 Neural crest AP 
patterning 
0.000394662 
 
Heat shock 
proteins 
Hsp90aa1.1 Heat shock 
response gene 
0.000331953 
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Hsp105 Heat shock 
response gene 
0.002679511 
 
Hsp110 Heat shock 
response gene 
0.006790721 
 
Metabolism Rapgef2 GTP exchange 
factor 
5.35E-05 
 
Cyctochrome b-245 NADPH oxidase 0.000523672 
 
Phosphofrucktokinase  Glycolysis 0.003049477 
 
glycosyltransferase-
like protein 
glycosylation of 
alpha-
dystroglycan 
0.006856805 
 
Cell-cell 
signalling 
Neuropilin 1 Membrane 
bound receptor 
0.003447966 
 
Gap junction gamma 
1 
Diffusion from 
cell to cell 
0.004515787 
 
Connective 
tissue 
Lectin Carbohydrate 
binding proteins 
2.98E-05 
 
Fibrillin  Elastic fibres  0.000220774 
 
Micro-fibrillar 
associated protein 2 
Elastin 
associated 
microfibrils 
0.000321755 
 
Versican Proteoglycan 0.004977814 
 
Eye 
development 
Mafb Lens 
development 
1.62E-05 
 
Slit Directs retinal 
ganglion 
0.006416862 
 
Matrix 
metalloprotease 
Mmp28 Breakdown 
extracellular 
matrix 
0.005479091 
 
Mmp13 Breakdown 
extracellular 
0.001096916 
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matrix 
Cysteine 
protease 
Calpain 8 Proteolytic 
enzyme 
0.002423052 
 
Cathepsin Z Proteolytic 
enzyme 
0.004530473 
 
Calpain 9 Proteolytic 
enzyme 
0.005898228 
 
Envelope 
component 
Cornifilin Component of 
cornified 
envelope 
5.78E-06 
 
Sciellin Component of 
cornified 
envelope 
0.003969336 
 
Cell adhesion Neural adhesion 
molecule (NCAM) 
Expressed on 
surface of 
neurons 
0.00057836 
 
Claudin1 Tight junctions 6.03E-07 
 
BMP antagonist Jiraiya BMP antagonist 0.000209636 
 
Follistatin BMP7 
antagonist 
0.000908341 
 
Other Myocyte enchancer 
factor 2 
Muscle 
development 
0.0002553 
 
Gart Purine synthesis 0.000837793 
 
Aquaporin3 Blood antigens 0.001956033 
 
Vimentin Epithelial to 
mesenchymal 
transition 
0.00349757 
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4.4.2 Genes upregulated in the neural crest samples  
 
 Perhaps the most striking thing seen in the genes upregulated 
after leflunomide treatment in the neural crest animal caps are the 
number of genes involved in cranial neural crest migration. These genes 
are not those usually expressed by the neural crest cells but by the 
surrounding ectoderm where they act as chemokines to promote the 
migration of the neural crest cells through the branchial arches (figure 
4.10 and table 4.3). Examples of these seen here to be upregulated 
include Sdf1 and Hyaluronan both of which are expressed in the 
ectoderm found ventrally to the branchial arches. These act as ligands to 
receptors expressed on the neural crest cells, the Cd44 and CXCR4 
receptors and so promoting neural crest migration ventrally by 
chemotaxis [59]. Interestingly the receptors themselves usually 
expressed by the neural crest cells were seen in the list of genes 
downregulated. This might suggest that the neural crest cells have not 
had the chance to form neural crest and so form the surrounding 
ectoderm instead.  
 One gene we expected to see upregulated was cyctochrome 
p450 (table 4.3). This gene usually gets upregulated by cells in response 
to drug treatment to allow them to metabolise the drug. This is a good 
result as we want the drug to be metabolised by the animal cap cells in 
order for it to carry out its function. It is therefore expected that we see 
this increase in cyctochrome p450 as leflunomide is a small molecule 
compound which gets metabolised for its activity and so adding it to 
animal caps should upregulate this drug metabolism gene.  
 It was interesting to see that Hexim1 was in the list of 
upregulated genes. As described in the introduction Hexim1 is found 
bound to P-TEFb and in turn bound to 7SK snRNP when P-TEFb is in its 
inactive form. HEXIM1 is therefore acting as a kind of CDK inhibitor. 
Increasing the level of Hexim1 expression would suggest that more 
HEXIM1 is made and therefore P-TEFb is more commonly found in its 
inactive form implying that P-TEFb is unable to carry out its role to 
promote transcriptional elongation in the neural crest cells. More genes 
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are then held in a paused state. It was hypothesised that leflunomide was 
inhibiting transcriptional elongation however this gives a potential 
mechanism to this hypothesis.  
 Another interesting gene shown to be upregulated was Geminin. 
The Geminin protein has been previously implicated to regulate 
transcription through epigenetic modification. It is capable of regulating 
the activity of the polycomb repressive complex, which acts to 
trimethylate H3K27 to induce a repressive transcription state. Previous 
studies have shown that Geminin was able to repress neuronal 
differentiation through this mechanism and maintains neuronal cells in a 
precursor state. Overexpression of Geminin has been shown to 
upregulate neuroectoderm precursor markers such as Sox2 and Sox3 
and downregulate genes involved in neuronal differentiation such as 
Neurod4 [275]. This could be interesting if this could be applied to neural 
crest differentiation as this RNA sequencing data has shown that genes 
involved in early neural crest formation are upregulated such as Wnt and 
BMP. Previous experiments have shown that leflunomide treatment 
causes a loss of neural crest derivatives and genes involved in early 
neural crest differentiation such as Sox10.  
 Many genes were seen to be upregulated which change the 
anterior posterior patterning of the embryos. Canonical Wnt signalling 
was seen to be upregulated in this neural crest sample after leflunomide 
treatment. Wnt signalling is known to be important for the induction of 
neural crest so it may seem strange that it should be upregulated when 
we are seeing a loss of neural crest derivatives. Recent studies have 
shown that Wnt signalling plays different roles in neural crest 
development depending on the stage at which it is expressed. 
Conditional β-catenin activation in mice has shown that if Wnt signalling 
is activated in the premigratory neural crest the number of melanophores 
decreases. If it is activated in migratory crest the craniofacial cartilage 
appears disorganised and less sensory neurons develop and the 
melanophores develop ectopically not appearing as they usually would 
[276].  
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 This is the phenotype we see after leflunomide treatment in stage 
38 embryos. Leflunomide treated embryos are seen to develop 
melanophores unable to migrate into the tail. These melanophores may 
be ectopically formed due to activation of Wnt/β-catenin signalling in the 
migratory neural crest. This also explains why we see a drastic loss in 
sensory neuron function and the abnormal craniofacial cartilage 
development also seen in mice with conditional activation of Wnt/β-
catenin signalling in premigratory neural crest. It is probably because of 
this upregulation of Wnt that we see an upregulation of other genes 
involved in anterior posterior patterning. Some of these are known to be 
direct targets of Wnt such as Gbx2 and Hoxd1. Without the neural crest 
cells present the dynamic of the anterior embryo is completely thrown off 
course. Signals from the neural crest cells are responsible for inhibiting 
many posteriorising and placodal genes and so this could explain why 
these anterior posterior patterning and placodal genes are shown as 
being upregulated.  
 It is well established that intermediate levels of BMP are required 
for early neural crest induction along with Wnt and FGF signals from the 
underlying mesoderm. This attenuated BMP signalling is achieved by the 
secretion of BMP antagonists such as Noggin and Chordin. This same 
attenuated BMP gradient is also known to be important for starting neural 
crest cell migration as the intial signal promoting neural crest to undergo 
epithelial to mesenchymal transition. The upregulation of BMP may be as 
a result of the other neural crest migration abnormalities seen. TGFβ is 
associated with changing neural crest cell fate. Exposing neural crest 
cells to TGFβ signals will cause them to switch fate into a smooth muscle 
lineage [89]. It is possible that as leflunomide treatment is reducing the 
amount of neuron, melanophore and cartilage derivatives that these 
neural crest cells are moving down a different lineage such as this 
instead. 
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Figure 4.10 Pie chart showing the categories of genes upregulated in the 
neural crest animal cap sample after leflunomide treatment. Each gene 
upregulated in this sample type was put into a category and is displayed based on 
what percentage of the total genes looked at that category represents. Each 
segment of the pie chart represents a category. 
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Table 4.3 Genes upregulated in neural crest animal cap sample after leflunomide 
treament 
Category Gene name Description p-value 
Wnt signalling Sp5 Downstream of β-
catenin 
6.17E-05 
 
Wnt1 Canonical Wnt 0.000111897 
 
Frizzled 8 Canonical Wnt 
receptor 
0.000512652 
 
Sp6 Downstream of β-
catenin 
0.006095883 
 
BMP signalling BMP7 BMP 1.58E-05 
 
Ventx2.1 Mediates BMP4 
signalling 
0.00027312 
 
Blimp1 Upregulates BMP 
signalling 
0.000518871 
 
Sizzled (Frzb3) Antagonises BMP 
signalling 
6.47E-25 
 
Cranial neural 
crest migration 
Nkx3.1 Promotes correct 
migration of 
cranial neural 
crest cells 
2.56E-05 
 
Sdf1 Cxcr4 ligand 
expressed in 
ectoderm 
surrounding NC 
to promote their 
migration 
0.000150424 
 
Hyaluronan Cd44 ligand 
expressed in 
ectoderm 
surrounding NC 
0.001817622 
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to promote their 
migration 
GATA binding 
factor 3 
Expressed in 
ventral 
surrounding 
ectoderm of 
branchial arches 
to promote NC 
migration 
0.004069282 
 
Cytochrome 
p450 
Cytochrome 
p450 
Drug metabolism 4.49E-15 
 
Inhibiting 
transcriptional 
elongation 
Hexim1 Binds to P-TEFb 
to keep it in an 
inactive state 
0.003333565 
 
Anterior 
posterior (AP) 
patterning 
Anterior 
gradient 2 
Setting up AP 
patterning 
3.46E-05 
 
Hoxd1 Hox gene 
expressed 
anteriorly. Set up 
AP patterning 
0.001101447 
 
Gbx2 Targetted by Wnt 
to pattern the 
anterior embryo 
0.002898934 
 
TGFβ Pinhead Nodal co-factor 0.000597899 
 
Cripto-1 Nodal co-factor 0.001215938 
 
Bambi TGFβ receptor 0.004012539 
 
Solute transport SLC16A3 Cell surface 
solute transport 
0.000374833 
 
SLC38A2 Cell surface 
solute transport 
0.000639699 
 
Epigenetics Geminin Expression of 0.000836454 
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geminin 
antagonizes the 
expression of 
neuronal 
differentiation 
markers 
Placode Tbx3 Expressed in 
lateral placodes 
0.000228121 
 
Other CB1 Cell surface 
receptor 
0.000182573 
 
Cidea Apoptosis 0.001319887 
 
Stathmin Microtubule 
dynamics 
0.0038627 
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4.4.3 Genes downregulated and upregulated in the neuroectoderm 
samples 
 
 The neuroectoderm sample was analysed in the same way as 
the neural crest. Genes were listed in order of those showing the most 
significant downregulation or upregulation of expression after leflunomide 
treatment. For this analysis only genes showing the most significant 
differences in expression have been analysed and separated into two 
groups, those downregulated and those upregulated. The result of those 
genes found to be downregulated after leflunomide treatment are shown 
as a pie chart in figure 4.11. The categories shown in the pie chart are 
broken down into a list of the individual genes comprising them, which 
can be seen in table 4.4. Most of the genes affected in this sample type 
showed a downregulation of gene expression, only a few showed 
upregulation and so these are listed in table 4.5 and have not been 
displayed as a pie chart.  
 The most striking thing seen in this sample is that the majority of 
genes downregulated are those which are involved in the development of 
the non-neural ectoderm. In early development the ectoderm is divided in 
two areas. Those closest to the Spemann organiser (at the dorsal side) 
which will receive the signals secreted from the organiser such as Noggin 
and Chordin and this region of ectoderm will form the neuro-ectoderm. 
The region of ectoderm found further from these signals will not be 
specialised into neuro-ectoderm and will form the non-neural ectoderm. 
In this sample we see many genes involved in the differentiation of the 
non-neural ectoderm and those expressed in the superficial ectoderm 
such as keratin, being downregulated.  
 This suggests that the neuroectoderm is expanding at the 
expense of the non-neural ectoderm. This is also confirmed as in the list 
of genes upregulated in this sample we see Sox1 which is a master 
regulater gene for maintaining neuro-ectoderm in a progenitor state and 
not a differentiated one. Also we see Xbf-2, which functions to convert 
ectodermal cells into a neuroectoderm lineage. This expansion of 
neuroecotderm is often seen when neural crest cells are not present. 
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Neural crest cells normally restrict the expansion of the neuroectoderm 
into the neural plate border regions.  
 Many of the results obtained for this sample are similar to those 
obtained for the neural crest sample. Both sample types see a 
downregulation of genes involved in metabolism, solute transport and 
cornified envelope development. The reasons for this are still unclear. 
Both samples show an upregulation in the expression of cytochrome 
p450, which occurs as a response to the addition of a drug to the sample 
as cyctochrome p450 is associated with drug metabolism.  Both samples 
also show differences in anterior posterior patterning genes however 
where they are upregulated in the neural crest sample they appear 
downregulated in the neuroectoderm sample. It is well known that 
disrupting neural crest development and the anterior signals such as Wnt 
and BMP will lead to alterations in the anterior posterior pattern of the 
embryo. Here we seem to see a reduction in the anterior structures as 
there are also many genes involved in cement gland formation, which 
appear downregulated. Lectins are highly expressed in the cement gland 
so this may also explain why these are downregulated.  
 Also interstingly there are many genes involved in blood 
development such as Alpha 1,3/4 fucosyltransferase Lewis 1,2 and 
B3gnt1 all involved in determinging antigens on the surface of blood 
cells. Also genes involved in maintaining blood cell pluripotency such as 
Elf1 and Et3vl and also Lapl02, which is involved in blood cell migration. 
This is not suprising as a loss of blood circulation phenotype is seen in 
Spt6 (a DSIF component) mutant Zebrafish. It is now well established 
through the work of several studies that erythropoiesis is regulated by 
RNA polymerase pausing and transcriptional elongation. TIF1-ϒ will 
recruit the P-TEFb complex to erythroid genes such as Gata-1 to promote 
erythropoiesis and so it is logical that we see this downregulation of 
genes involved in erythropoiesis. It should however be mentioned that it 
is strange that these blood genes are expressed in the neuroectoderm 
sample and the reason for this is unkown.  
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Figure 4.11 Pie chart showing the categories of genes downregulated in the 
neuroectoderm animal cap sample after leflunomide treatment. Each gene downregulated 
in this sample is sorted into categories based on the gene function. Each segment of the pie 
chart represents a category. 
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Table 4.4 Genes downregulated in neuroectoderm animal cap sample after 
leflunomide treament 
Category Gene name Description p-value 
Non-neural ectoderm 
development 
Otogelin 
 
Mucociliary 
epithelial 
development 
 
6.88E-22 
 
Epidermal type I 
cytokeratin 
Protein found in 
outer skin 
7.95E-21 
 
Keratin Protein found in 
outer skin 
2.29E-20 
 
B2 keratin Protein found in 
outer skin 
2.56E-18 
 
Grainyhead-like 3  Switches 
neuroectoderm 
fate to epidermal 
ectoderm 
1.87E-13 
 
Ezrin  
 
Ectodermal 
microvilli 
development 
1.33E-12 
 
XIRG 
 
Expressed in non-
neural ectoderm 
1.18E-09 
 
Znf750 
 
Expressed in non-
neural ectoderm 
1.51E-09 
 
XK70 keratin 
 
Protein found in 
outer skin 
3.35E-09 
 
Kruppel like factor 
4 
 
Important for skin 
development 
1.37E-08 
 
Cytokeratin type II 
 
Protein found in 
outer skin 
6.14E-08 
 
Grainyhead-like-1 Expressed in non-
neural ectoderm. 
Gene silenced by 
Geminin 
1.01E-07 
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Type I keratin Protein found in 
outer skin 
2.08E-07 
 
Mid1ip1 
 
Mucociliary 
epithelial 
development 
 
2.67E-07 
 
Keratin 19 
 
Protein found in 
outer skin 
8.29E-07 
 
Esrp1 
 
Epithelial cell 
specific splicing 
1.11E-06 
 
Keratin 18 
 
Protein found in 
outer skin 
4.19E-06 
 
Eps8l1 
 
Epidermal growth 
factor receptor 
4.65E-06 
 
S1pr1 
 
Endothelial 
differentiaition 
8.71E-06 
 
Keratin 8 
 
Protein found in 
outer skin 
1.74E-05 
 
Tfap2c 
 
Epidermal 
trancription factor 
0.000197197 
 
Dlx3 
 
Expressed in non-
neural ectoderm 
0.000400418 
 
Cement gland Muc2 
 
Expressed in the 
cement gland 
5.10E-18 
 
Fam3d 
 
Expressed in the 
cement gland 
2.07E-10 
 
Galnt6.2 
 
Expressed in the 
cement gland 
4.85E-10 
 
Neptune Expressed in the 
cement gland 
2.34E-06 
 
Gale 
 
Expressed in the 
cement gland 
3.42E-06 
 
Golm1 
 
Expressed in the 
cement gland 
5.81E-05 
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Pitx1 
 
Expressed in the 
cement gland 
0.000213274 
 
Blood Alpha 1,3/4 
fucosyltransferase 
Lewis 1 
 
 
Blood cell antigens 2.09E-09 
 
KIT ligand Expressed on 
blood cells 
1.75E-07 
 
B3gnt1 
 
Blood cell antigens 9.51E-05 
 
Elf1 Transcriptional 
programme of 
haemopoeititc 
stem cells 
0.000216757 
 
Lapl02 Blood cell 
differentiation/migr
ation 
0.000286255 
 
Alpha 1,3/4 
fucosyltransferase 
Lewis 2 
Blood cell antigens 0.000405235 
 
Etv3l 
 
Transcriptional 
programme of 
haemopoeititc 
stem cells 
0.000431928 
 
Fat hydrolysis LipaseH 
 
Hydrolyses fat 2.95E-09 
 
Lipid desaturase 
 
Hydrolyses fat 2.42E-07 
 
Fa2h 
 
Sphingolipid fatty 
acid hydroxylase 
0.000352598 
 
Apoptosis Dapk2 
 
Apoptosis 3.16E-09 
 
Deoxyribonuclease 
gamma 
Apoptosis 4.29E-09 
 
growth arrest and 
DNA-damage-
inducible 
Causes DNA 
damage and 
2.05E-05 
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growth arrest by 
removing 
methylation marks 
Mixed lineage 
kinase 2 
Apoptosis 0.000327953 
 
Rassf6 
 
Apoptosis 0.000335887 
 
Cysteine protease Calpain 1 
 
Cysteine protease 1.06E-06 
 
Calpain 2 
 
Cysteine protease 0.000176406 
 
AP patterning Anterior gradient 2 
 
Anterior posterior 
patterning 
2.81E-10 
 
Anterior gradient 1 Anterior posterior 
patterning 
1.68E-06 
 
Np77 Anterior posterior 
patterning 
7.53E-06 
 
Lectins Epidermal lectin Carbohydrate 
binding protein 
4.64E-23 
 
X-epilectin 
 
Carbohydrate 
binding protein 
4.18E-08 
 
Xgalectin-VIa 
 
Carbohydrate 
binding protein 
6.19E-05 
 
Cornified envelope 
component 
Sciellin 
 
Cornified envelope 
component 
3.19E-11 
 
Cornifelin1 
 
Cornified envelope 
component 
8.26E-05 
 
Solute transport Synaptotagmin 1  
 
Membrane-
trafficking protein 
6.82E-07 
 
Slc7a4 
 
Cationic amino 
acid transporter 
 
1.15E-06 
 
Nipal4 
 
Mg2+ transporter 2.07E-05 
 
Solute carrier 
family 18 
Solute transport 2.52E-05 
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SLC12A8 
 
Cation-chloride 
cotransporter 
 
6.09E-05 
 
Chloride channel 
ClC-5 
 
 
Chloride transport 6.06E-05 
 
Metabolism Glutamine 
fructose-6-
phosphate 
transaminase 1 
Glutamate 
metabolism 
2.02E-09 
 
Rab27a 
 
GTPase 2.55E-08 
 
Rab25  
 
GTPase 1.67E-05 
 
Arl4c  
 
GTP exchange 8.94E-05 
 
Ectonucleoside 
triphosphate 
diphosphohydrolas
e 4 
 
Hydrolyses 
nucleotide 
triphosphates 
0.000133012 
 
Movement of 
melanosomes 
Rab27a 
 
Part of a complex 
which moves 
melanosomes 
along actin 
2.55E-08 
 
Melanoregulin 
 
Moves 
melanosomes 
along actin 
0.000215623 
 
Cell surface 
receptors 
Gpr160 
 
G-protein coupled 
receptor 
1.86E-06 
 
Tetraspanin 1  
 
Transmembrane 
receptor 
0.000137467 
 
Cranial neural crest Dlx2 Cranial neural 
crest migration 
7.44E-05 
 
Nkx3.1 Cranial neural 
crest migration 
0.000343902 
 
Other Cytidine 
monophospho-N-
acetylneuraminic 
acid hydroxylase 
 
Cell cell interaction 1.47E-07 
 
Peripheral myelin 
protein 
 
Component of 
myelin 
 
1.22E-05 
 
Annexin II 
 
Diverse cellular 
functions 
2.95E-05 
 
Rab3d 
 
Regulates noggin 
secretion to inhibit 
2.97E-05 
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BMP 
 
Calcium/calmoduli
n-dependent 
protein kinase 
(CaM kinase) II 
gamma 
 
Calcium 
homeostasis 
 
3.37E-05 
 
Sp7 
 
Bone 
differentiation 
 
5.53E-05 
 
Arginase 
 
Urea cycle 
 
8.31E-05 
 
Frrs1 
 
Iron reduction 0.000165395 
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Table 4.5 Genes upregulated in neuroectoderm animal cap sample after 
leflunomide treament 
Category Gene name Description p-value 
Neurogenesis Xbf-2 Converts cells 
from epidermal to 
neuroectoderm  
4.31E-08 
 
Sox1 Ectoderm 
differentiation into 
neuroectoderm 
0.000598916 
 
Muscle 
development 
Murc Muscle related 
extracellular 
matrix 
glycoprotein 
0.000451026 
 
Cytochrome 
p450 
Cytochrome 
p450 
Drug metabolism 0.005792073 
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4.4.5 Genes downregulated and upregulated in the ectoderm samples 
 
 Not many changes were seen in the ectoderm sample after 
leflunomide treatment. This was to be expected as leflunomide treatment 
appears to be relatively specific for neural crest cells and so if something 
as broad as the ectoderm were being significantly affected by preventing 
transcriptional elongation we would expect a much more severe and less 
specific phenotype at stage 38. The genes that are affected are listed in 
table 4.6 which shows all the genes downregulated and table 4.7 which 
shows all the genes upregulated after leflunomide treatment. It is 
immediately apparent that there are very few genes affected.  
 The interesting genes showing a downregulation include heat 
shock protein 90aa1.1. This was also seen to be downregulated in the 
neural crest sample. Heat shock proteins are classic examples of genes 
which will undergo polymerase pausing and so it is good to see these 
genes in the RNA sequencing data as it gives reassurance that 
leflunomide is in fact specifically inhibiting these genes which undergo 
pausing and transcriptional elongation. Also seen to be downregulated is 
CTP synthase 1-A, which is involved in pyrimidine synthesis. This result 
is expected as leflunomides main function is to inhibit pyrimidine 
synthesis. 
 When we look at the genes upregulated in this sample we see 
cytochrome p450 again. This is upregulated in all three samples as it is 
important for the metabolism of drugs. This again is good to see as it 
gives reassurance that the drug leflunomide as been sufficiently added to 
the sample. HEXIM1 is also upregulated, which again gives us evidence 
that leflunomide is acting to inhibit transcriptional elongation by inhibiting 
P-TEFb’s action. Some of the other genes shown to be upregulated in 
this sample type were downregulated in the neural crest sample. These 
include MMP13, Claudin1 and lectin. This could suggest a possible cell 
fate switch between the neural crest cells and the non-neural ectoderm. 
This is possible as the neural crest cells also upregulated markers 
normally found in the ectoderm surrounding the crest cells. Further 
investigation into this is required. 
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Table 4.6 Genes downregulated in ectoderm animal cap sample after leflunomide 
treament 
Category Gene name Description p-value 
Heat shock 
protein 
Hsp90aa1.1 
 
Heat shock 
protein 
6.68E-07 
 
Pyrimidine 
synthesis 
CTP synthase 1-A 
 
Enzyme involved 
in pyrimidine 
synthesis 
1.15E-05 
 
Actin binding Coro1a 
 
Actin binding 
protein 
5.99E-05 
 
Metabolism Chromosome 
condensation 1 
 
GTP exchange 0.000289312 
 
  
 
 
Table 4.7 Genes upregulated in ectoderm animal cap sample after leflunomide 
treament 
Category Gene name Description p-value 
Cytochrome p450 Cytochrome 
p450 
Drug 
metabolism 
2.79E-21 
 
Matrix 
metalloprotease 
Mmp13 Breakdown 
extracellular 
matrix 
0.000164963 
 
Cell adhesion Claudin 1 Tight junctions 2.48E-07 
 
Inhibiting 
transcriptional 
elongation 
HEXIM1 Binds P-TEFb in 
its inactive form 
3.10E-05 
 
Anti-oxidant 
defence 
Gstp1 Anti-oxidant 
defence 
5.55E-05 
 
Lectin Lectin Carbohydrate 
binding protein 
0.000450621 
 
Chitinase Ctbs Endoderm 
differentiation 
0.000365471 
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4.7 in situ hybridisation of potential novel neural crest genes found 
in the RNA sequencing experiment. 
 
4.7.1 in situ hybridisation of Crisp, Riddle3 and Riddle4 
 
 The neural crest sample of the RNA sequencing revealed some 
downregulated genes, which had very little information about them in the 
literature and only some suggestions about their potential role in neural 
crest development. These genes were Crisp, Riddle 3 and Riddle 4, all of 
which showed huge knockdown in expression after leflunomide 
treatment. To further characterise these genes, in situ hybridisations were 
carried out to see where and when they were expressed. These in situs 
were carried out at stages 15 and 18 when neural crest cells are 
specified (figure 4.12). In situs were also carried out at other stages but 
no specific expression patterns were detected and so are not shown 
here.  
 Crisp was shown to be expressed in the edges of the neural plate 
at the neural plate border at stages 15 (figure 4.12A) and 18 (figure 
4.12B). The expression pattern is however very faint, which may reflect 
the level of Crisp expression or the quality of the probe used. Riddle3 and 
4 were both seen to be expressed in the neural plate border of stage 15 
embryos (figure 4.12C and E). The expression for both at stage 18 is 
however very interesting. Patches of very high expression appear at the 
neural plate border in the shape and position associated with neural crest 
cells (figure 4.12D and F). This expression appears to be very specific 
for neural crest. There is also expression seen in the surrounding 
ectoderm however not as highly expressed as in the neural crest region. 
It could be suggested from this in situ data that Crisp, Riddle 3 and Riddle 
4 are all expressed in the neural crest however to confirm this further 
experiments should be carried out such as a double in situ with a known 
neural crest marker and functional studies using morpholinos to knock 
down the protein levels of these genes.  
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Figure 4.12 Novel neural crest genes. (A) in situ hybridisation for Crisp shows 
expression in the neural plate border at stage 15 (B) and at stage 18. (C and E) In 
situ hybridisation for Riddle 3 and 4 at stage 15 shows expression in the neural plate 
border. (D and F) in situ hybridisation for Riddle 3 and 4 show expression in the 
ectoderm and potentially in the neural crest at the neural plate border.  
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4.6 Discussion 
 
 The aims of this chapter were to establish an animal cap assay, 
which could be used to narrow down the investigation to analyse the 
effect of inhibiting transcriptional elongation specifically on neural crest 
cells. Animal cap assays are a useful tool when using Xenopus as an 
animal model as they can be induced to become a variety of different 
tissue types. To induce a neural crest cell fate the embryos should be 
injected with Wnt and a BMP antagonist, here we have used Noggin. To 
start it was necessary to establish a concentration of Wnt and Noggin 
RNA to be injected to sufficiently induce the neural crest cell fate. This 
was found to be 500pg of Noggin and 100pg of Wnt and so all 
subsequent experiments used these concentrations to induce neural 
crest. In addition to this, preliminary PCR and in situ experiments 
suggested that leflunomide was capable of knocking down neural crest 
markers in these neural crest animal caps. It would appear from these 
experiments that the knockdown of neural crest specifiers Slug and 
FoxD3 is much greater in the animal cap when compared to the 
experiments carried out in the whole embryos. This may be because the 
animal cap assay reduced the amount of signals, which would normally 
be received from the underlying mesoderm.  
 With a suitable animal cap assay designed, the main aim of this 
chapter was to obtain RNA sequencing from animal caps to determine 
genes affected by leflunomide treatment. For this 6 samples were 
produced; a neural crest sample, a neuroectoderm sample and a control 
ectoderm sample all with and without leflunomide treatment. The 
neuroectoderm sample was generated by the injection of Noggin alone 
and acts as a control to see which genes downregulated in the neural 
crest sample are neural crest specific and not globally expressed in 
neural tissue. The ectoderm sample acts similarly as a control to see 
whether inhibiting transcriptional elongation is specific to neural crest or 
whether it is a genome wide phenomenon.  
 The results obtained suggest that there is a lot of specificity for 
the inhibition of transcriptional elongation and neural crest cell 
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development. Many neural crest specifying genes were seen to be 
downregulated after leflunomide treatment. It is known that transcriptional 
elongation cannot be completely specific for neural crest development as 
many other studies have been carried out which show that it is important 
in a variety of other cell types. What is reassuring is that genes found to 
be paused in these other cell types and tissues also appeared in these 
RNA sequencing data. All of the samples displayed a loss of heat shock 
proteins, which were one of the first classes of genes to be shown to 
undergo RNA polymerase pausing. The neural crest sample showed two 
specific heat shock proteins Hsp105 and 110 which have not previously 
been shown to undergo pausing as they are both recently discovered and 
so there is not a great deal about them in the literature. Investigating the 
role of these and their ability to undergo pausing in neural crest cells 
could be interesting for follow on experiments. 
 Another cell type, which is often associated with the inhibition of 
RNA polymerase pausing is blood cells. Spt6 knockdown in Zebrafish 
has been shown to lead to a reduction in circulating blood cells and it is 
now thought that this occurs as the erythropoiesis specific transcription 
factor TIF1-ϒ is able to recruit the P-TEFb complex to genes involved in 
erythropoiesis such as Gata1. It was therefore not unexpected for us to 
see many genes involved in blood differentiation and migration appearing 
to be downregulated in this RNA sequencing data.  
 Many of the neural crest genes shown to be downregulated were 
those which were previously thought to be sensitive to leflunomide 
treatment in the whole embryo in situ experiments shown in chapter 3. 
These included Sox10, FoxD3, Slug and Sox9. c-Myc also showed a 
decrease by 2-fold but was not seen in the top most significant genes 
which seems surprising. There are possible explanations for this, firstly 
although the neural crest sample shows a decrease in myc expression, 
the neuroectoderm shows a large increase in myc expression and it is 
known that animal caps induced to become neural crest by Wnt and 
Noggin injection also show an increase amount of neuroectoderm gene 
expression and so it is possible that myc expression is knocked down 
specifically in the neural crest but upreguated in other tissue types. The 
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other suggestion is that myc is known to be directly downstream of Wnt 
and so the increase in Wnt expression seen in the neural crest sample 
could be increasing the myc expression. The whole embryo in situs of 
myc were carried out in embryos at stage 13 when the neural crest is pre-
migratory. It is possible that something is happening between stage 13 
and 15 to gradually increase Wnt expression and therefore gradually 
increase myc expression. I think it is possible that myc itself is 
undergoing pausing at stage 13 and this is causing an increase in Wnt 
signals as a feedback mechanism to rescue myc expression. This is just 
a theory and needs further investigation.  
 As mentioned for reasons which remain unclear the neural crest 
samples show an increase in Wnt expression. Wnt is known to play 
different roles in neural crest development depending on the time at 
which it is expressed. Early on in neural crest development it is required 
for induction. However, if it is expressed later on in neural crest 
development as the crest cells are beginning to migrate it almost has the 
reverse effect and decreases the amount of neural crest derivatives 
seen. Conditional mouse knock outs of Wnt activated specifically in the 
migratory neural crest show a loss of sensory neuron function, ectopic 
melanophores and disorganised cranio-facial cartilage. This matches the 
phenotype we see after leflunomide treatment in stage 38 Xenopus.  
 Finally, I believe it could be interesting to carry out follow on 
experiments to investigate the ability of the neural crest sample to 
downregulate receptors which they normally express (CXCR4 and Cd44) 
and in turn upregulate the ligands (Sdf1 and Hyaluronan) which are 
usually expressed by the surrounding ectoderm. This could indicate that 
the neural crest cells are able to switch fate into this surrounding 
ectoderm. It is possible that this change in ligand-receptor expression has 
been induced by the increase in canonical Wnt signalling in these cells. 
This would also co-incide with the alteration of cranio-facial cartilage seen 
when Wnt is upregulated in migratory neural crest cells. This again is just 
a theory and will require further experiments discussed later.  
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Chapter V 
Investigating the expression and 
function of the P-TEFb complex in 
neural crest development 
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5.1 Introduction 
 
 The results obtained using leflunomide so far suggest that 
transcriptional elongation is a process important in the development of 
neural crest cells specifically at the point of their specification. To further 
investigate this, known components of the transcriptional elongation 
machinery were investigated with respect to Xenopus neural crest. The 
complex known to be responsible for promoting transcriptional elongation 
is the P-TEFb complex so it made sense to investigate where and when 
the expression of P-TEFb components occurred in Xenopus 
development. The components of this complex are Cdk9, the kinase 
responsible for phosphorylating the negative transcriptional elongation 
complexes and an associated cyclin. The cyclin most associated with 
Cdk9 is CyclinT1 however, there is also mention in the literature of Cdk9 
forming a complex with CyclinT2 and CyclinK so these were also 
investigated [277-279]. Cdk9 has different alleles present in the tetrapoid 
Xenopus genome, known as Cdk9a and Cdk9b. Both of these alleles 
were investigated in these experiments.  
 To investigate the expression of these components in situ 
hybridisation was carried out to visualise the temporal and spatial 
expression patterns. Double in situs were also carried out to observe 
overlap in the expression of the P-TEFb components with a known neural 
crest marker. This would allow us to determine whether this complex is 
expressed in neural crest cells. Following on from this functional studies 
were carried out using morpholinos designed to prevent the translation of 
the P-TEFb components. Experiments were carried out to analyse the 
effect of inhibiting the translation of this complex on neural crest by 
assaying the development of neural crest derivatives such as 
melanophores, cranial facial cartilage and sensory neurons. In addition, 
the expression of genes involved in neural crest induction and 
specification were analysed after P-TEFb knockdown by in situ 
hybridisation.  
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5.2 The expression pattern of P-TEFb complex components 
 
5.2.1 Cdk9a expression 
 
 Cdk9a is one of two Cdk9 alleles found in the Xenopus genome. 
To start off the investigation into the temporal and spatial expression of 
the P-TEFb complex, an in situ hybridisation of Cdk9a was carried out at 
different stages of Xenopus development from stage 10.5 up to stage 38 
(figure 5.1). This experiment will allow us to see where Cdk9a mRNA is 
expressed at these stages as we predict that it would be expressed in the 
neural crest cells and potentially their migrating derivatives. During 
gastrulation at stage 10.5 Cdk9a was seen to be expressed in the 
surrounding ectoderm of the embryo but not in the involuting mesoderm 
and endoderm (figure 5.1A). The expression pattern appeared darker in 
the dorsal side at the dorsal blastopore lip. These dorsal regions will 
eventually give rise to dorsal structures such as neural crest and neural 
tube.  
 At neurula stages the expression pattern appears specific for the 
neural plate and neural plate border regions. This is first seen in embryos 
at stage 12.5 (figure 5.1B) and the expression pattern continues to be 
neural specific at stages 15 and 18 (figure 5.1C and D). At stages 15 and 
18 the expression pattern appears to be in the edges of the neural plate 
at the neural plate border, which is the region in which the neural crest 
cells will form. In order to be certain if this expression is expressed in 
these regions a double in situ should be carried out with a known neural 
crest marker (see below). At stage 22 the expression of Cdk9a can be 
seen in the migrating neural crest of the branchial arches (figure 5.1E). 
This expression in the branchial arches also persists in the migrating 
crest in tailbud stages 26 and 32 (figure 5.1F and G). It is also seen to be 
expressed in the differentiated branchial arches at stage 38 once the 
embryos reach tadpole stage (figure 5.1H). This suggests that Cdk9a is 
potentially expressed in the neural crest cells during their specification 
and also in the migrating neural crest derivatives.  
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Figure 5.1 The expression pattern of Cdk9a. (A) Expression in the dorsal ectoderm at 
stage 10.5. (B) Expression in the early neural plate at stage 12.5. (C,D) Expression in the 
neural plate (NP) and neural plate border (NPB) at stage 15 and 18. (E, F, G) Expression 
in the branchial arches (BA), otic vesicle (Ov) and eye (E) at stages 22, 26 and 32. (H) 
Expression in the branchial arches at stage 38. A=anterior, P=posterior, D=dorsal and 
V=ventral.  
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5.2.2 Cdk9b expression 
 
 Cdk9b is the second Cdk9 allele in the Xenopus laevis genome 
and so an in situ hybridisation was also carried out on this allele. Similar 
to Cdk9a, Cdk9b acts as the kinase enzyme in the P-TEFb complex, 
which promotes positive transcriptional elongation [154]. This in situ was 
also carried out to gauge the spatial and temporal expression of the P-
TEFb complex in Xenopus embryos from gastrula all the way up to 
tadpole stages (figure 5.2). At gastrula stage 10.5 the expression of 
Cdk9b can be seen in the dorsal ectoderm at the dorsal blastopore lip 
(figure 5.2A), which was also the case for Cdk9a. No expression is seen 
in the involuting mesoderm and endoderm. At neurula stages 13, 15 and 
18 the expression of Cdk9b is seen in the neural plate and neural plate 
border where neural crest cells will form (figure 5.2B, C and D). 
 In tailbud stage embryos the expression of Cdk9b is seen in the 
neural crest derived branchial arches and also the eye and otic vesicle. 
This is shown in a stage 25 and 30 embryo (figure 5.2E and F). This 
expression pattern is the same as that seen for Cdk9a. Finally in a 
tadpole embryo at stage 38 the expression is seen in the migrated crest 
of the branchial arches (figure 5.2G). All of the expression patterns 
obtained for Cdk9b (figure 5.2) are comparable to those obtained for 
Cdk9a (figure 5.1). The expression seems to be in the neural plate 
border regions where the neural crest are formed and then it is still 
expressed in the neural crest derivatives as they migrate. To ensure that 
this expression does overlap with the neural plate border at neurula 
stages, a double in situ hybridisation should be carried out with a known 
neural crest marker (see below).  
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Figure 5.2 The expression pattern of Cdk9b. (A) Expression in the dorsal 
ectoderm at the dorsal blastopore lip (DBL) at stage 10.5. (B) Expression in the 
early neural plate (NP) and neural plate border (NPB) at stage 13. (C,D) 
Expression in the neural plate and neural plate border at stage 15 and 18. (E, F) 
Expression in the branchial arches (BA), otic vesicle (Ov) and eye (E) at stages 
25 and 30. (G) Expression in the branchial arches at stage 38. A=anterior, 
P=posterior, D=dorsal and V=ventral.  
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5.2.3 CyclinT1 expression 
 
 CyclinT1 is the cyclin component most commonly found to be 
associated with Cdk9 in the P-TEFb complex. CyclinT1 is responsible for 
receiving developmental signals, which promote the activity of the P-
TEFb complex, driving it to the correct gene to release RNA Pol ll from 
pausing. It also allows the connection of the P-TEFb complex to the 
super elongation complex. As CyclinT1 is also a component of P-TEFb it 
was thought to be important to carry out this in situ to compare the 
expression pattern obtained to that of Cdk9. This in situ was also carried 
out on Xenopus embryos ranging from gastrula stage 10 up to tadpole 
stage 38 (figure 5.3). The expression pattern obtained for CyclinT1 at 
gastrula stage 11 appears only in the ectoderm and not the mesoderm or 
endoderm (figure 5.3A). This should be confirmed by sectioning stage 
10.5 embryos. This was the same expression seen for Cdk9a and b. At 
neurula stages 15 and 18 the expression pattern is confined to the neural 
plate and neural plate border (figure 5.3B and C).  
 In tailbud stage embryos at stage 26 and 32 the expression 
pattern is found in the branchial arches, otic vesicle and the eye (figure 
5.3D and E). At tadpole stage 38 the expression still appears in the 
neural crest derived branchial arches (figure 5.3F). These expression 
patterns obtained for CyclinT1 match those obtained for Cdk9a and b at 
all stages of Xenopus development. Expression appears to reside in the 
neural plate border of neurula stage embryos, the region in which neural 
crest will form. This again must be confirmed using a double in situ of 
CyclinT1 with a known neural crest marker. Later on at tailbud stages 26 
and 32 and tadpole stage 38, the expression is seen in the neural crest 
derived branchial arches. These results would suggest that the P-TEFb 
complex and therefore transcriptional elongation is important in the 
development of neural crest cells.  
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 Figure 5.3 The expression pattern of CyclinT1. (A) Expression in the dorsal ectoderm at stage 11. (B,C) Expression in the neural plate (NP) and neural plate 
border (NPB) at stage 15 and 18. (D,E) Expression in the branchial arches (BA), 
otic vesicle (Ov) and eye (E) at stages 26 and 32. (F) Expression in the branchial 
arches at stage 38. A=anterior, P=posterior, D=dorsal and V=ventral.  
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5.2.4 CyclinT2 expression 
 
 CyclinT2 acts in the same way as CyclinT1. It has been shown to 
associate with Cdk9 acting as the cyclin associated with the enzymatic 
Cdk. CyclinT2 is however less commonly refered to in the literature as 
being in a complex with Cdk9. It is thought to be CyclinT1 which is 
predominantly associated with Cdk9 in the P-TEFb complex. This aside it 
was still deemed important for this study to investigate the temporal and 
spatial expression of CyclinT2 so that it could be compared to that of 
CyclinT1. An in situ hybridisation was carried out for CyclinT2 on 
Xenopus embryos ranging from gastrula stage 10.5 up to tadpole stage 
38 (figure 5.4). The expression pattern obtained was the same as those 
obtained for the two Cdk9 alleles and CyclinT1. At gastrula stage 10.5 
the expression was mostly seen in the dorsal ectoderm (figure 5.4A), the 
region of ectoderm fated to become neural structures. At the early 
neurula stage 12.5, the expression is still seen in the ectoderm but starts 
to be confined to the neural plate (figure 5.4B).  
 At neurula stages 15 and 17 the in situ expression pattern for 
CyclinT2 is seen in the neural plate and the neural plate border, the 
region in which neural crest cells will form (figure 5.4C and D). At tailbud 
stages 25 and 30 the expression is seen in the branchial arches formed 
from the migrating neural crest (figure 5.4D and E). Finally at stage 38 in 
tadpole embryos the expression can still be seen in the branchial arches 
as the crest have fully migrated and differentiated. The result obtained for 
CyclinT2 is comparable to the expression pattern of Cdk9 and CyclinT1. 
Much like these expression patterns, CyclinT2 appears to be expressed 
in the regions where the early neural crest cells are specified. This must 
be confirmed by double in situ hybridisation. The expression pattern is 
again seen in the migrating crest of the branchial arches much like Cdk9 
and CyclinT1.  
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Figure 5.4 The expression pattern of CyclinT2. (A) Expression in the dorsal 
ectoderm at stage 10.5. (B) Expression in the early neural plate at stage 12.5. (C,D) 
Expression in the neural plate (NP) and neural plate border (NPB) at stage 15 and 18. 
(E, F) Expression in the branchial arches (BA), otic vesicle (Ov) and eye (E) at stages 
25 and 30. (H) Expression in the branchial arches at stage 38. A=anterior, 
P=posterior, D=dorsal and V=ventral.  
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5.3 Double in situ hybridisation of P-TEFb components and neural 
crest marker Sox10 
 
5.3.1 Whole embryo P-TEFb and Sox10 in situ hybridisation 
 
 In situ hybridisation experiments of the P-TEFb complex 
components, Cdk9a, Cdk9b, CyclinT1 and CyclinT2 demonstrated an 
expression pattern in the neural plate border region of neurula stage 
embryos. This region is where the neural crest cells form and become 
specified. As we are interested in whether P-TEFb and transcriptional 
elongation is important for neural crest development it is important to see 
if the expression of these P-TEFb components overlaps with the 
expression of neural crest cell markers. For this next experiment the P-
TEFb components underwent an in situ hybridisation using NBT (nitro 
blue tetrazolium) to detect alkaline phosphatase activity. This gives the 
blue precipitate wherever the P-TEFb component is expressed. 
Immediately after this a second in situ is carried out for the known neural 
crest marker Sox10. Sox10 is visualised using fast red to detect alkaline 
phosphatase activity and so the neural crest regions are labelled on the 
embryo in red. This was carried out in stage 17 embryos for Cdk9a, 
Cdk9b, CyclinT1 and CyclinT2 (shown in blue) in combination with Sox10 
(shown in red).  
 The results obtained suggest that each of the P-TEFb comonents 
are co-expressed in the same regions as the neural crest marker Sox10 
(figure 5.5). This was seen to be true for Cdk9a (figure 5.5A), Cdk9b 
(figure 5.5B), CyclinT1 (figure 5.5C) and CyclinT2 (figure 5.5D). In the 
whole embryo the expression patterns appear to overlap however it is 
difficult to be certain, as it is unclear if the expression is found at the 
same depth into the embryo. When the red and blue precipitates overlap 
the colour seen is a darker brown/red. To be able to be sure of whether 
the expression seen is in the same plane in terms of depth and therefore 
within the same cells, these double in situ embryos were sectioned and 
the fast red detected by fluorescence making the colour difference easier 
to judge. 
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Figure 5.5: Double in situ hybridisation of P-TEFb component and neural crest 
marker Sox10. (A) Stage 17 embryo showing Cdk9a expression (blue) and Sox10 
expression (red). (B) Stage 17 embryo showing Cdk9b expression (blue) and Sox10 
expression (red). (C) Stage 17 embryo showing CyclinT1 expression (blue) and 
Sox10 expression (red). (D) Stage 17 embryo showing CyclinT2 expression (blue) 
and Sox10 expression (red). 
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5.3.2 Sectioned P-TEFb and Sox10 in situ hybridisation 
  
 Embryos which had undergone a double in situ for a P-TEFb 
component (blue) and Sox10 (red) were sectioned to more clearly see if 
there is an overlap in the two expression patterns. After sectioning, the 
blue expression pattern obtained after a Cdk9a in situ appears to be in 
the neural plate and at the edges of the neural plate, in the neural plate 
border (figure 5.6A). The expression for Sox10 in seen as two patches 
either side of the neural plate as Sox10 is only expressed in the neural 
plate border in the developing neural crest cells (figure 5.6B). When this 
is magnified further in the areas, which express Sox10 can be outlined 
(figure 5.6Bi) and seen to correspond with an area of blue expression 
representing Cdk9a (figure 5.6Ai). This would suggest that Cdk9a and 
Sox10 are co-expressed at the neural plate border within the neural crest 
cells.  
 This was also seen for the other P-TEFb components 
investigated here. Cdk9b expression appears the same as Cdk9a 
expression in the sectioned embryos. The expression is seen in the 
neural plate and neural plate border (figure 5.6C). The outlined region of 
Sox10 expression represents the area in which neural crest cells are 
found (figure 5.6Di).  This region clearly overlaps with the blue Cdk9b 
expression outlined in figure 5.6Ci. The CyclinT1 expression (figure 
5.6E) and the CyclinT2 expression (figure 5.6G) after sectioning can be 
seen in the neural plate and neural plate border. The expression of 
Sox10 in these sectioned embryos is seen in the neural plate border 
(figure 5.6F and H). When this region of Sox10 expression is outlined 
(figure 5.6Fi and Hi) and can be seen to overlap with the expression of 
CyclinT1 and T2 in the neural plate border (figure 5.6Ei and Gi). This 
suggests that components of the P-TEFb complex are co-expressed in 
with Sox10 within neural crest cells at the time of neural crest cell 
specification and may therefore be playing a role in the development of 
these cells at this time.  
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Figure 5.6: Sectioned embryos after a double in situ for P-TEFb components (blue) and 
Sox10 (red). (A) 5x magnification Cdk9a expression (blue) in the neural plate and neural plate 
border. (Ai) 20x magnification Cdk9a expression outlined in the neural plate border. (B) 5x 
magnification Sox10 expression. (Bi) 20x Sox10 expression outlined in the neural plate border. 
(C) 5x magnification Cdk9b expression (blue) in the neural plate and neural plate border. (Ci) 
20x magnification Cdk9b expression outlined in the neural plate border. (D) 5x magnification 
Sox10 expression. (Di) 20x Sox10 expression outlined in the neural plate border. (E) 5x 
magnification CyclinT1 expression (blue) in the neural plate and neural plate border. (Ei) 20x 
magnification CyclinT1 expression outlined in the neural plate border. (F) 5x magnification 
Sox10 expression. (Fi) 20x Sox10 expression outlined in the neural plate border. (G) 5x 
magnification CyclinT2 expression (blue) in the neural plate and neural plate border. (Gi) 20x 
magnification CyclinT2 expression outlined in the neural plate border. (H) 5x magnification 
Sox10 expression. (Hi) 20x Sox10 expression outlined in the neural plate border. 
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5.4 Morpholino knockdown of P-TEFb components 
 
5.4.1 in vitro translation 
 
 Once the expression of the P-TEFb compex components had 
been established the next step was to carry out functional experiments 
using morpholinos to block the translation of the P-TEFb components. 
This would prevent the activity of the P-TEFb complex therefore 
preventing transcriptional elongation from occurring. Morpholinos were 
designed for Cdk9a, Cdk9b and CyclinT1 refer to chapter 2 materials and 
methods for morpholino sequences. Before a morpholino can be used its 
activity must be established in vitro using an in vitro translation method. 
For this experiment an in vitro translation is set up using the translation 
machinery of rabbit reticulocytes and a plasmid containing the gene of 
interest in this case a P-TEFb component. The gene of interest will be 
transcribed and translated in an eppedorf tube by the rabbit reticulocyte 
machinery. To be able to detect the protein made, the methionine added 
to the reaction is radioactively labelled and so the levels of protein 
present can then be seen by imaging on a phosphorimager. When a 
translation blocking morpholino is added to the reaction you would expect 
to see less protein produced compared to your control.  
 Cdk9a, Cdk9b and CyclinT1 proteins were successfully 
translated from their plasmids using the in vitro translation method (figure 
5.7). To the same amount of plasmid an increasing amount of 
corresponding morpholino was added at concentrations of 40ng, 80ng 
and 100ng. All three P-TEFb components saw a dose dependent 
decrease in protein levels due adding increasing concentrations of 
morpholino. This suggests that the morpholinos are capable of efficiently 
preventing translation and can be used in further experiments. Luciferase 
comes with the in vitro translation kit to be used as a positive control to 
ensure translation is taking place. As an extra control the highest 
concentration of morpholino was added to luciferase to prove that each 
morpholino is specific for its target gene and cannot block luciferase 
protein translation (figure 5.7) 
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Figure 5.7 in vitro translation of Cdk9a, Cdk9b and CyclinT1. Each sample was 
loaded in duplicate as a loading control. The lanes labelled plasmid show the amount 
of protein produced by the plasmid alone. Subsequent lanes show protein produced 
after increasing morpholino concentrations at 40ng, 80ng and 100mg. Control lanes 
show expression of a luciferase control plasmid and adding 100ng of each morpholino 
to this luciferase control plasmid.  
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5.4.2. Phenotype seen after Cdk9a morpholino knockdown 
 
 To study the function of Cdk9a in Xenopus development, a 
morpholino was designed to block the transcription of the Cdk9a protein. 
This would prevent the enzymatic activity of the P-TEFb complex and 
therefore prevent transcriptional elongation. Cdk9a morpholino was 
injected into both cells of a two-cell stage embryo at varying 
concentrations to determine a concentration, which would give a 
consistant phenotype. From the in vitro translation it could be estimated 
that somewhere between 80ng and 100ng would be most effective. At 
the same time a standard control morpholino is injected in the same way 
corresponding to the highest concentration of Cdk9a morpholino used.  
 This experiment demonstrated that most of the control 
morpholino injected embryos displayed a wild type phenotype with a 
normal number of melanophores (figure 5.8A). This wild type phenotype 
was seen at a high frequency in most of the injected embryos (figure 
5.8E). Injection of 40ng of morpholino appeared to have little affect on the 
development of the embryos again; most appeared wild type (figure 
5.8B). A small number of embryos started to display some loss of 
pigmentation after injection of 80ng of Cdk9a morpholino (figure 5.8C). 
This pigment loss is seen in the eye and lateral stripe. After 100ng of 
morpholino injection embryos display a clear loss of pigmentation in the 
eye, lateral stripe head and tail (figure 5.8D). This is seen in 28% of the 
injected embryos as demonstrated in a group image (figure 5.8F). These 
data have been quantified based on whether the injected embryos 
displayed a wild type or pigment loss phenotype and are shown in figure 
5.9 and table 5.1. Melanophores are neural crest derived which indicates 
that Cdk9a may be functioning in the development of the neural crest. 
This phenotype obtained also mimics that which was seen after 
leflunomide treatment. It could be suggested from this result that blocking 
P-TEFb activity results in defects of neural crest derived melanophores. 
Following this other neural crest derivatives should be investigated. 
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Figure 5.8 The phenotype obtained after Cdk9a knockdown. All embryos were 
injected into both cells at the 2 cell stage (A) 100ng standard control morpholino 
(CoMo). (B) 40ng Cdk9a morpholino (C) 80ng Cdk9a morpholino showing pigment loss 
in the eye and lateral stripe (black arrow heads). (D) 100ng Cdk9a morpholino  showing 
pigment loss in the eye, lateral stripe, head and tail (black arrow heads). (E) Group of 
control morpholino injected embryos. (F) Group of 100ng Cdk9a morpholino injected 
embryos. Mo=morpholino.  
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Figure 5.9 Graph showing the percentage of embryos showing a pigment loss 
phenotype after Cdk9a morpholino injection. From left to right 100ng control 
morpholino (n=119), 40ng Cdk9a morpholino (n=73) 80ng Cdk9a morpholino (n=76) 
and 100ng Cdk9a morpholino (n=138). *=p<0.05 by Kruskall Wallis statistical test 
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5.4.3 Phenotype seen after CyclinT1 knockdown 
 
 Along with Cdk9a it was important to investigate the function of 
CyclinT1. CyclinT1 is another component of P-TEFb and so it was 
hypothesised that the phenotype seen after CyclinT1 knockdown would 
be similar to that obtained after Cdk9a knockdown. CyclinT1 is not 
responsible for the enzymatic activity of P-TEFb however it responsible 
for receiving signals to activate the complex and connect the complex to 
the super elongation complex to allow it to carry out its role in 
transcriptional elongation. It is therefore a key regulator of transcriptional 
elongation and it could therefore be assumed that the knockdown of this 
protein would prevent transcriptional elongation from occurring. Similarly 
to the knockdown of Cdk9a, CyclinT1 morpholino was injected into both 
cells of a two-cell stage embryo at a range of concentrations. These 
injected embryos were left to develop until stage 38 when they were fixed 
and their phenotype observed. It could be estimated from the in vitro 
translation that the most effective concentration would be between 40ng 
and 80ng.  
 Embryos injected with the standard control morpholino 
demonstrated a wild type phenotype (figure 5.10A). This was seen in 
most of the embryos injected as demonstrated in the group image (figure 
5.10E). After 20ng of morpholino injected the embryos mostly displayed a 
wild type phenotype (figure 5.10B). A small percentage of embryos 
injected with 40ng of morpholino started to display a pigment loss 
phenotype with some embryos displaying a loss of melanophores in the 
lateral stripe (figure 5.10C). After 60ng injections of morpholino a large 
percentage of embryos displayed a pigment loss phenotype (figure 
5.10D and F). This pigment loss is seen in the lateral stripe, eye, head 
and tail. These data were quantified based on whether the embryos 
displayed a wild type or pigment loss phenotype and are shown as a 
graph in figure 5.11 and in table 5.2. This mimics the phenotype seen 
after Cdk9a knockdown and that obtained after leflunomide treatment 
giving further evidence for a role of transcriptional elongation in the 
development of neural crest cells. 
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Figure 5.10 The phenotype obtained after CyclinT1 knockdown. All embryos were 
injected into both cells at the 2 cell stage (A) 60ng standard control morpholino (CoMo). 
(B) 20ng CyclinT1 morpholino (C) 40ng CyclinT1 morpholino showing pigment loss in the 
eye and lateral stripe (black arrow heads). (D) 60ng CyclinT1 morpholino  showing 
pigment loss in the eye, lateral stripe, head and tail (black arrow heads). (E) Group of 
control morpholino injected embryos. (F) Group of 60ng CyclinT1 morpholino injected 
embryos. Mo=morpholino.  
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Figure 5.11 Graph showing the percentage of embryos showing a pigment 
loss phenotype after CyclinT1 morpholino injection. From left to right 60ng 
control morpholino (n=105), 20ng CyclinT1 morpholino (n=87) 40ng CyclinT1 
morpholino (n=94) and 60ng CyclinT1 morpholino (n=95). *=p<0.05 by Kruskall 
Wallis statistical test. 
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5.4.4 Phenotype seen after Cdk9b morpholino knockdown and Cdk9a/b 
combined morpholino knockdown 
 
 To follow on from the knockdown of Cdk9a and CyclinT1 it was 
important to knockdown the other Cdk9 allele in the Xenopus genome, 
Cdk9b. Knocking out this allele should give the same phenotype seen 
when Cdk9a was knocked down. Following on from this a double 
knockdown of both alleles was achieved by co-injecting both the a and b 
allele morpholinos. Cdk9b morpholino was injected at increasing 
concentrations in both cells of a two-cell stage embryo. These were left to 
develop until stage 38 to analyse the phenotype. At the same time 
increasing concentrations of a mixture of Cdk9a and Cdk9b morpholino 
were co-injected in the same way and fixed at the same stage.  
 Injection of a standard control morpholino showed a wild type 
phenotype in 84% of the embryos injected (figure 5.12A, E and I). 
Injection of 40ng of Cdk9b morpholino also demonstrated a mostly wild 
type phenotype (figure 5.12B). Injection of 80ng of Cdk9b morpholino 
gave 11% of embryos with some pigment loss in the lateral stripe but the 
phenotype was not very strong (figure 5.12C). Injection of 100ng of the 
Cdk9b morpholino gave 17% of embryos with pigment loss in the lateral 
stripe, head, eye and tail (figure 5.12D) however this phenotype is not as 
strong as that obtained after Cdk9a or CyclinT1 knockdown. It also did 
not occur as frequently. This may reflect the efficiency of the morpholino. 
Morpholino efficiency greatly varies between genes depending on their 
design. Co-injection of 20ng of Cdk9a and b morpholino gave a mostly 
wild type phenotype (figure 5.12F). Some pigment loss is seen after 
injection of 40ng of a and 20ng of b (figure 5.12G). Injection of 60ng of 
Cdk9a and 40ng of Cdk9b morpholino gives a stronger pigment loss 
phenotype in 29% of the embryos (figure 5.12H and J). These data were 
quantified and are displayed in a graph showing the percentage of 
embryos with wild type or pigment loss phenotypes in figure 5.13 and 
table 5.3. 
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Figure 5.12 The phenotype obtained after Cdk9b knockdown and both Cdk9a and b 
knockdown. All embryos were injected into both cells at the 2 cell stage (A) 100ng standard 
control morpholino (CoMo). (B) 40ng Cdk9b morpholino (C) 60ng Cdk9b morpholino showing 
pigment loss in the lateral stripe (black arrow heads). (D) 100ng Cdk9b morpholino  showing 
pigment loss in the lateral stripe, head and tail (black arrow heads). (E) 100ng standard control 
morpholino (CoMo). (F) 20ng of Cdk9a and 20ng Cdk9b morpholino co-injected (G) 40ng of 
Cdk9a and 20ng Cdk9b morpholino. (H) 60ng Cdk9a and 40ng Cdk9b morpholino  showing 
pigment loss in the lateral stripe and head (black arrow heads). (I) Group of control morpholino 
injected embryos. (J) Group of 60ng Cdk9a and 40ng of Cdk9b morpholino injected embryos. 
Mo=morpholino.  
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Figure 5.13 Graph showing the percentage of embryos showing a pigment loss 
phenotype after CyclinT1 morpholino injection. From left to right 100ng control morpholino 
(n=77), 60ng Cdk9b morpholino (n=77) 80ng Cdk9b morpholino (n=62) and 100ng Cdk9b 
morpholino (n=62), 20ng Cdk9a 20ng Cdk9b morpholino (n=70) 40ng Cdk9a 20ng Cdk9b 
morpholino (n=81) and 60ng Cdk9a 40ng Cdk9b morpholino (n=103). *=p<0.05 by Kruskall 
Wallis statistical test. 
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5.4.5 The effect of Cdk9 and CyclinT1 knockdown on craniofacial 
development 
 
 To investigate the role of the P-TEFb in neural crest development 
other neural crest derivatives were observed. Craniofacial cartilage is 
derived from cranial neural crest cells and can be stained for using an 
alcian blue stain. This experiment was previously carried out after 
leflunomide treatment, which showed a disorganisation in branchial 
cartilage. Alcian blue will stain glycosaminoglycans specific to cartilage 
and so the blue stain observed can be assumed to be only cartilage. 
Here embryos were injected in one cell of two at the two cell stage with 
either standard control morpholino, Cdk9a morpholino or CyclinT1 
morpholino and left to develop until stage 45 when they were fixed and 
underwent alcian blue staining to visualise the development of cranio-
facial cartilage. This cartilage was then dissected and imaged. 
 Injection of the standard control morpholino into one half of the 
embryo had no effect on the development of the cranio-facial cartilage 
(figure 5.14A). Both sides appeared the same demonstrating the wild 
type development represented in the schematic diagram in figure 5.14B. 
After injection of the Cdk9a morpholino into half of the embryo, the 
injected half (on the right hand side) appeared to display defects in 
cartilage development (figure 5.14C). The branchial cartilage appears 
smaller and disorganised compared to the control side of the embryo. 
The Meckel’s and Ceratohyal cartilage appears relatively unaffected. 
After injection of the CyclinT1 morpholino into half of the embryo, the 
injected half (on the right hand side) also appeared to display defects in 
cartilage development (figure 5.14D). The branchial cartilage again 
appears smaller and very disorganised compared to the control side of 
the embryo. Similarly to Cdk9a knockdown, the Meckel’s and Ceratohyal 
cartilage appeared mostly unaffected. This would suggest that 
knockdown of the P-TEFb complex affects the development of cranial 
neural crest cells. 
  187 
 
 
Figure 5.14: The effect of P-TEFb knockdown on cranio-facial 
cartilage. (A) Dissected 100ng control morpholino (CoMo) 
injected embryos at stage 45 after alcian blue staining. (B) 
Diagram representing normal cranio-facial cartilage development. 
M=Meckels cartilage, C=Ceratohyal, B=Branchial cartilage. (C) 
Dissected cranio-facial cartilage of a 100ng Cdk9a morpholino 
injected embryo at stage 45. Embryos show a disorganisation in 
the development of the branchial cartilage (black arrow). (D) 
Dissected cranio-facial cartilage of a 60ng CyclinT1 morpholino 
injected embryo at stage 45. Embryos show a disorganisation in 
the development of the branchial cartilage 
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5.4.6 The effect of Cdk9a and CyclinT1 knockdown on sensory neuron 
development 
 
 Sensory neurons are a neural crest cell derivative and as 
demonstrated previously after leflunomide treatment their development  
can be tested simply by poking the embryo and observing the reaction. 
Here the embryos were injected in both cells at the two cell stage with 
either a control morpholino, a Cdk9a morpholino or a CyclinT1 
morpholino. These embryos were left to develop at 18oC until reaching 
stage 38 when the embryos have a full sensory response. Embryos then 
underwent a poke from a pipette tip straight to the back of the embryo or 
a stroke i.e. running the pipette tip from the head to the tail of the embryo. 
If the embryos swim away they were scored 1, if they twitched they were 
scored 0.5 and if they failed to react they were scored 0. For each 
injection type, 30 embryos were tested in 3 rounds of 10 and the average 
of these experiments is displayed in figure 5.15.  
 Injection of the control morpholino had no effect on the 
development of the embryo’s sensory neurons. Almost 100% of embryos 
gave a full reaction and swam away from both a poke and a stroke 
(figure 5.15). Injection of Cdk9a morpholino saw a significant decrease in 
the embryo’s ability to react (figure 5.15). Most embryos either did not 
react or merely twitched after both a poke (figure 5.15 top panel) or 
stroke (figure 5.15 bottom panel). Similarly knockdown of CyclinT1 also 
significantly reduced the reaction capability of the embryos after a poke 
(figure 5.15 top panel) and a stroke (figure 5.15 bottom panel). Videos 
of these embryos displaying these phenotypes can be seen in appendix 
3. These embryos mostly did not respond or a few displayed a twitch. 
This suggests that knockdown of P-TEFb complex components leads to a 
disruption in the development of sensory neurons in Xenopus embryos 
further suggesting that transcriptional elongation is important to the 
development of neural crest cells. This also confirms the sensory neuron 
phenotype seen after leflunomide treatment in chapter three.  
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Figure 5.15: Poke and stroke analysis of senory neuron development after morpholino 
injection. (Top panel) Embryos undergo poking to the dorsal side and their response is tallied 
as follows. Swim=1, twitch=0.5 no response=0. The average of 30 embryos is shown taken 
from 3 sperate experiments using 10 embryos for each. (Bottom panel) Embryos undergo 
stroking of a pipette tip from the head region to the tail and their response is tallied as follows. 
Swim=1, twitch=0.5 no response=0. The average of 30 embryos is shown. For both conditions 
embryos were injected with 100ng control morpholino, 100ng Cdk9a morpholino or 60ng of 
CyclinT1 morpholino. *=p<0.05 by students t-test.  
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5.5 in situ hybridisation after knockdown of P-TEFb components 
 
5.5.1 Neural plate and neural plate border genes 
 
 The experiments shown so far in this chapter indicate that 
knockdown of Cdk9 and CyclinT1 in Xenopus embryos results in a loss of 
neural crest derivatives such as melanophores, cranio-facial cartilage and 
sensory neurons. To investigate the stage at which transcriptional 
elongation is important in neural crest development, in situs were carried 
out for neural plate border and neural crest specifying genes. Neural 
crest cells are initially induced at stage 12 at the neural plate border. This 
occurs because of the upregulation of neural plate border genes such as 
Zic1, Zic3 and Pax3. To investigate the effect of knocking down P-TEFb 
components on these genes, embryos were injected with morpholinos for 
Cdk9a, Cdk9b and CyclinT1 in one cell of a two-cell stage embryo. These 
were left to develop until stage 12 when they were fixed to undergo in situ 
hybridisation for neural plate border markers. Embryos were also fixed at 
stage 15 to investigate P-TEFb knockdown on general neural plate 
development by carrying out in situ hybridisation for neural plate marker 
Sox2. Morpholinos were co-injected with LacZ capped RNA and after 
fixing a β-gal stain was carried out causing the injected half of the embryo 
to appear red.  
 The results of this in situ showed that knockdown of all three P-
TEF-b components, Cdk9a, Cdk9b, CyclinT1 and a combination of both 
Cdk9a and b cause no change in the expression of neural plate border 
markers Zic1, Zic3 and Pax3 (figure 5.16B-E, G-J and L-O) compared to 
the control morpholino injection (figure 5.16A, F and K). There was also 
no change seen to the expression of neural plate marker Sox2 (figure 
5.16Q-T) when compared to the control morpholino injected embryos 
(figure 5.16P). These results suggest that transcriptional elongation is 
not important at these early induction stages of neural crest development. 
These results are also comparable to the results obtained after 
leflunomide treatment and subsequent in situ for neural plate border 
markers.
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Figure 5.16 in situ of neural plate border markers after P-TEFb knockdown. (A,F,K,P) 
Standard control morpholino injected embryos showing wild type expression of Zic1, Zic3, 
Pax3 and Sox2 respectively. (B,G,L,Q) 100ng Cdk9a morpholino injected embryos showing 
no change in expression of Zic1, Zic3, Pax3 and Sox2 respectively. (C,H,M,R) 100ng Cdk9b 
morpholino injected embryos showing no change in expression of Zic1, Zic3, Pax3 and 
Sox2 respectively. (D,I,N,S) 60ng CyclinT1 morpholino injected embryos showing no 
change in expression of Zic1, Zic3, Pax3 and Sox2 respectively. (E,J,O,T) 60ng Cdk9a and 
40ng Cdk9b morpholino injected embryos showing no change in expression of Zic1, Zic3, 
Pax3 and Sox2 respectively. Injected side is always on the left and is marked by β-gal stain. 
Zic1, Zic3 and Pax3 in situ hybridisations are carried out on stage 12 embryos. Sox2 in situ 
hybridisation is carried out on stage 15 embryos. 
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 Following on from neural crest induction, the cells undergo 
specification due to the upregulation of neural crest specifier genes. To 
investigate the effect of inhibiting transcriptional elongation on neural 
crest specification, the P-TEFb components Cdk9a, Cdk9b, CyclinT1 and 
a combination of both Cdk9a and Cdk9b were knocked down using 
morpholinos injected into one cell of a two-cell stage embryo. This left 
half of the embryo unaffected acting as an internal control. These 
embryos were fixed at stage 15 (or stage 13 for c-Myc an early neural 
crest specifier) to undergo in situ for various neural crest specifying 
genes. Morpholinos were co-injected with LacZ capped RNA so the 
injected side appears red after β-gal stain. 
 The most strikingly obvious knock down of gene expression is 
seen after in situ for c-Myc (figure 5.17B-E) and Sox10 (figure 5.17G-J) 
when compared to the control morpholino injected embryos after the 
same in situs (figure 5.17A and F). The knock down of c-Myc expression 
was seen specifically in the anterior regions, which give rise to the neural 
crest cells. c-Myc expression appeared unaffected in other areas such as 
the posterior region where c-Myc expression is present in presumptive 
neural tissue. Sox10 expression is seen to be completely lost in a large 
percentage of the injected embryos. Sox10 is thought to reside directly 
downstream of c-Myc in the neural crest gene regulatory network and so 
it is logical to see a downregulation of this gene [2]. Some knockdown or 
alteration in expression is seen in other neural crest specifying genes 
Sox9, Slug and FoxD3 (Figure 5.17L-O, Q-T and V-Y) when compared 
to the control morpholino injected controls (figure 5.17K, P and U). 
These genes reside downstream of c-Myc but have many other signalling 
pathways feeding into them and so it is very likely that we would not see 
a complete knockdown of these genes. These results suggest that 
transcriptional elongation is important for neural crest development at the 
stage of specification and is particularly important for c-Myc expression. 
These results are also comparable to those obtained after leflunomide 
treatment.  
5.5.2 Neural crest specifier genes 
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Figure 5.17 in situ of neural crest specifier markers after P-TEFb knockdown. 
(A,F,K,P,U) Standard control morpholino injected embryos showing wild type expression of 
c-Myc, Sox10, Slug, Sox9 and FoxD3. (B,G,L,Q,V) 100ng Cdk9a morpholino injected 
embryos showing knockdown of c-Myc and Sox10 (black arrows) and some alteration to the 
expression of Slug, Sox9 and FoxD3. (C,H,M,R,W) 100ng Cdk9b morpholino injected 
embryos showing knockdown of c-Myc and Sox10  (black arrows) and some alteration to the 
expression of Slug, Sox9 and FoxD3. (D,I,N,S,X) 60ng CyclinT1 morpholino injected 
embryos showing knockdown of c-Myc and Sox10 (black arrows) and some alteration to the 
expression of Slug, Sox9 and FoxD3. (E,J,O,T,Y) 60ng Cdk9a and 40ng Cdk9b morpholino 
injected embryos showing knockdown of c-Myc and Sox10 (black arrows) and some 
alteration to the expression of Slug, Sox9 and FoxD3. Injected side is always on the left and 
is marked by β-gal stain. c-Myc in situ hybridisation is carried out on stage 13 embryos and 
all other in situ hybridisations are carried out on stage 15 embryos 
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5.5.3 Quantification of neural crest specifier, neural plate and neural plate 
border in situs 
 
 Embryos which had undergone in situ hybridisation for neural 
plate, neural plate border and neural crest specifying genes (figure 5.16 
and 5.17) were scored based on whether they displayed a wild type, 
partial loss or loss phenotype. Examples of these are shown in figure 
5.18A. The in situs carried out were for neural plate border genes Zic1, 
Zic3 and Pax3. Neural plate marker Sox2, and neural crest specifiers, c-
Myc, Sox10, Slug, Sox9 and FoxD3. After injection of standard control 
morpholino most of the embryos showed wild type expression for all of 
these genes (figure 5.18B and table 5.4). A very small percentage, 
below 10% for each gene displayed a partial loss. After Cdk9a and 
CyclinT1 morpholino injection a large percentage of embryos at around 
40%, displayed a loss of c-Myc and Sox10 expression (figure 5.18C,D, 
table 5.5 and 5.6). Many of these embryos at aound 40% again 
displayed a partial loss leaving around 80% of injected embryos 
displaying some level of expression loss. The other neural crest 
specifiers displayed around 20% partial loss but not much complete loss 
is seen (figure 5.18C,D, table 5.5 and 5.6). Zic1, Zic3, Pax3 and Sox2 all 
mostly display the wild type phenotype.  
 The percentage of embryos displaying a loss phenotype after 
Cdk9b morpholino injection is considerably smaller than those injected 
with Cdk9a or CyclinT1 morpholino (figure 5.18E and table 5.7). Only 
around 10% of embryos displayed a loss of c-Myc and Sox10 expression 
and around 30% displaying a partial loss. This gives approximately 40% 
of embryos displaying a knockdown phenotype after Cdk9b morpholino 
injection which is half that seen after Cdk9a or CyclinT1 injection. It could 
be suggested that the Cdk9b morpholino is not as efficient. Injecting a 
combination of Cdk9a and Cdk9b at lower concentrations shows levels of 
knockdown phenotype similar to that of Cdk9a and CyclinT1 morpholino 
injection alone (figure 5.18F and table 5.8).  
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Figure 5.18 Quantification of gene knockdown after morpholino injection. (A) 
Examples of wild type, partial loss and loss phenotypes using Sox10 expression. (B) The 
percentage of embryos showing a wild type, partial loss, loss or expansion phenotype after 
injection of a standard control morpholino. (C) The percentage of embryos showing a wild 
type, partial loss, loss or expansion phenotype after injection of 100ng Cdk9a morpholino. 
(D) The percentage of embryos showing a wild type, partial loss, loss or expansion 
phenotype after injection of 60ng CyclinT1 morpholino. (E) The percentage of embryos 
showing a wild type, partial loss, loss or expansion phenotype after injection of 100ng Cdk9b 
morpholino.(F) The percentage of embryos showing a wild type, partial loss, loss or 
expansion phenotype after injection of 60ng Cdk9a morpholino and 40ng Cdk9b 
morpholino.Embryos underwent in situ for Sox10, c-Myc, Sox9, FoxD3, Slug, Zic1, Zic3, 
Pax3 and Sox2. N numbers are shown at the bottom of each graph. Zic1, Zic3 and Pax3 in 
situ hybridisations were carried out on stage 12 embryos. c-Myc in situ hybridisations were 
carried out on stage 13 embryos. Sox10, Slug, Sox9, FoxD3 and Sox2 in situ hybridisations 
were carried out on stage 15 embryos. 
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Table 5.4 Quantification of expression after control morpholino injection 
 
 Table 5.5 Quantification of expression after Cdk9a morpholino injection 
 
 
 Total 
embryos 
Wild type Partial 
loss 
Loss Expansion 
Sox10 33 29 (89%) 4 (11%) 0 (0%) 0 (0%) 
c-Myc 31 27 (87%) 4 (13%) 0 (0%) 0 (0%) 
Sox9 35 33 (94%) 2 (6%) 0 (0%) 0 (0%) 
FoxD3 36 35 (97%) 1 (3%) 0 (0%) 0 (0%) 
Slug 48 38 (79%) 10 (21%) 0 (0%) 0 (0%) 
Zic1 33 31 (93%) 2 (7%) 0 (0%) 0 (0%) 
Zic3 57 55 (93%) 2 (7%) 0 (0%) 0 (0%) 
Pax3 42 40 (95%) 2 (5%) 0 (0%) 0 (0%) 
Sox2 32 27 (84%) 5 (16%) 0 (0%) 0 (0%) 
 Total 
embryos 
Wild type Partial 
loss 
Loss Expansion 
Sox10 51 10 (20%) 22 (43%) 19 (37%) 0 (0%) 
c-Myc 32 10 (31%) 15 (47%) 7 (22%) 0 (0%) 
Sox9 31 13 (42%) 18 (58%) 0 (0%) 0 (0%) 
FoxD3 55 31 (56%) 23 (42%) 1 (2%) 0 (0%) 
Slug 51 28 (55%) 22 (43%) 1 (2%) 0 (0%) 
Zic1 32 32 (100%) 0 (0%) 0 (0%) 0 (0%) 
Zic3 62 59 (95%) 3 (5%) 0 (0%) 0 (0%) 
Pax3 38 35 (92%) 3 (8%) 0 (0%) 0 (0%) 
Sox2 44 43 (98%) 0 (0%) 0 (0%) 1 (2%) 
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Table 5.6 Quantification of expression after CyclinT1 morpholino injection 
 
Table 5.7 Quantification of expression after Cdk9b morpholino injection 
 Total 
embryos 
Wild type Partial 
loss 
Loss Expansion 
Sox10 35 18 (51%) 14 (40%) 3 (9%) 0 (0%) 
c-Myc 45 26 (58%) 14 (31%) 5 (11%) 0 (0%) 
Sox9 33 24 (73%) 8 (24%) 1 (3%) 0 (0%) 
FoxD3 43 33 (77%) 9 (21%) 1 (2%) 0 (0%) 
Slug 33 26 (79%) 7 (21%) 0 (0%) 0 (0%) 
Zic1 27 27 (100%) 0 (0%) 0 (0%) 0 (0%) 
Zic3 30 30 (100%) 0 (0%) 0 (0%) 0 (0%) 
Pax3 25 25 (100%) 0 (0%) 0 (0%) 0 (0%) 
Sox2 34 34 (100%) 0 (0%) 0 (0%) 0 (0%) 
 Total 
embryos 
Wild type Partial 
loss 
Loss Expansion 
Sox10 46 6 (13%) 23 (50%) 17 (37%) 0 (0%) 
c-Myc 30 6 (20%) 12 (40%) 12 (40%) 0 (0%) 
Sox9 39 15 (38%) 21 (54%) 3 (8%) 0 (0%) 
FoxD3 32 19 (59%) 12 (38%) 1 (3%) 0 (0%) 
Slug 37 19 (51%) 16 (43%) 2 (6%) 0 (0%) 
Zic1 32 32 (100%) 0 (0%) 0 (0%) 0 (0%) 
Zic3 70 70 (100%) 0 (0%) 0 (0%) 0 (0%) 
Pax3 54 50 (93%) 4 (7%) 0 (0%) 0 (0%) 
Sox2 54 49 (91%) 0 (0%) 0 (0%) 5 (9%) 
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Table 5.8 Quantification of expression after Cdk9a and Cdk9b morpholino 
injection 
 Total 
embryos 
Wild type Partial 
loss 
Loss Expansion 
Sox10 30 8 (26%) 11 (37%) 11 (37%) 0 (0%) 
c-Myc 50 18 (36%) 22 (44%) 10 (20%) 0 (0%) 
Sox9 57 36 (63%) 12 (37%) 0 (0%) 0 (0%) 
FoxD3 58 48 (83%) 10 (17%) 0 (0%) 0 (0%) 
Slug 53 45 (85%) 8 (15%) 0 (0%) 0 (0%) 
Zic1 42 42 (100%) 0 (0%) 0 (0%) 0 (0%) 
Zic3 63 63 (100%) 0 (0%) 0 (0%) 0 (0%) 
Pax3 49 49 (100%) 0 (0%) 0 (0%) 0 (0%) 
Sox2 43 43 (100%) 0 (0%) 0 (0%) 0 (0%) 
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5.5.4 In situ of sensory neuron genes after P-TEF b knockdown 
 
 Knocking down the P-TEFb components was shown to reduce 
the embryo’s ability to respond to mechanical stimulus suggesting a 
defect in sensory neurons. To further investigate this in situs were carried 
out post morpholino injection to look at the expression of various genes 
known to be downstream in the neural crest gene regulatory network, 
which lead to neural crest differentiation into sensory neurons. Runx1 
and Islet1 are both genes which reside downstream of Sox10 in the 
neural crest gene regulatory network to promote sensory neuron 
differentiation [280]. Ngnr is involved in sensory neuron differentiation 
however these sensory neurons are not neural crest derived [280]. These 
neurons develop in parallel to those derived from neural crest. For this 
experiment embryos were injected with a standard control morpholino, 
Cdk9a morpholino or a CyclinT1 morpholino in one cell of a two-cell 
stage embryo. Morpholinos were co-injected with lacZ and so the injected 
half of the embryo appeared red after β-gal stain. 
 Injection of the Cdk9a and CyclinT1 morpholino resulted in a 
downregulation of Runx1 and Islet1 expression on the injected side of the 
embryo with 30-40% of embryos displaying a complete loss of expression 
(figure 5.19B,C,E and F) when compared to the control morpholino 
injected embryos (figure 5.19A and D). No downregulation was seen in 
Ngnr expression after Cdk9a or CyclinT1 morpholino injection (figure 
5.19H and I). These embryos appeared the same as the control 
morpholino injected embryos (figure 5.19G). These data have been 
quantified based on embryos displaying a wild type, partial loss or loss 
phenotype and the data are shown in figure 5.20 and table 5.9. These 
results show that genes involved in neural crest differentiation into 
sensory neurons are downregulated after knockdown of P-TEFb. These 
genes reside downsteam of Sox10 and so it is logical to see a 
downregulation in these. It also confirms the loss of sensory neuron 
function seen in the stage 38 embryos by the poke and stroke assay. No 
change was seen in Ngnr expression suggesting that P-TEFb is relatively 
specific for neural crest development in this situation. 
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Figure 5.19 in situ of sensory neuron markers after P-TEFb knockdown. 
(A,D,G) Standard control morpholino injected embryos showing wild type 
expression of Islet1, Runx1 and Ngnr. (B,E,H) 100ng Cdk9a morpholino injected 
embryos showing knockdown of  expression of Islet1 and Runx1 (black arrows) 
and wild type Ngnr expression. (C,F,I) 60ng CyclinT1 morpholino injected 
embryos showing knockdown of  expression of Islet1 and Runx1 (black arrows) 
and wild type Ngnr expression. Injected side is shown on the left and stained red 
by β-gal stain. All embryos are fixed at stage 18. 
  201 
5.5.5 Quantification of sensory neuron markers after P-TEFb knockdown  
 
Table 5.9  Quantification of sensory neuron markers after P-TEFb knockdown 
 
 Morpholino Total 
embryos 
Wild type Partial 
loss 
Loss 
Runx1 Control  37 32 (86%) 5 (14%) 0 (0%) 
Cdk9a  46 14 (30%) 15 (32%) 17 (38%) 
CyclinT1  36 14 (39%) 10 (28%) 12 (33%) 
Islet1 Control  31 23 (74%) 8 (26%) 0 (0%) 
Cdk9a 32 9 (28%) 13 (40%) 10 (32%) 
CyclinT1 35 11 (31%) 13 (37%) 11 (32%) 
Ngnr1 Control 38 34 (89%) 4 (11%) 0 (0%) 
Cdk9a 39 33 (85%) 6 (15%) 0 (0%) 
CyclinT1 33 27 (81%) 6 (19%) 0 (0%) 
Figure 5.20 Graph showing quantification of sensory neuron markers after P-TEFb 
knockdown. From left to right shows the percentage of embryos showing a wild type, 
partial loss or loss phenotype for Runx1, Islet1 and Ngnr1 after standard control 
morpholino (CoMo), 100ng Cdk9a morpholino or 60ng CyclinT1 morpholino. N numbers 
are shown at the top of the graph.  
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5.5.6 in situ hybridisation of trigeminal placode markers after P-TEFb 
knockdown 
 
 The data collected so far suggest that transcriptional elongation 
is important for neural crest specification by regulating the expression of 
c-Myc. To further confirm this other genes known to reside downstream 
of c-Myc were investigated. Studies using c-Myc morpholinos in Xenopus 
have shown that knockdown of c-Myc also affects the development of 
trigeminal placodes along with neural crest. Trigeminal placodes and 
neural crest are often found to develop alongside each other giving rise 
to similar cell types [141]. Trigeminal placodes are though to give rise to 
the cranial sensory neurons. To investigate the effect of P-TEFb 
knockdown on trigeminal placode development, in situ hybridisation was 
carried out for trigeminal markers, Tbx2, NeuroD and Elrd after 
morpholino injection [104, 281, 282]. These embryos were injected in one 
cell of a two-cell stage embryo. The injected side was detected by β-gal 
stain. 
 All three of these trigeminal markers Tbx2, NeuroD and Elrd 
showed a loss of expression after injection of Cdk9a morpholino or 
CyclinT1 morpholino (figure 5.21B,C,E,F,H and I) when compared to the 
control morpholino injected embryos (figure 5.21A,C and F). The 
trigeminal placode expression can be seen as a small patch at the 
anterior end on both sides of the embryo. Loss of these patches are 
indicated by black arrows on figure 5.21. It can be seen on these 
embryos that other placodes marked by the in situ are unaffected. These 
include the lateral placodes, which arise directly underneath the 
trigeminal placodes and can be seen after Tbx2 in situ (figure 5.21A,B 
and C). This suggests that P-TEFb knockdown specifically affected 
placodes, which have c-Myc upstream in their gene regulatory network 
giving further evidence for the regulation of c-Myc by transcriptional 
elongation. The embryos in this experiment were quantified based on 
whether thay displayed a wild type, partial loss or loss phenotype and the 
data are shown in figure 5.22 and table 5.10. 
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Figure 5.21 in situ of trigeminal placode markers after P-TEFb knockdown. 
(A,D,G) Standard control morpholino injected embryos showing wild type expression 
of Tbx2, NeuroD and Elrd. (B,E,H) 100ng Cdk9a morpholino injected embryos 
showing knockdown of  expression of Tbx2, NeuroD and Elrd (black arrows). (C,F,I) 
60ng CyclinT1 morpholino injected embryos showing knockdown of  expression of 
Tbx2, NeuroD and Elrd (black arrows). Injected side is shown on the left and stained 
red by β-gal stain. All embryos are at stage 18.  
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5.5.7 Quantification of trigeminal marker in situs after P-TEFb knockdown 
Table 5.10 Quantification of trigeminal placode markers after P-TEFb knockdown 
 
 Morpholino Total 
embryos 
Wild type Partial 
loss 
Loss 
Tbx2 Control 36 34 (94%) 2 (6%) 0 (0%) 
Cdk9a 53 16 (30%) 14 (26%) 23 (44%) 
CyclinT1 34 5 (15%) 11 (32%) 18 (53%) 
NeuroD Control 33 29 (88%) 4 (12%) 0 (0%) 
Cdk9a 51 26 (51%) 16 (31%) 9 (18%) 
CyclinT1 44 8 (18%) 18 (41%) 18 (41%) 
Elrd Control 33 31 (94%) 2 (6%) 0 (0%) 
Cdk9a 33 10 (30%) 12 (36%) 11 (34%) 
CyclinT1 40 9 (22%) 11 (28%) 20 (50%) 
Figure 5.22 Graph showing quantification of trigeminal placode markers after P-
TEFb knockdown. From left to right shows the percentage of embryos showing a wild 
type, partial loss or loss phenotype for Tbx2, NeuroD and Elrd after standard control 
morpholino (CoMo), 100ng Cdk9a morpholino or 60ng CyclinT1 morpholino. N numbers 
are shown at the top of the graph.  
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5.6 Rescue experiments 
 
5.6.1 Mutagenesis expression construct rescue experiments 
 
 In order to prove that the loss of gene expression we see is 
specifically due to the loss of Cdk9 or CyclinT1 by morpholino 
knockdown, it is important to carry out rescue experiments. For these 
experiments rescue constructs are made using site directed mutagenesis 
to alter the morpholino binding site within Cdk9a, Cdk9b and CyclinT1. 
These mutated versions of the genes of interest are cloned into a vector 
containing a poly-A linker at the 3’ end of the gene so that cRNA can be 
transcribed from it and used to inject into the Xenopus embryo as a 
rescue construct. Here we use Sox10 expression as a readout of the 
level of rescue resulting when these rescue constructs were co-injected 
with the morpholinos of Cdk9a and Cdk9b. CyclinT1 has not been done 
yet as there have been some problems with the cloning process which 
have still not been resolved.  
 Embryos injected with the Cdk9a morpholino (figure 5.23A) or 
Cdk9b morpholino (figure 5.23B) show 73% and 42% of embryos with a 
loss of Sox10 expression in the injected side. Embryos were co-injected 
with 100pg of rescue construct along with the same dose of morpholino 
and (figure 5.23C and D) fewer of these embryos displayed loss of 
Sox10 expression. 54% of Cdk9a and 100pg of rescue construct injected 
embryos and 11% of Cdk9b and 100pg of rescue construct injected 
embryos showed loss of expression. This suggests that the rescue 
construct partially rescued the knockdown of Sox10 seen from 
morpholino injection. Embryos injected with Cdk9a morpholino and 
500pg of rescue construct (figure 5.23E) display greater levels of rescue. 
Only 26% of these embryos showed a loss of Sox10 expression, which is 
much less compared to the 73% showing loss after morpholino injection 
alone.  Injection of 500pg of rescue construct after Cdk9b morpholino 
injection also shows a degree of rescue similar to that of 100pg (figure 
5.23 F). These data are shown as a graph (top panel figure 5.23) and in 
table 5.11.
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Figure 5.23 Mutagenesis rescues. (A) 100ng Cdk9a morpholino showing loss of Sox10 
expression. (B) 100ng Cdk9b morpholino showing loss of Sox10 expression. (C) 100ng Cdk9a 
morpholino co-injected with 100pg mutant Cdk9a RNA showing a partial loss of Sox10. (D) 
100ng Cdk9b morpholino co-injected with 100pg mutant Cdk9b RNA showing a partial loss of 
Sox10. (E) 100ng Cdk9a morpholino co-injected with 500pg mtant Cdk9a RNA showing 
rescue of Sox10 expression. (F) 100ng Cdk9b morpholino co-injected with 500pg Cdk9b RNA 
showing rescue of Sox10 expression. Injected side is always on the left as indicated by a red 
β-gal stain. The panel on the right shows a quantification of the wild type, partial loss, loss 
phenotypes counted displayed as a graph of the percentage of embryos showing these 
phenotypes and also in table 5.11. n numbers are shown at the top of the graph. 
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5.6.2 c-Myc rescues 
 
 Transcriptional elongation may regulate neural crest development 
by regulating the expression of neural crest specifier c-Myc. To test this 
theory a rescue experiment was carried out in which Cdk9 and CyclinT1 
morpholinos were co-injected with c-Myc capped RNA. This capped RNA 
should replace the c-Myc expression lost due to P-TEFb knockdown 
allowing neural crest cells to develop normally again. The level of the 
rescue was measured by using a Sox10 in situ as Sox10 is known to be 
expressed downstream of c-Myc in the neural crest gene regulatory 
network. If Sox10 transcription is also regulated by P-TEFb we would not 
expect c-Myc to rescue. Embryos were injected in one cell of a two cell 
stage embryo with the morpholino and a dose range of c-Myc RNA.  
 Injection of Cdk9a or CyclinT1 morpholinos resulted in a loss of 
Sox10 expression (figure 5.24A and B) when compared to a control 
morpholino injected embryo (figure 5.24G). When embryos were co-
injected with 100pg of c-Myc capped RNA there was seen to be a 
decrease in the number of embryos showing a complete loss of Sox10 
expression and some rescue was apparent (figure 5.24C and D). After 
injection of 500pg of c-Myc RNA even fewer embryos displayed a loss of 
Sox10 expression and expression was almost completely restored 
(figure 5.24E and F). Injection of 500pg of c-Myc alone showed little 
change to Sox10 expression, however a small percentage of embryos 
displayed an upregulation phenotype (figure 5.24H). These embryos 
were quantified based on whether they displayed a wild type, partial loss, 
loss or expansion phenotype and these data are displayed in figure 5.24 
as a graph and in table 5.12. These data show a shift from a large 
percentage embryos displaying a loss phenotype to embryos displaying 
predominantly a partial loss or wild type phenotype after myc RNA 
injection. The percentage of loss seen goes from 38% to 8% after 100pg 
of myc injection rescuing Cdk9a morpholino injection. This goes down 
further to 3% after injection of 500pg of myc. A similar trend is seen when 
rescuing CyclinT1 knockdown. This suggests that myc is capable of 
partially rescuing the effects of P-TEFb knockdown.  
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Figure 5.24 Rescuing P-TEFb knockdown with c-Myc. (A) 100ng Cdk9a morpholino 
showing loss of Sox10 expression. (B) 60ng CyclinT1 morpholino showing loss of Sox10 
expression. (C) 100ng Cdk9a morpholino co-injected with 100pg c-Myc RNA showing a partial 
loss of Sox10. (D) 60ng CyclinT1 morpholino co-injected with 100pg c-Myc RNA showing a 
partial loss of Sox10. (E) 100ng Cdk9a morpholino co-injected with 500pg c-Myc RNA 
showing rescue of Sox10 expression. (F) 60ng CyclinT1 morpholino co-injected with 500pg c-
Myc RNA showing rescue of Sox10 expression. (G) Control morpholino injected embryos 
showing wild type Sox10 expression. (H) 500pg of c-Myc RNA injection showing expansion of 
Sox10 expression. Injected side is always on the left as indicated by a red β-gal stain. The 
panel on the right shows a quantification of the wild type, partial loss, loss and expansion 
phenotypes counted displayed as a graph of the percentage of embryos showing these 
phenotypes and also in table 5.11. n numbers are shown at the top of the graph.  
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5.7 Discussion 
 
 The aims of this chapter were to test the hypothesis suggested 
from results obtained using leflunomide treatment that regulation of 
transcriptional elongation is important for neural crest development. To 
do this we investigated the expression of the P-TEFb complex and 
observed the effects on neural crest development caused by knocking it 
down. Knocking down the P-TEFb complex prevents transcriptional 
elongation from occurring and leaves genes in a paused state unable to 
be fully transcribed. Based on the results obtained using leflunomide it 
was hypothesised that the P-TEFb complex would be expressed in the 
neural crest cells and knocking down this complex would result in a 
reduced amount of neural crest derivatives. Initially, in situ hybridisation 
experiments were carried out for the P-TEFb components Cdk9a, Cdk9b, 
CyclinT1 and CyclinT2. This revealed that the P-TEFb components were 
expressed in the ectoderm of gastrula stage embryos, the neural plate 
and neural plate border of neurula stage embryos and the branchial 
arches of tailbud and tadpole stage embryos. This suggested that the P-
TEFb components were expressed in the neural crest cells at the neural 
plate border and in the migrating neural crest of the branchial arches. 
Double in situ hybridisation of the P-TEFb components with Sox10 a 
known neural crest marker confirmed that these components were 
expressed in the neural crest cells at the neural plate border. 
These in situ results suggest that P-TEFb plays a role in the 
development of neural crest cells. To confirm this morpholinos were 
designed for Cdk9a, Cdk9b and CyclinT1 to knock down the protein 
levels of the P-TEFb proteins. Initially morpholino efficiency was tested 
using an in vitro translation system. This combines a plasmid containing 
Cdk9a, Cdk9b and CyclinT1 and the corresponding morpholino in an in 
vitro translation. The aim of this is to block the translation of the plasmid 
using varying concentrations of the morpholino. This was achieved and 
all of the morpholinos obtained were shown to be capable of knocking 
down their specific protein. It could be suggested from this experiment 
that CyclinT1 was the most efficient morpholino being capable of 
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complete knockdown at using 60ng of morpholino. Cdk9a was able to 
knockdown protein at around 80ng. Cdk9b however was not very efficient 
as some protein was still detected after 100ng of morpholino was added. 
This is likely due to the design of the morpholino. Morpholino efficiency is 
known to vary greatly based on the position at which they bind and the 
surrounding nucleotides increasing or decreasing binding efficiency 
similar to the binding of a primer.  
Initial experiments knocking down the P-TEFb components 
showed that the development of neural crest derivatives was impaired. 
The first neural crest derivatives to be investigated were melanophores. 
Knockdown of Cdk9a and CyclinT1 resulted in a large percentage of 
embryos displaying a pigment loss phenotype. Knockdown of Cdk9b 
resulted in a similar phenotype however occurring much less frequently 
probably because this morpholino is not as efficient as the Cdk9a or 
CyclinT1 morpholino. Knockdown of both the Cdk9a and Cdk9b allele 
resulted in a large percentage of embryos showing a pigment loss 
phenotype. The frequency to which this occurred was similar to that of 
Cdk9a or CyclinT1 alone showing that lower morpholino concentrations 
could be used if both alleles were knocked down reducing the 
redundancy. Due to the inefficiency of the Cdk9b morpholino it was not 
used for all subsequent experiments. 
Knockdown of Cdk9a and CyclinT1 also resulted in defects of other 
neural crest derivatives including cranial facial cartilage. An alcian blue 
stain of morpholino injected embryos revealed a disorganisation in the 
branchial cartilage of the injected side. This result is comparable to that 
obtained after leflunomide treatment. There was also seen to be a loss of 
sensory neuron function as assayed by the poke and stroke method. 
Embryos injected with morpholino show a reduced response to external 
stimulus. This phenotype was also seen in the leflunomide treated 
embryos and further suggests that P-TEFb is playing an important role in 
neural crest development. Following on from this in situ hybridisation was 
carried out for genes involved in neural crest differentiation into sensory 
neurons such as Runx1 and Islet1. Both of these show a loss of 
expression after P-TEFb knockdown.  
  211 
 To investigate when P-TEFb and transcriptional elongation is 
playing a role in neural crest development, in situ hybridisation was 
carried out for markers at various stages of neural crest development. 
Firstly neural plate border markers which are expressed during early 
neural crest induction. In situs for these showed no change in expression 
suggesting that P-TEFb is not important for the transcription of these 
early genes. Following on from this a broad range of neural crest 
specifiers were investigated. This showed that the genes predominantly 
effacted by P-TEFb knockdown were c-Myc and Sox10. This was also 
shown to be the case for leflunomide treatment. c-Myc is an early neural 
crest specifier which has been implicated in other studies to be regulated 
by RNA polymerase pausing and transcriptional elongation. Sox10 is a 
neural crest specifier thought to be expressed directly downstream of c-
Myc. Other neural crest specifiers show some alteration of their 
expression not commonly a total loss of expression probably due to a 
number of other gene networks feeding into these to maintain their 
expression.  
 To confirm the importance of c-Myc expression regulation by P-
TEFb and transcriptional elongation, other genes downstream of c-Myc 
were investigated by in situ hybridisation. It is known that c-Myc lies 
upstream in the gene regulatory network governing the expression of 
trigeminal placodes. Knockdown of c-Myc in Xenopus leads to a loss of 
trigeminal placode markers. Here we show that similarly knockdown of P-
TEFb also results in a knockdown of trigeminal placode markers Tbx2, 
NeuroD and Elrd. This gives strong evidence for the regulation of c-Myc 
expression by P-TEFb. Following on from this rescue experiments were 
carried out aiming to rescue the loss of Sox10 expression following 
morpholino injection by co-injecting with c-Myc RNA. These experiments 
suggest that injection of myc RNA is capable of rescuing the loss of 
Sox10 expression seen resulting from a loss of P-TEFb suggesting that 
c-Myc is a target of the P-TEFb complex. This suggests that c-Myc itself 
undergoes RNA polymerase pausing and that P-TEFb is able to promote 
the transcriptional elongation of c-Myc.  
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6.1 Discussion 
 
6.1.1 The phenotype seen after inhibiting transcriptional elongation 
  
  The molecular mechanisms controlling neural crest cell 
specification and differentiation are complex and consist of many layers 
of regulation to ensure the cells move down the correct lineage and form 
the correct cell types. Here we provide evidence for an additional layer of 
regulation at the transcriptional elongation level. Other cell types, which 
have been described in other studies to undergo regulation at the level of 
transcriptional elongation are multipotent in nature. These include 
embryonic stem cells and haematopoietic stem cells. Based on this it 
seems logical that a multipotent cell population such as neural crest cells 
would also require this regulation. The aim of this work was to investigate 
the precise time at which transcriptional elongation is important for neural 
crest development and if it is important in the development of these cells 
to determine what genes are primarily affected and which are secondary 
targets. 
  The methods in which transcriptional elongation have been 
investigated in this study involved the use of the small molecule 
compound leflunomide as an inhibitor of transcriptional elongation. 
Secondly through the use of morpholino knockdowns against 
components of the P-TEFb complex to prevent positive transcriptional 
elongation from occurring. Both of these methods gave comparable 
results. Both demonstrate a disruption in the development of neural crest 
derivatives including melanophores, sensory neurons and cranio-facial 
cartilage. Melanophores develop incorrectly appearing rounded rather 
than dendritic in many cases and not migrating to the positions they are 
usually found in structures such as the underside of the tail (figure 3.1). 
Interestingly during the leflunomide study it was demonstrated that 
X.tropicalis, the diploid relative of X.laevis displayed a more striking 
phenotype (figure 3.3). This is likely due to the decreased number of 
alleles present in the diploid embryos, which require knock down before a 
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phenotype is seen. This suggests that this diploid species may be better 
suited for this type of chemical screen in future. A similar result has been 
seen in other studies, which have used Spt5 (a component of DSIF) 
mutant lines of Xenopus tropicalis and Zebrafish. The Xenopus Spt5 
mutant known as cyd vicious has only a thin line of melanophores 
running along its neural tube. It is also paralysed suggesting a loss of 
sensory neuron function [283]. The zebrafish Spt5 mutant embryos 
appeared to have a complete loss of melanophores and reduced blood 
circulation [148].     
  The phenotype we see at stage 38 after inhibition of 
transcriptional elongation is one associated with the disruption of normal 
neural crest development. As well as abnormal melanophore 
development we also see what can be suggested as a complete loss of 
sensory neuron development. The embryos treated with leflunomide and 
those which had undergone morpholino injection displayed almost no 
response to external stimulation by poking. To confirm this loss of 
sensory neuron development an in situ hybridisation was carried out for 
known senory neuron markers downstream of Sox10, Runx1 and Islet1 
[280]. Both of these markers showed a loss of expression after 
morpholino knockdown of Cdk9 and CyclinT1, the components of P-TEFb 
(figure 5.19). It was also seen in this study that inhibiting transcriptional 
elongation resulted in defects in the development of the neural crest 
derived cranio-facial cartilage. The cartilage was never completely 
missing but appeared disorganised in its structure (figure 5.14).  
  This phenotype we are seeing suggests that transcriptional 
elongation is playing a role in neural crest development. There are 
different possibilities as to why the different neural crest lineages 
investigated display varying levels of irregularity. Firstly we see a 
complete loss of sensory neurons, a large loss of melanophores and a 
disorganisation of cranio-facial development. This could be explained by 
the fact that according to the in situ and RNA sequencing data, we see 
the most significant loss in Sox10 expression. Sox10 is known to be 
important in the differentiation of neural crest cells into melanophores and 
sensory neurons but not cranio-facial cartilage. This requires another 
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member of the SoxE family, Sox9, which showed a moderate knockdown 
by in situ after leflunomide treatment and morpholino injection.  
   
6.1.2. Wnt upregulation and neural crest development 
 
  It is also possible that the neural crest defects we see are due to 
changes in Wnt signalling during neural crest development. The RNA 
sequencing carried out in chapter 4 shows that Wnt signalling 
components are upregulated after leflunomide treatment at stage 15 in 
Xenopus animal caps. Recent studies using conditional activation of β-
catenin have shown that upregulation of Wnt signalling during early 
induction of neural crest cells leads to increased numbers of neural crest 
derivatives mostly melanophores [276]. However if Wnt signalling is 
Figure 6.1 β-catenin activation in migratory neural crest leads to 
craniofacial malformation, loss of peripheral neurons and ectopic Mitf 
expression. (A) Control X-GAL stain shows normal neural crest in the face. 
(B,C) Malformations of the snout and ear after β-catenin activation. (D) 
normal peripheral neuron development in control embryo. (E) Loss of 
peripheral neurons after β-catenin activation. (F) No Mitf expression in control 
embryo. (G) Ectopic Mitf expression after β-catenin activation. Retrieved from 
[276] 
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upregulated later in neural crest development when the neural crest cells 
are specified, there is a loss of neural crest derivatives such as sensory 
neurons resulting in what are described as ‘malformations’ of the cranio-
facial cartilage and ectopic expression of melanophores (figure 6.1) 
[276]. This same study found that although melanophores appear 
reduced in their normal positions, a Mitf and DCT in situ revealed 
melanophores to be located in unusual places including the kidney, 
spleen and diaphragm [276]. This phenotype could match the phenotype 
seen in the Xenopus embryos in this study. To confirm this it would be 
interesting to carry out a Mitf or DCT in situ on the leflunomide treated or 
morpholino injected embryos and section them to look for ectopic 
expression.  
 
6.1.3. c-Myc is important for transcriptional elongation in neural crest 
cells 
 
  To identify where and when transcriptional elongation is 
important for neural crest development, in situ hybridisation experiments 
were carried out after leflunomide treatment and morpholino knockdown 
for various markers of neural crest development. To confirm these 
findings RNA sequencing was carried out on animal caps induced to 
become neural crest. These experiments showed that inhibiting 
transcriptional elongation has no effect on the development of early 
neural plate border markers such as Zic1, Zic3 and Pax3. The first 
changes in gene expression were seen when looking at genes involved 
in neural crest specification and differentiation. The two genes 
demonstrating the greatest level of knockdown by in situ were c-Myc an 
early neural crest specifier and Sox10 a neural crest specifier also 
expressed in the migrating neural crest. What is most likely is that c-Myc 
is the direct target of transcriptional elongation inhibition and Sox10 is a 
secondary target as it is thought to lie directly downstream of c-Myc [2].  
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 c-Myc is known to be an early neural crest specifier; previous 
knock down studies in Xenopus have shown that myc is important for the 
expression of downstream neural crest specifiers such as Sox10 and the 
development of neural crest derivatives such as melanophores and 
craniofacial cartilage [33]. It was also shown in this same study that 
knock down of c-Myc also knocks down the expression of trigeminal 
placode markers such as Six1 and there is a loss of Sox10 expression in 
the trigeminal, seventh (VII), ninth (IX), and tenth (X) cranial ganglia 
(figure 6.2). This would suggest that if c-Myc is the primary target of 
inhibiting transcriptional elongation in neural crest cells than we should 
see a loss of trigeminal placode markers after morpholino knockdown of 
P-TEFb components. In situ hybridization for trigeminal placode markers 
Tbx2, NeuroD and Elrd showed precisely this after knockdown of both 
Cdk9 and CyclinT1 giving strong evidence that myc undergoes 
polymerase pausing and transcriptional elongation (figure 5.21).  
Figure 6.2 Myc knockdown leads to a loss of trigeminal placodes. (A) myc 
morpholino injected side of an embryo showing loss of Sox10 expression in the 
trigeminal, seventh (VII), ninth (IX), and tenth (X) cranial ganglia. (B) Control side 
showing normal expression. (C) Loss of Six1 expression after myc morpholino 
injection (white arrow head). Adapted from [33] 
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  It makes sense for myc to be the primary target for regulation by 
transcriptional elongation and RNA polymerase pausing in neural crest 
cells. Previous studies using stem cell lines have shown that c-Myc 
undergoes pausing by knocking out a component of the SEC, Med26 
[199]. That combined with its known role in neural crest specification 
makes it a clear candidate. To ensure that Sox10 was not a direct target 
and that its downregulation is a secondary effect of myc knockdown, 
rescue experiments were carried out using a myc expression construct 
after morpholino knockdown of Cdk9 and CyclinT1. This experiment 
Figure 6.3 A model for the position of P-TEFb in neural crest development. P-TEFb 
seems to be targeting c-Myc directly. Loss of P-TEFb leads to a downregulation of c-Myc, 
Sox10 and alterations in the expression of the other transcriptional factors shown on this 
model. This could suggest that c-Myc is directly feeding into Sox10 and that the other changes 
seen are downstream alterations found due to this Sox10 knockdown. This model is a very 
simplified diagram of the neural crest gene regulatory network as not all genes involved in this 
network are shown here. To keep the model simple only a few examples from each level are 
shown. These levels are induction signals, neural plate border specifiers, neural crest 
specifiers, neural crest effector genes and neural crest derivatives.  
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succeeded in rescuing Sox10 expression suggesting that Sox10 is not 
itself a target of P-TEFb but must be knocked down due to the loss of 
upstream c-Myc signals (figure 5.23). This is shown as a model 
demonstrating the position P-TEFb plays a role in neural crest 
development in figure 6.3.  
  What remains unclear is the dynamic in this scenario between c-
Myc, BMP and Wnt signalling. It is well known from studies in colon 
cancer that myc lies downstream of Wnt signalling [284]. However we 
see a downregulation of c-Myc and an upregulation of Wnt. The 
downregulation of myc that we see in the RNA sequencing is not as 
drastic as we would have expected from our in situ data. My hypothesis is 
that Wnt has upregulated in an attempt to maintain an equilibrium with 
myc, after myc was downregulated by inhibition of transcriptional 
elongation at stage 12 during early neural crest specification. Wnt has 
upregulated in response to bring the myc levels back up. This is just a 
hypothesis and needs further investigation. It is also unclear why BMP 
appears upregulated after leflunomide treatment in neural crest animal 
caps at stage 15 and BMP antagonist follistatin appears downregulated 
(table 4.2 and 4.3). Different types of crosstalk between BMP and Wnt 
may occur in a tissue dependent fashion. It is possible for Wnt and BMP 
to have a common target in the same tissue or cell [285]. An example of 
this was found in the developing mouse kidney. In this specific tissue 
high levels of BMP signals resulted in increased canonical Wnt signalling. 
This resulted in a phospho-Smad1/Tcf4/β-catenin complex, which was 
identified to upregulate c-Myc expression giving evidence for both Wnt 
and BMP synergistically upregulating c-Myc [286].  
  It would be interesting to see if upregulation of BMP Smad1 
signalling can increase c-Myc expression in neural crest cells. For future 
work we also want to try to show that Wnt signalling is able to stabilize 
the c-Myc protein in neural crest cells. This has been implicated in 
Drosophila as inhibition of GSK3β leads to an accumulation of the myc 
protein [287]. What seems strange is that both BMP and Wnt are so 
clearly upregulated when there is no clear explanation why. Studies in 
other cancer cell types have shown that myc and Wnt are in a feedback 
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loop with each other. This occurs because myc can inhibit Wnt 
antagonists such as secreted frizzled receptor proteins (SFRPs) [288]. 
The only SFRP, which appears upregulated in the RNA sequencing data 
is Sizzled (Frzb3) which after recent studies has been identified not to 
inhibit Wnt at all but instead engages in a feedback loop with BMP by 
inhibiting tolloid enzymes which usually inhibit Chordin, which 
downregulates BMP. So Sizzled will inhibit BMP but BMP upregulates 
Sizzled [289].  
  Interestingly Sizzled is known to be inhibited in neural crest 
development by Slug. It could be possible that by reducing myc 
expression by inhibiting transcriptional elongation there is a reduction in 
downstream transcription factors like Slug [290]. Less myc means less 
Slug which means more Sizzled. All of these patterns are seen in the 
RNA sequencing. It is also suggested in the literature that Sizzled is 
capable of upregulating c-Myc however there is little evidence to back 
this up [291]. This still begs the question of how Wnt is upregulated. One 
possiblilty is through the feedback loop it is thought to undergo with c-
Myc. c-Myc upregulates Wnt by inhibiting Wnt inhibitors and Wnt 
upregulates c-Myc [288]. This is still unclear and needs further 
investigation. 
   
6.1.4 A fate switch for neural crest cells 
  
  Another interesting result, which came out of the RNA 
sequencing data was the changes in the expression of chemokine 
receptors and ligands normally found on neural crest cells. Neural crest 
cells normally express the receptors such as Cxcr4 and CD44 on their 
cell surface [41]. The underlying ectoderm found ventrally to the 
migrating neural crest cells will express the corresponding ligands, 
stromal cell derived factor (Sdf1) and Hyaluronan. In situ hybridisation 
experiments in Xenopus laevis have shown that Cxcr4 is expressed in 
both the premigratory and migratory NCCs (figure 6.4A-D) [41]. Sdf1 is 
expressed in the ectoderm always ahead of the neural crest cells (figure 
6.1E-I). The cells find themselves attracted to the ligand expressing 
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ectoderm by chemotaxis. Sdf1 is known to be a strong chemoattractant 
and is known to be required for normal cranial neural crest migration and 
misexpression can lead to a loss in the organisation of the cranial neural 
crest [292].  
 
 
 
Sdf1 and Cxcr4 chemotaxis is known to function by promoting 
Rac1 activity, a Rho-GTPase responsible for creating the migratory 
shape of the cells. Rac1 causes the cells to protrude forward 
lamellipodia, which are stabilized allowing the cell to migrate towards the 
Sdf1 chemoattractant signal.  In the case of neural crest cells, there will 
be a large number of cells all migrating at once. These cells will bump 
into each other and upon doing so the lamellipodia retract allowing the 
cell to control its direction based on what the other neural crest cells are 
doing. When one neural crest cell comes into contact with another it will 
draw in its lamellipodia and form new ones on the adjacent side of the 
cells. This process is known as contact inhibition locomotion (CIL). This 
Figure 6.4 Sdf1 and Cxcr4 expression in Xenopus laevis. (A) Twist expression 
shows the position of premigratory and (B) migratory neural crest cells (arrow heads) 
(C) Cxcr4 is expressed in the premigratory NCCs (D) Cxcr4 is expressed in the 
migrating NCCs (E) Sdf1 is expressed in the ventral ectoderm (F) Sdf1 expression 
moves ventrally with the NCCs. (G) A schematic of the migrating NCCs in relation to the 
position of Sdf1. (H) Section showing the expression of Cxcr4 in the NCCs (I) Section 
showing expression of Sdf1 in the surrounding ectoderm. Retrieved from referece [59] 
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occurs as the contacting cells will express N-cadherins on their surface 
which will promote the non-canonical Wnt pathway which upregulates 
RhoA and downregulates Rac1 allowing cells to repolarise (figure 6.5). 
CIL between neural crest cells has been shown to be essential for 
chemotaxis to occur [59].  
This role of Sdf1 and Cxcr4 in neural crest development helps to 
identify an explanation for the results obtained in the RNA sequencing 
data shown in chapter four. This data suggests that Sdf1 normally 
expressed by the surrounding ectoderm is upregulated in the neural crest 
sample and the receptor Cxcr4 normally expressed by the cells is 
downregulated after leflunomide treatment. This further backs up the 
hypothesis that transcriptional elongation is important for neural crest 
development. It also gives a suggestion as to what these neural crest 
cells are becoming. If they are no longer becoming neural crest cells then 
it is likely that they have undergone a fate switch potentially into 
surrounding ectodermal cells. This is possible as the neural crest cell 
sample treated with leflunomide was seen to be upregulating several 
Figure 6.5 Contact inhibition locomotion and chemotaxis of neural crest cells. 
The right half of the figure (red) shows how Sdf1 and Cxcr4 promote chemotaxis by 
upregulating Rac1 allowing cell protrusions. This is balanced to direct the cells by 
non-canonical Wnt signalling which will upregulate Rho after contact with other cells to 
cause protrusions to withdraw by inhibiting Rac1 shown on the left half of the figure 
(blue). Retrieved from reference [285]  
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markers normally found in the surrounding ectoderm such as Sdf1, 
Nkx3.1, Hyaluronan and Gata binding factor 3. This also gives a possible 
suggestion as to why the Xenopus embryos treated with leflunomide and 
injected with P-TEFb morpholinos are seen to have disorganised cranial 
facial cartilage at tadpole stages. It is likely that the cells are not migrating 
properly due to this receptor/ligand switch.  
The only question here that remains to be answered is what is 
causing Sdf1 to be upregulated. Very little is known as to what causes 
Sdf1 expression. It is possible, based on the RNA sequencing data, that 
the Sdf1 expression is caused by canonical Wnt signalling as Wnt 
signalling was seen to be greatly upregulated after leflunomide treatment. 
This could potentially explain why other studies in which Wnt has been 
upregulated later on in neural crest development have seen a 
disorganisation of the cranio-facial cartilage. This is just a hypothesis and 
requires further work to verify. Further experiments, which could be 
carried out include in-situ hybridisation of Sdf1 and Cxcr4 on whole 
embryos to see if the expression pattern of these is altered after 
leflunomide treatment or knockdown of P-TEFb. It would also be good to 
confirm the result seen in the RNA sequencing using animal caps. PCR 
could be carried out for both Sdf1 and Cxcr4 to observe a switch in their 
expression levels. To further investigate the possibility of Wnt 
upregulation promoting Sdf1 expression a small molecule compound 
activating Wnt signalling could be applied at different stages of neural 
crest development and the expression of both Sdf1 and Cxcr4 could be 
observed. Compounds used to activate Wnt are usually those, which 
inhibit GSK3 responsible for the degradation of β-catenin. An example of 
one often used is 6-bromoindirubin-3’-oxime (BIO), a GSK3 inhibitor 
[293].  
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6.1.5 HEXIM1 upregulation after leflunomide treatment  
 
 There are three possible forms of the P-TEFb complex, two 
active forms (when P-TEFb is bound to the SEC and Brd4) and one 
inactive form (when P-TEFb is bound to HEXIM1), which are all present 
in the cell nucleus. This type of regulation of the P-TEFb complex is 
important to ensure that transcriptional elongation occurs at the correct 
time in development. P-TEFb is held in an inactive state by reversible 
binding with the 7SK small nuclear ribonucleoprotein particle (snRNP) 
and the inhibitory domain of HEXIM1. When transcriptional elongation is 
required this binding is reversible and the P-TEFb complex binds with the 
SEC in response to developmental cues. These activating signals 
provide specificity for P-TEFb to its target genes [157].  
 After leflunomide treatment it was seen that HEXIM1 was 
upregulated in the neural crest, neuroectoderm and ectoderm samples. 
This gives evidence that leflunomide is inhibiting transcriptional 
elongation as an increase in HEXIM1 would suggest that more P-TEFb is 
being held in its inactive form. It is thought that leflunomide is able to do 
this due to its known mechanism as an inhibitor of DHODH. This 
mechanism involves the metabolism of leflunomide into A771726. This 
metabolite will inhibit de novo synthesis of pyrimidines and therefore RNA 
transcription and DNA replication [294]. Leflunomide is a good candidate 
for our experiments as it is already FDA approved for rheumatoid arthritis 
treatment where it is thought to inhibit DHODH in lymphocytes to have an 
anti-inflammatory effect [295]. 
 This study shows that leflunomide is inhibiting transcriptional 
elongation through P-TEFb inhibition and suggests that it is not altering 
the methylation patterns on the genes. The fact that all three cell types 
show an increase in this indicate that this is an effect of leflunomide 
addition. What is interesting is that although all three cell types have 
increased HEXIM1 levels the neural crest sample is the only one that 
shows decreases in its specific gene expression i.e. neural crest specific 
genes. No neuroectoderm specific genes such as Sox2 were 
downregulated in the neuroectoderm sample and no ectoderm specific 
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genes were downregulated in the ectoderm sample. This suggests that 
regulation of transcriptional elongation is relatively specific for neural 
crest development. It may be involved in other cell types not investigated 
here but this data does suggest that it is not required for all genes and all 
cells types.  
 
6.1.6 Geminin upregulation  
 
 Geminin regulates the polycomb repressive complex (PRC) which 
carries out histone modifications to silence specific genes. Through this 
mechanism, Geminin has been shown in Xenopus to be involved in 
maintaining the pluripotent state of cells and maintaining the neural 
precursor cell fate [275]. Geminin expression is downregulated after 
neural differentiation [275]. This was one of the genes, which was seen to 
be highly upregulated in the RNA sequencing data. This seemed 
interesting because of the links made between geminin, epigenetics and 
transcription regulation and so it could help us to explain some of the 
results that we see after inhibiting transcriptional elongation in Xenopus. 
 Recent studies investigating the role of Geminin in Xenopus 
development have used microarrays to analyse a wide spread of genes 
affected by upregulating the expression of Geminin and so it was 
interesting to compare these results to those obtained in the RNA 
sequencing data obtained here. There were many cross overs between 
the two data sets. For example both the microarray after Geminin 
overexpression and the RNA sequencing shown in chapter four see a 
downregulation of c-Myc, Cxcr4 and Tiarin. Also the microarray shows 
downregulation of Tbx2, the trigeminal placode marker downregulated 
after P-TEFb knockdown shown by in situ in chapter five. The microarray 
data also demonstrates an upregulation of neuroprogenitor genes such 
as Sox1, which seems to be the trend seen in the neuroectoderm sample 
after RNA sequencing. The microarray data is mostly focused on genes 
involved in neurogenesis and so it is hard to make a full comparison but it 
is good to see some cross over between these similar studies.  
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6.1.7 Heat shock proteins 
 
 The transcription of heat shock proteins is rapidly induced upon 
stress or heat to cells. Their function is to prevent cells apoptosing in 
response to these stresses. Missexpression of these are associated with 
cancer and ageing [242, 245]. It is well charatersied that heat shock 
proteins will undergo transcriptional pausing at their promoter region and 
subsequent transcriptional elongation [220, 246, 247]. P-TEFb is 
recruited by these heat signals to allow transcriptional elongation to occur 
[250]. It was good to see that all three of the samples sent for RNA 
sequencing had a decrease in heat shock protein expression. This gives 
us confidence that leflunomide is acting to inhibit transcriptional 
elongation.   
 What appears interesting is that some heat shock proteins have 
been associated with aspects of neural crest development. Upregulation 
of hsp70 leads to c-Myc upregulation in cancer cells [243]. Hsp105/110 
expression pattern studies have identified these to potentially be 
expressed in the neural crest along with some other neural tissue types 
such as the brain [296]. Interestingly Hsp105/110 expression was 
relatively specific to the neural crest animal cap sample. It was also one 
of the genes identified to be downregulated by leflunomide treatment. For 
future work it would be interesting to further investigate the role of these 
heat shock proteins in neural crest development. It could be possible that 
these are a primary target of inhibiting transcriptional elongation, which 
might lead to defects in neural crest development.  
 
6.1.8. Conclusions and future work 
 
 The work shown in this thesis suggests that regulation of 
transcriptional elongation is important for the development of neural crest 
cells. Inhibiting transcriptional elongation results in a decrease in the 
expression of c-Myc and Sox10 and other neural crest markers leading to 
defects in the normal development of neural crest derivatives such as 
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melanophores, sensory neurons and cranio-facial cartilage. c-Myc has 
been shown here to be particularly sensitive to inhibition of transcriptional 
elongation and so it is possible that c-Myc is a primary target of RNA 
polymerase pausing and this results in the neural crest defects seen 
here. Other studies have shown that c-Myc is sensitive to polymerase 
pausing. The loss of Sox10 expression can be rescued by injection of c-
Myc RNA suggesting that Sox10 is not a primary target of RNA 
polymerase pausing.  
 To further confirm that c-Myc is a primary target it would be good to 
rescue the loss of Sox10 expression with c-Myc but still see a loss of 
endogenous c-Myc. This could be done perhaps by rescuing with human 
c-Myc RNA but carrying out an in-situ for Xenopus c-Myc. In this situation 
the probes must be carefully designed not to cross react. Alternatively a 
probe could be made for the c-Myc 3’UTR which would only recognise 
endogenous c-Myc and not the c-Myc injected. Although c-Myc has been 
shown to be paused in other cell types it would also be a good 
experiment to show this in the Xenopus whole embryo and animal cap. 
This could be done using ChIP PCR or sequencing with antibodies 
against RNA polymerase II to see where along the gene body the 
polymerase is most commonly found. After inhibiting transcriptional 
elongation we would hypothesise that RNA polymerase II will be most 
commonly found at the promoter region of c-Myc indicating a that the 
gene is held in a paused state.  
 Although RNA polymerase pausing is known to be important in 
other cell types such as blood cells and stem cells, it could be suggested 
that it is also specific for neural crest cells. There has been a debate in 
the literature recently as to whether pausing is seen to some extent in all 
cell types or whether it is a phenomena specific to certain cells. The 
results obtained here show that when the three cells types neural crest, 
neuroectoderm and ectoderm have transcriptional elongation inhibited 
the only cell type to show specific changes was the neural crest sample. 
All three samples displayed an increase in HEXIM1 expression 
suggesting that P-TEFb is held in an inactive state, however the neural 
crest sample was the only sample to also display a loss in its orginal fate. 
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The neural crest specifier genes such as Sox10 and Slug were seen to 
be downregulated and genes expressed in the surrounding ectoderm 
were upregulated in their place. The neuroectoderm did not lose its 
orginal cell fate. Genes expressed in neuroprogenitor cells such as Sox1 
were seen to be upregulated and genes involved in ectoderm formation 
were downregulated. This would suggest that more neuroectoderm is 
present irrespective of ectoderm and that the neuroectoderm cell fate is 
not lost upon inhibiting transcriptional elongation. The ectoderm cell type 
showed no changes in any ectoderm specific genes and so it can be 
suggested that this cell type was not afftected by inhibiting transcriptional 
elongation. These data indicate that transcriptional elongation is not 
important for the development of all cell types but could be considered 
relatively specific for neural crest cells.  
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